Cancer Incidence Report Saudi Arabia 2003 Report...5 This is the seventh incidence report published...

Kingdom of Saudi ArabiaMinistry of Health

National Cancer Registry

Cancer Incidence ReportSaudi Arabia

2003

Part001.indd 1 18-08-2007 11:45:44 AM

Report prepared by: Haya S. Al-Eid, BDS, DFE, CTR

Suad Omer Arteh, MA

Reviewed by: Shouki Bazarbashi, MD Ali Al-Zahrani, MD, PhD

Part001.indd 2 18-08-2007 11:45:44 AM

3

AcknowledgmentForewordFirst and foremost we would like to acknowledge the Ministry of health for the financial supportof the National Cancer Registry (NCR). The production of this report has been made possible by the active cooperation of staffs from hospitals, clinics, pathology laboratories, and others within the Kingdom of Saudi Arabia. The Registry is indebted to all those who have helped in identifying and collecting cases and whose support has been given over many years.

The statistics in this report have been derived from data collected from all sectors of patient care, both governmental and private. We hope the individuals and institutions will find the report useful.

We would also like to acknowledge the relentless support of his Excellency Dr. Hamad Al Manea, Minister of Health and Dr. Mansour Al Hawasi, Deputy Minister of Health for the ongoing operation of the National Cancer Registry. We are in debt for the support given to us by the King Faisal Specialist Hospital and Research Centre administration represented by Dr. Qassim Al Qasabi, Chief Executive Director and Dr. Adnan Ezzat, Executive Director, Medical and Clinical Operation.

Special thanks to our registry staff who worked hard to make this publication possible, and to all previous staff involved in NCR operation for the report period.

Last but not least, we would like to thank the pharmaceutical companies F. Hoffman-La Roche, sanofi-aventis and Novartis Oncology for theirgenerous support for the NCR.

This annual report of the National Cancer Registry (NCR) incorporates cancer incidence data for the entire country. It represents the ongoing effort by the ministry of health, the medical services at ministry of defense, national guard and security forces, college of medicine from all major universities across Saudi Arabia, other health care facilities, physicians, and cancer registrars throughout the country.

This information is presented in the hope that it will assist health care providers, public health officials,voluntary organizations, and concerned citizens in their efforts to prevent and control cancer in Saudi Arabia.

The report summarizes information on new cases of cancer (incidence) for citizens and residents of Saudi Arabia. It also incorporates comparative data from other parts of the world. The report provides information on cancer of all types combined and the 10 most frequently diagnosed cancers in both sexes.

The report represents the cancer incidence in the 10th year of the NCR operation which is considered an important milestone. Cancer incidence trends over the past 10 years will be presented in a separate report that will be devoted mainly for this purpose.

The NCR is committed to preserving the confidentiality of information obtained for medical,educational, research, and statistical purposes. Thus the NCR demands strict confidentialityand the protection of the identity of both cancer patients and reporting sources in registry data. The NCR does not release any identifying information regarding patients, hospitals, or physicians except under the authority of the Ministry of Health.

Shouki Bazarbashi, MDChairman

Part001.indd 3 18-08-2007 11:45:44 AM

4

Part001.indd 4 18-08-2007 11:45:44 AM

5

This is the seventh incidence report published by the National Cancer Registry of Saudi Arabia. Previous publications include the 1994 Summary Report, 1994-1996 Incidence Report, 1997-1998 Incidence Report, 1999-2000 Incidence Report, 2001 Incidence Report, and 2002 Incidence Report. The current publication covers the year 2003. In the future, publications spanning a more extended period (5-10 years) will have the advantage of presenting more stable incidence rates and time-trends studies.

The structure of this report can be outlined as follows:

Part I Materials and Methods

This part of the report contains information about the background of the National Cancer Registry and methods used in collecting and analyzing the data. We present the basics of coding and classificationof tumor topography, morphology and extent of disease at the time of diagnosis. Also we describe the software programs we have used to analyze the data.

Part II Overview of Cancer Incidence

Part II contains figures and tables that show overallcancer incidence in Saudi Arabia for the year 2003. We present these figures and tables mainly by sexand in certain areas we have it analyzed by different age groups. There are bar charts representing the age distribution of cancer incidence for the year 2003 among Saudis by sex and age groups. We present incidence and morphology tables for the most common types of cancers among adults and children. In addition, tables list the total number of cases, the Age-Standardized Incidence Rate (ASR) per 100,000 population, Crude Incidence Rate (CIR) and Cumulative rates by primary site and sex. Separate bar charts depict the most common types of cancer, by sex, in each of the 13 administrative regions of Saudi Arabia.

Part III Incidence of Selected-Sites

In this part the incidence of the top ten cancers among Saudi males and females are outlined. A standardized layout presents data for all patients and for both sexes where applicable. For each

selected site the number and the percentage of all newly diagnosed cases for the year 2003, the ASR for each sex, and the specific cancer rank for bothsexes. In addition, ASR for the specified canceramong Saudis is compared with ASR among other populations from selected countries.

Part IV Cancer Incidence among Non-Saudis

This part presents the incidence of cancer cases among Non-Saudis including the most common types of cancer. The analysis of the Non-Saudis is performed separately due to the nature of the expatriate population in Saudi Arabia in which a large part of the population, particularly among males, falls in the 25-44 age group.

Part V Incidence Tables

Part V contains the following detailed tables for all newly diagnosed cancer types among Saudis and Non-Saudis for 2003:

• Distribution of cancer cases among Saudis by age group and sex

• Distribution of cancer cases among Non-Saudis by age group and sex

• Cancer Incidence (per 100,000 population) among Saudis by age group and sex

• Cancer Incidence (per 100,000 population) among Non-Saudis by age group and sex

• Age-standardized incidence rate, crude incidence rate and relative frequencies among Saudis by cancer site, sex and administrative regions

Part VI Appendices

Appendix A: Regional listing of all health care facilities from which cancer cases have been reported. The objective is to receive feedback from facilities that have not been included in order to improve our case-finding and reporting processes.

Appendix B: Names of the members of the Board of Directors.

Appendix C: Data request form which may be copied, filled and submitted to the NCR MainOffice.

Appendix D: Copy of the cancer registration abstract form which is completed by cancer registrars for each cancer case.

Introduction

Part001.indd 5 18-08-2007 11:45:44 AM

Table of Contents

Foreword ....................................................................................................................................................................... 3Acknowledgment ......................................................................................................................................................... 3Introduction .................................................................................................................................................................. 5

PART I ................................................................................................................................................... 9

Background on Saudi Arabia .................................................................................................................................... 10National Cancer Registry ........................................................................................................................................ 10Definitions of Statistical Terms ................................................................................................................................ 13

PART II ................................................................................................................... 15

Cancer in Saudi Arabia 2003 ................................................................................................................................... 16Adult Cancers in Saudi Arabia, 2003 (above 14 years) ...................................................................................... 22Childhood Cancers in Saudi Arabia 2003 (14 years and below) ..................................................................... 24Cancer in the 13 Administrative Regions of the Kingdom ............................................................................... 26International Comparison of Age-Standardized Incidence Rates .................................................................. 31

PART III .................................................................................................................. 33

Cancer Incidence for Specific Sites, 2003 ............................................................................................................. 35Female Breast (C 50) ................................................................................................................................................ 36Colo-rectal (C18-C20) ............................................................................................................................................. 38Non-Hodgkin Lymphoma (C82-C85;C96) .......................................................................................................... 40Thyroid (C 73) ............................................................................................................................................................ 42Leukemia (C91-C95) ................................................................................................................................................. 44Liver (C 22) ................................................................................................................................................................. 46Skin (Non-Melanoma) (C 44) ................................................................................................................................. 48Stomach (C 16) .......................................................................................................................................................... 50Hodgkins disease (C 81) .......................................................................................................................................... 52Lung (C33-C34) ......................................................................................................................................................... 54Bladder (C 67) ............................................................................................................................................................ 56Prostate (C 61) ........................................................................................................................................................... 58Corpus Uteri (C 55) ................................................................................................................................................. 60Ovary (C 56) .............................................................................................................................................................. 62

PART IV .................................................................................................................. 65

Cancer Among Non-Saudi Population 2003 ........................................................................................................ 67

Part001.indd 6 18-08-2007 11:45:44 AM

PART V .................................................................................................................... 69

Table 5-1-1 Age Distribution of Cancer Cases among Saudi Males, 2003 .................................................... 70Table 5-1-2 Age Distribution of Cancer Cases among Saudi Females, 2003 ................................................ 71Table 5-1-3 Cancer Incidence Cases among Saudi Males by Age Group (per 100,000), 2003 ................. 72Table 5-1-4 Cancer Incidence Cases among Saudi Females by Age Group (per 100,000), 2003 ............. 73Table 5-2-1 Age Standardized Rates and Relative Frequencies among Saudi Males by Cancer Site and Administrative Region, 2003 .............................................................................................................. 74-77Table 5-2-2 Age Standardized Rates and Relative Frequencies among Saudi Females by Cancer Site and Administrative Region, 2003 .............................................................................................................. 78-81Table 5-3-1 Age Distribution of Cancer Cases among non-Saudi Males, 2003 ............................................ 82Table 5-3-2 Age Distribution of Cancer Cases among non-Saudi Females, 2003 ....................................... 83Table 5-3-3 Incidence Rates for Cancer Cases among non-Saudi Males by Age Group (per 100,000), 2003 ............................................................................................................................. 84Table 5-3-4 Incidence Rates for Cancer Cases among non-Saudi Females by Age Group (per 100,000), 2003 ............................................................................................................................. 85

PART VI .................................................................................................................. 87

APPENDIX A: Reporting Health Care Facilities .................................................................................. 88-90APPENDIX B: Members of NCR Board of Directors ........................................................................ 91-92APPENDIX C: NCR Data Request Form ..................................................................................................... 93APPENDIX D: Cancer Registration Abstract Form ................................................................................... 94

Part001.indd 7 18-08-2007 11:45:44 AM

8

Part001.indd 8 18-08-2007 11:45:45 AM

PART IMATERIALS AND METHODS

Part001.indd 9 18-08-2007 11:45:45 AM

10

Saudi Arabia is a vast country extending over four-fifths of theArabian Peninsula. It stretches from theArabian Gulf in the east to the Red Sea in the west. It is approximately 2,149,700* square kilometers in area and is divided into 13 administrative regions (Figure 1-1).

The Saudi national population for year 2003 was 16,109,198**. Of these, 8,077,700 were males and 8,031,498 were females. The Non-Saudi population in 2003 was 6,009,451**; of these 4,171,663 were males and 1,837,787 females.

Figures 1-2 and 1-3 show the Saudi and Non-Saudi population pyramids by sex and age group respectively.

Figure 1.1 Administrative Regions of Saudi Arabia

Figure 1.2 Population Pyramid of Saudis (%) by Sex and Age Group, 2003

National Cancer Registry

The National Cancer Registry (NCR) of Saudi Arabia is a population-based registry established in 1992 under the jurisdiction of the Ministry of Health (MOH) by the order of His Excellency the Minister of Health. The NCR commenced reporting cancer cases from 01 January 1994.

Objectives:

The primary goal of the NCR is to define thepopulation-based incidence of cancer in Saudi Arabia. Additional objectives include programs for early detection and cancer screening, as well as cancer research projects. Organizational Structure:

A Board of Directors was appointed to include representatives from the MOH, King Faisal Specialist Hospital and Research Center (KFSH&RC), and the Medical Services Departments of the Ministry of Defense and Aviation, Ministry of Interior, the National Guard, King Saud University, King Faisal University, King Abdul-Aziz University and King Khalid University. The Board is charged with the responsibility of overseeing the NCR’s establishment, defining demographic and cancer-related data to becollected, approving research requests, and reporting findings, as well as disseminating informationcollected while ensuring the confidentiality of alldata reported to the NCR.

* Source: Demographic and Health Indicators for Countries of the East Mediterranean, WHO, Regional Office for the EM, 1999** Source: Central Department for Statistics (CDS) data, Ministry of Planning, with a 2.5% growth rate for Saudis and a 2.3% growth rate for Non- Saudis (web site http:\\www.planning.gov.sa).

Figure 1.3 Population Pyramid of non-Saudis (%) by Sex and Age Group, 2003

Background on Saudi Arabia

6.46.86.5

5.74.64.4

3.43.0

2.51.9

1.30.90.80.60.5

0.7

0246810

FemalesMale

6.46.87.0

5.74.8

4.33.5

3.02.3

1.71.2

0.90.8

0.60.50.6

0 2 4 6 8 10

0 - 45 - 9

10-1415-1920-2425-2930-3435-3940-4445-4950-5455-5960-6465-6970-74

75+ 91,05582,750

98,652130,990

149,318194,370270,490363,545

485,566

560,575683,582

766,611915,226

1,126,4881,084,434

1,027,846

112,74575,322100,633123,391142,383216,545305,412401,469480,082554,752707,060740,914924,7051,054,5121,098,7331,039,039

8,077,700 8,031,498

2.62.42.11.8

3.57.3

8.37.9

6.04.0

2.31.0

0.50.20.10.1

0246810

7,065

6,2347,66614,62921,146

42,51571,101119,103

185,731264,858

234,632156,242138,929163,803193,349210,785

FemalesMale

5.75.3

4.53.8

4.36.4

7.25.1

3.21.9

1.20.6

0.40.20.20.2

0 2 4 6 8 10

0 - 45 - 9

10-1415-1920-2425-2930-3435-3940-4445-4950-5455-5960-6465-6970-74

75+8,7749,61116,29438,64582,928188,691330,371500,207659,215693,406612,292291,391146,841172,507202,246218,243

4,171,663 1,837,787

Part001.indd 10 18-08-2007 11:45:50 AM

11

The NCR Main Office, including administrative and technical staff, is located in the premises of the KFSH&RC in Riyadh. Additionally, five regionalbranches and four hospital-based offices were setup to ensure comprehensive data collection from all over the Kingdom (Figure 1-4).

Regional Offices:

1 Central Region: King Khalid University Hospital in Riyadh, covering Riyadh, Qassim, and Hail Health Regions.

2 Eastern Region: King Fahad Hospital of the University, Al Khobar, covering Dammam, Al Ahsa, and Hafr Al-Batin Health Regions.

3 Western Region: King Abdulaziz Hospital and Cancer Center, Jeddah, covering Jeddah, Makkah, Taif and Qunfudah Health Regions.

4 Southern Region: King Khalid University, Abha, covering Asir, Baha, Najran, Jazan and Bisha Health Regions.

5 Madinah/Northern Region: King Fahad Hospital, Madinah, covering Madinah, Tabuk, Jouf and Northern Health Regions.

Offices at the Medical Service Division or OncologyDepartment of the following establishment

1 Ministry of Defense and Aviation, Armed Forces Hospital, Riyadh

2 National Guard, King Fahad Hospital, Riyadh.

3 Ministry of Interior, Security Forces Hospital, Riyadh.

4 King Faisal Specialist Hospital and Research Centre, Riyadh.

5 King Abdul Aziz University Hospital, Jeddah

Each of the NCR offices operates under thesupervision of a member of the Board of Directors who is responsible for the daily management of that office. Staffing consists of tumor registrars andsecretarial staff.

The NCR Main Office indirectly supervises theregional offices and is responsible for ensuring theaccuracy and quality of data collected in all of the regions. Quality control processes include verificationof site, morphology, and staging information as well as case linkage (tumor and patient), and consolidation of data. The Main Office also prepares periodicreports for dissemination of information to the medical community, government establishments, international organizations and the media.

Format

The format of the current report is similar to the previous reports.

Figure 1.4 Organizational Chart of the National Caner Registry of Saudi Arabia

Ministry of HealthSaudi Arabia

National Cancer RegistryMain Office

Central Region (Riyadh, Qassim & Hail)

King Faisal Specialist Hospital& Research Centre (Riyadh)

National Guard Hospitals

Armed Forces Hospitals

Security Forces Hospitals

Madinah Region (Madinah, Tabuk, Jouf & Northern Region)

Southern Region (Asir, Baha, Jazan & Najran)

Western Region (Jeddah, Makkah, Taif & Qunfudah)

Eastern Region (Dammam, Ahsa & Hafr Al Batin)

Part001.indd 11 18-08-2007 11:45:51 AM

12

A ministerial decree has categorized cancer as a mandatory notifiable disease. This ensures theopportunity for comprehensive data collection. The NCR strives for full access to cancer data from all Ministry of Health, governmental and private hospitals, as well as clinics and laboratories throughout the Kingdom. Cancer data are abstracted from patients’ medical records, based on clinical and/or histopathological diagnosis, by NCR-trained cancer registrars.

The data abstract (see appendix D) includes personal identification (name, ID Number, sex,age), demographic information (address, telephone number, nationality), and tumor details (diagnosis date, primary site, histology, behavior, grade, stage, basis of diagnosis). The primary site (topography) and histology (morphology) of the malignancies are identified and coded according to the International Classification of Diseases for Oncology 3rd Edition (ICD-O-3), published by the World Health Organization (WHO), 2000.

Effective from year 2001, changes were made in coding of cancer types and behaviors as well as staging according to International guidelines. The new SEER Summary Stage 2000 guidelines should result in increased accuracy and consistency in the coding of stage. There are some differences in the timing rules for determining stage and some sites are coded differently using the new guidelines. However, the new criteria and guidelines should improve the usefulness of staging as a predictor of prognosis and survival as the changes reflect a new understandingof the natural history of cancer. The new guidelines, SEER Summary Stage Manual 2000, is available on the web at: http:/seer.cancer.gov/tools/ssm/. Cases diagnosed on or after 01 January 2003 are classifiedaccording to the updated ICD-O-3. Improvements in the understanding of cancer pathology over the last decade are reflected in the changes to ICD-O-3. While there have not been any changes in the primary site codes, there are significant changesregarding histology (cell types). Leukemias and lymphomas, particularly are affected. Some cases that were previously considered benign are now

The computer software programs used for data entry and incidence tables output are CanReg 4.31, developed by the International Agency for Research on Cancer, (IARC) Lyon, France.

The second part of the report includes the overall cancer incidence in Saudi Arabia and the relevant epidemiological and clinicopathological details for the 14 most common cancers among Saudi nationals for the year 2003. For each cancer site, the number and the percentage of all newly diagnosed cases for the year 2003, the age-standardized incidence rate (ASR) per 100,000 population for each sex, and the specific cancer rank in comparison to all cancersfor both sexes are presented. Useful international statistics for the specified cancer include the rankingof the cancer worldwide. The source for this information is summarized on page 64.

counted as malignant. Also small number of cancers that were previously coded as borderline tumors are now considered benign. Counts of ovarian cancers, lymphomas and leukemias as well as some hematopoietic diseases will change due to changes in either reportability or definition. However,as with the new staging guidelines, the ICD-O changes reflect advances in the understanding ofthe pathology and behavior of cancers.

It should be noted that ICD-O-3 codes are converted to ICD-10 for analysis purposes. Since the WHO has not yet converted the ICD-10 hematopoietic disease behavior changes, our software, CanReg 4.31, cannot include these cases for analysis and they have been excluded. Every effort is made to accurately code patient and tumor information, to ensure that all data can be reviewed, linked, and consolidated, as appropriate, so that each malignancy is counted only once for statistical analysis.

Data management

Part001.indd 12 18-08-2007 11:45:51 AM

13

Definitions ofTerms

Age-Specific Incidence Rate (AIR)

The number of cancer cases occurring during a specific period in a population of a specific ageand sex group, divided by the number of midyear population of that age and sex group.

Age-Standardized Rate (ASR)

The Age-standardized rate is a summary measure of a rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age structure. The most frequently used standard population is the World Standard Population (see below). The calculated incidence is known as the World Standardized Incidence Rate. The rate is expressed per 100,000 populations.

In reviewing the data, its collection and analysis, two qualifying statements can be made:

* Doll R. Payne P. Waterhouse J. Cancer incidence in Five Continents Vol. I. International Union Against Cancer. 1966

NotificationThe relevant data incorporate details for all patients presented over the year 2003. For each cancer there are five figures:

1. An arithmetic line graph represents the age-specific incidence rate (AIR) for all agegroups at five-year intervals. The graph isplotted by sex, where applicable.

2. A table lists the percentages of the most common histology sub-types for each specific cancer.

3. A pie chart shows the distribution of the clinical stages of each cancer such as localized, regional, distant metastasis and unknown.

4. A bar chart shows regional distribution of ASR for particular cancer across the administrative regions by males and females.

5. A bar chart shows comparison of age-standardized incidence rate (ASR) for each cancer type in Saudi Arabia with ASR in selected countries.

a. The number of patients presenting with malignant disease from Riyadh region exceeds the anticipated number per population. The reason for this is that Riyadh has many referral centers providing patients from outside the region with cancer-related care. Many of these patients fail to provide their permanent address, but instead, provide a temporary Riyadh address. This situation is partially resolved through tumor and patient linkage of cases from all regions based on identifiers suchas national ID.

b. As previously noted, the software used in analyzing this report, CanReg 4.31, does not include in situ cases in the incidence tables. These cases were added to the total cancer cases in the overview.

The data included in this report were abstracted up to June 2005. 2003 incident cases which are identified after this date (late reporting) will benoted in subsequent incidence reports. It is anticipated that the number of late-reported cases will decrease as case ascertainment processes are improved.

Age Class Population

0-4 12,0005-9 10,00010-14 9,00015-19 9,00020-24 8,00025-29 8,00030-34 6,00035-39 6,00040-44 6,00045-49 6,00050-54 5,00055-59 4,00060-64 4,00065-69 3,00070-74 2,00075+ 2,000

Total 100,000

Part001.indd 13 18-08-2007 11:45:52 AM

14

Cumulative Incidence rate

Cumulative incidence is the probability or risk of individuals developing the disease during a specifiedperiod. For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to develop a particular cancer before the age of 65 (or 70, or 75) if they had the rates of cancers currently observed. Like the age standardized rate, it permits comaprison between populations of different age structures. In this report the age ranges 0-64 and 0-74 years are used. The cumulative rate is the summation of the cancer age-specific rates;which are computed for five-yearage intervals. The cumulative rate is five times thesum of the age-specific rates calculated over thefive-year age groups.

ICD-10The World Health Organization’s International Classification of Diseases, tenth edition.

ICD-O-3The World Health Organization’s International Classification of Diseases for Oncology,3rd Editionhas been the standard coding system for neoplasms for over 25 years. The coding system includes a four character code for primary site, a four-digit numeric code for cell type, one-digit code for behavior and a one-digit code for tumor aggressiveness (grade).

Crude Incidence Rate Incidence Rate

The crude incidence rate for a cancer site is the total number of cases registered as a proportion of the total population. It denotes the approximate number of cases occurring in each 100,000 individuals. All rates are thus, expressed as per 100,000 population.

Cancer rates vary greatly with age and the crude rate is strongly influenced by the demographic structureof the population. Hence, if the population structure changes over time the crude rate over that period may be artificially altered. It is not appropriate tocompare crude rates across geographical areas of cancer registries with different population age structures. Therefore, in order to to assess time trends in registration data or compare incidence across geographical areas or between registries it is necessary to first standarize the rates withrespect to age.

An incidence rate is defined as the rate at which a new event occurs in a population. It is calculated as the number of new cases of disease arising in a population over a defined time period, divided bythe population at risk of developing that disease.

Metastasis

Metastasis is the distant spread of cancer from its original site to other organs of the body, including lymph nodes, skeletal and or visceral organs.

Rank

This measure reflects the importance of a specificcancer site relative to other sites, in terms of the number of registrations. Ranking illustrates the most and least frequent cancer sites in a population according to their frequency.

Relative Frequency

This statistic is defined as the number of specificcancer cases registered relative to the total number of all cancer. It is expressed as a percentage.

Summary Stage

Staging is the grouping of cancer cases into broad categories based on the extent of disease.

Part001.indd 14 18-08-2007 11:45:52 AM

PART IIOVERVIEW OF CANCER INCIDENCE

2003

Part002.indd 15 18-08-2007 11:55:07 AM

16

* ICD-10 conversion failure ** Unknown nationalities, in situ cases and ICD-10 conversion failures are excluded from analysis

Table 2.1 Distribution of Cancer Cases in Saudi Arabia by Nationality and Sex 2003

As shown on table 2-1, 8,382 cases were analyzed, of which 6,516 (77.7%) were Saudis and 1,866 (22.3%) were Non-Saudis. Among the Saudis, 3,263 (50.1%) were male and 3,253 (49.9 %) were female. The male to female ratio was 100:100. The crude incidence rate (CIR) of all cancers among the Saudi population was 40.4/100,000 (40.5/100,000 among males and 40.3/100,000 among females). The overall age-standardized incidence rate (ASR) for all Saudis with a world standard population reference was 67.5/100,000 (68.7/100,000 in males and 66.3/100,000 in females). For all sites, the age-specific incidence rate (AIR) increased with age forboth males and females. After the age of 64 years, the increase was nearly two folds for males compared to females. The mean age at diagnosis was 53 years for men and 48 years for women. The five geographicregions with the highest ASR were Eastern region at 100.8/100,000, Riyadh region at 94.8/100,000, Makkah region at 77/100,000, Northern region at 71.3/100,000, and Tabuk region at 66.7/100,000

Between January and December 2003, the total number of cancer incident cases reported to the NCR was 8,840. Overall, cancer was more predominant in men than in women. Cancers affected 4,565 (51.6%) males and 4,275 (48.4%) females, with a male to female ratio of 107:100. 6,644 cases were reported among Saudis, 1,913 among Non-Saudis. The total number of cases excluded from analysis included 283 cases of unknown nationalities. Other exclusions were 156 in situ cases. The current software program CanReg-4 version 4.31, does not include in situ cases in the statistical analysis. Also, 24 were ICD-O-3 coded cases that failed to convert to ICD-10 codes as described in the Data Management (see page 12). This puts the total number of exclusions from the analysis as 458 cases. Table 2-1 illustrates the distribution of the cases by sex.

Diagnosis of malignancy was confirmed histologicallyand/or cytologically in 97.3% of the cases. Clinically confirmed cases were 0.2%;radiologically confirmedcases were 1.8%; and cases confirmed by othermethods were 0.6%. The method of diagnosis was unknown for 0.1% of the cases.

Reported Cancer Incidence Cases in Saudi Arabia, 2003

Saudis Non-Saudis Unknown Nationality All

Male Female Total Male Female Total Male Female Total Total

Total 3327 3317 6644 1093 820 1913 145 138 283 8840

Invasive 3271 3266 6537 1075 793 1868 144 135 279 8684

In Situ 56 51 107 18 27 45 1 3 4 156

ICD 10 * 8 13 21 1 1 2 0 1 1 24

Analyzed ** 3263 3253 6516 1074 792 1866 144 134 278 8382

Part002.indd 16 18-08-2007 11:55:07 AM

17

Figure 2.1 Percentage Distribution of Cancer Incidence among Saudis by Sex according to Age Group, 2003

The total number of cancer cases analyzed among Saudis during the year 2003 were 6,516. Of those cases 51.7% (3,263) were reported among men and 48.3% (3,253) among women.

Figure 2.2 Percentage Distribution of Most Frequent Types of Cancer by Sex among Saudis, 2003* 2 Cases (1 male and 1 female) of unknown age are included only in the total as they may not be added to any age group

Cancer among Saudis 2003

4.6 4.4

6.3

10.7

16.2

7.9

3.5

5.3

11.2

13.512.2

4.1

0

2

4

6

8

10

12

14

16

18

0-14 15-29 30-44 45-59 60-74 75+

Perc

enta

ge

Age Group

Male

Female

17.7

2.1

2.4

2.6

2.7

2.7

2.8

3.7

3.9

4.7

4.9

01020304050

Female (3253)*Male (3263)*

15.9

1.6

1.7

1.7

1.7

1.7

2.8

3.3

3.8

5.3

10.4

10 20 30 40 50

All ages

Breast

Thyroid

Colo-rectalNon-Hodgkin Lymphoma

Leukemia

Skin

Corpus uteri

Liver

Ovary

Hodgkin disease

Other Sites

Colo-rectal

Non-Hodgkin Lymphoma

Liver

Leukemia

Lung

Prostate

StomachBladder

Skin

Hodgkin diseaseOther Sites

4.2

1.3

1.9

2.1

2.5

2.7

7.2

8.38.5

17.8

01020304050

Female (230)Male (298)

5.5

1.5

1.9

1.9

2.8

2.8

3.4

4.55.5

13.6

10 20 30 40 50

0-14 years

Leukemia

Brain, Nervous system


Hodgkin disease

Bone

Connective, soft tissue

KidneyEye

Adrenal gland

Other sites

Leukemia

Hodgkin diseaseBrain, Nervous systemNon-Hodgkin Lymphoma

EyeConnective, soft tissueKidneyAdrenal gland

BoneOther sites

6.3

1.1

1.6

1.6

2.2

2.2

3.3

3.9

6.6

6.6

9.5

01020304050


8.1

1.3

1.6

1.9

2.1

3.0

4.3

5.2

6.2

8.1

13.4

10 20 30 40 50

15-29 years

ThyroidHodgkin disease

LeukemiaBreast


OvaryBone

Connective, soft tissueBrain, Nervous system

NasopharynxOther Sites

LeukemiaHodgkin disease


Brain, Nervous systemBoneColo-rectal

TestisNasopharynxConnective, soft tissueSkin

Other Sites

11.2

1.4

1.4

1.4

1.5

2.0

2.0

2.4

2.5

2.6

3.4

4.1

01020304050


10.7

1.1

1.21.3

1.3

2.4

2.5

2.6

2.9

4.1

21.6

12.0

10 20 30 40 50

30-44 years

Breast

ThyroidColo-rectalLeukemia

Non-Hodgkin LymphomaOvary

Cervix Uteri

SkinKidney

Corpus Uteri

NasopharynxOther Sites

Colo-rectal

Non-Hodgkin LymphomaThyroid

BladderHodgkin diseaseNasopharynxLeukemiaStomach

SkinConnective, soft tissueTestisOther sites

13.11.31.31.31.51.82.32.72.72.93.33.5

6.4

1020304050


13.31.11.11.51.61.62.02.02.62.6

5.616.3

4.4

0 10 20 30 40 50

45-59 years

BreastColo-rectal

ThyroidCorpus uteri

Non-Hodgkin LymphomaOvary

Cervix uteriSkin

StomachLiver

KidneyLeukemia

Other sites

Colo-rectalNon-Hodgkin LymphomaLiverLungStomachBladderNasopharynxLeukemiaSkinPancreasProstateThyroidOther Sites

16.0

1.5

1.5

3.2

3.4

3.4

4.5

4.8

5.5

6.3

6.9

01020304050


14.5

1.3

1.4

1.6

1.8

2.4

2.5

3.2

3.8

4.0

6.3

10 20 30 40 50

60-74 years

Breast

Colo-rectal

Non-Hogkin LymphomaLiver

Corpus uteriSkin

ThyroidStomach

Gallbladder etc.Lung

Other Sites

Liver

Colo-rectal

LungProstate


Skin

Bladder

StomachLeukemiaKidney

Other Sites

14.8

1.4

1.8

2.9

3.1

3.9

4.7

5.7

5.9

6.4

6.5

8.7

01020304050


10.6

1.3

1.3

1.3

1.4

1.5

1.5

2.2

2.9

3.1

4.1

3.2

10 20 30 40 50

75+ years

ProstateLiverStomachSkinNon-Hodgkin LymphomaColo-rectal

BladderLungOesophagusPancreasKidneyOther Sites

Colo-rectalNon-Hodgkin Lymphoma

SkinBreast

LiverStomach

Thyroid

BladderOesophagus

LungCorpus uteri

Other Sites

Part002.indd 17 18-08-2007 11:55:10 AM

18

Table 2.2 Ten Most Common Cancers among Saudis, 2003 (All Ages)

Figure 2.3 Ten Most Common Cancers among Saudis by Sex, 2003

Cancer No. %

Breast 692 10.6

Colo-rectal 566 8.7

Non Hodgkin Lymphoma 521 8.0

Thyroid 428 6.6

Leukemia 423 6.5

Liver 360 5.5

Skin 271 4.2

Stomach 248 3.8

Hodgkin disease 243 3.7

Lung 242 3.7

317

303

251

239

183

178

173

168

158

139

9.7%

9.3%

7.7%

7.3%

5.6%

5.5%

5.3%

5.1%

4.8%

4.3%

Colo-rectal

NHL

Liver

Leukemia

Lung

Prostate

Stomach

Bladder

Skin

Hodgkin disease

3253Female

Breast

Thyroid

Colo-rectal

NHL

Leukemia

Skin

Corpus uteri

Liver

Ovary

Hodgkin disease

676

343

249

218

184

113

112

109

109

104

20.8%

10.5%

7.7%

6.7%

5.7%

3.5%

3.4%

3.4%

3.4%

3.2%

3263Male

Part002.indd 18 18-08-2007 11:55:13 AM

19

Figure 2.5 Age Standardized Rate ( ASR) Regional Distribution (per 100,000) of All Sites of Cancer among Saudis, 2003

Figure 2.4 Age-Specific Incidence Rates (AIR) for All Cancers among Saudis, 2003

0

50

100

150

200

250

300

350

400

450

500

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

)0 00,0 01 rep( RI A

Age Groups

male female

34.3

32.8

47.9

54.0

58.6

60.5

47.7

68.5

66.8

60.6

76.5

92.5

102.3

28.3

49.4

40.7

46.9

60.2

58.8

79.7

59.6

66.6

82.0

77.5

97.0

99.3

0 20 40 60 80 100 120

Jazan

Hail

Baha

Asir

Madinah

Najran

Jouf

Qassim

Tabuk

Northern

Makkah

Riyadh

Eastern

FemaleMale

Part002.indd 19 18-08-2007 11:55:14 AM

20

Table 2.3 Number, Percentage, ASR,CIR, and Cumulative Rates (per 1000) of New Cases by Primary Site and Sex among Saudis, 2003

Site No. % Crude ASR No. % Crude ASR Cumulative RateRate World 0-64 0-74 Rate World 0-64 0-74

All sites Total 3263 100 40.5 68.7 40.08 103.72 3253 100 40.3 66.3 46.31 87.52All sites but C - 44 3105 95 38.5 65.1 38.40 97.47 3140 96.5 38.9 63.7 44.97 83.03Lip 4 0.1 0 0.1 0.05 0.16 5 0.2 0.1 0.1 0.08 0.20Tongue 28 0.9 0.3 0.6 0.43 0.87 33 1.0 0.4 0.8 0.63 1.01Mouth 24 0.7 0.3 0.6 0.36 0.99 28 0.9 0.3 0.7 0.31 1.07Salivary glands 13 0.4 0.2 0.2 0.16 0.25 9 0.3 0.1 0.2 0.19 0.24Tonsil 5 0.2 0.1 0.1 0.04 0.22 3 0.1 0 0.1 0.02 0.13Other Oropharynx 0 0.0 0 0 0.00 0.00 0 0.0 - 0 0.00 0.00Nasopharynx 84 2.6 1 1.7 1.42 1.84 39 1.2 0.5 0.7 0.58 0.79Hypopharynx 7 0.2 0.1 0.1 0.08 0.22 2 0.1 0 0 0.00 0.12Pharynx unspec. 3.00 0.09 - 0.10 0.08 0.14 1 0.0 0 0 0.03 0.03Oesophagus 61 1.9 0.8 1.4 0.69 2.54 48 1.5 0.6 1.1 0.67 1.82Stomach 173 5.3 2.1 4 2.05 6.73 75 2.3 0.9 1.8 1.01 2.88Small intestine 13 0.4 0.2 0.3 0.17 0.45 10 0.3 0.1 0.2 0.19 0.35Colon 174 5.3 2.2 4 2.69 5.89 144 4.4 1.8 3.4 2.53 4.60Rectum 143 4.4 1.8 3.3 2.32 4.90 105 3.2 1.3 2.5 1.61 3.66Anus 10 0.3 0.1 0.3 0.26 0.35 10 0.3 0.10 0.2 0.12 0.39Liver 251 7.7 3.1 6.2 3.33 10.61 109 3.4 1.4 2.8 1.96 4.44Gallbladder etc. 35 1.1 0.4 0.9 0.55 1.28 56 1.7 0.7 1.4 1.00 2.23Pancreas 65 2.0 0.8 1.6 0.95 2.54 36 1.1 0.4 0.9 0.45 1.39Nose, sinuses etc. 10 0.3 0.1 0.2 0.11 0.25 3 0.1 0 0.1 0.01 0.06Larynx 55 1.7 0.7 1.3 0.87 2.04 4 0.1 0 0.1 0.04 0.04Trachea,Bronchus,Lung 183 5.6 2.3 4.7 2.85 7.60 59 1.8 0.7 1.4 0.84 2.30Other Thoracic organs 12 0.4 0.10 0.30 0.18 0.37 10 0.3 0.1 0.1 0.05 0.11Bone 41 1.3 0.5 0.5 0.35 0.53 37 1.1 0.5 0.4 0.31 0.31Melanoma of Skin 10 0.3 0.1 0.2 0.06 0.35 7 0.2 0.1 0.2 0.03 0.30Other Skin 158 4.8 2 3.6 1.68 6.25 113 3.5 1.4 2.6 1.34 4.49Mesothelioma 5 0.15 0.10 0.10 0.09 0.14 7 0.2 0.10 0.2 0.16 0.21Kaposi sarcoma 26 0.8 0.3 0.6 0.44 0.87 5 0.2 0.10 0.1 0.08 0.13Connective,Soft tissue 66 2.0 0.8 1.1 0.78 1.28 53 1.6 0.7 0.8 0.52 0.79Breast 16 0.5 0.2 0.4 0.24 0.59 676 20.8 8.4 13.9 11.31 16.00Vulva − − − − − − 6 0.2 0.1 0.1 0.12 0.23Vagina − − − − − − 0 0.0 0 0 0.00 0.00Cervix Uteri − − − − − − 87 2.7 1.1 1.9 1.37 2.43Corpus Uteri − − − − − − 112 3.4 1.4 2.8 1.89 4.15Uterus unspec. − − − − − − 9 0.3 0.1 0.2 0.21 0.21Ovary − − − − − − 109 3.4 1.4 2 1.50 2.60Other Female Genital − − − − − − 5 0.2 0.1 0.1 0.16 0.16Placenta − − − − − − 6 0.2 0.1 0.1 0.09 0.09Penis 1 0.0 0 0 0.03 0.03 − − − − − −Prostate 178 5.5 2.2 4.2 0.99 8.51 − − − − − −Testis 38 1.2 0.5 0.5 0.36 0.36 − − − − − −Other male genital 4 0.1 - 0.1 0.05 0.09 − − − − − −Kidney 77 2.4 1 1.6 1.01 2.48 62 1.9 0.8 1.3 1.11 1.43Renal Pelvis 6 0.18 0.10 0.20 0.15 0.26 2 0.06 - 0.10 0.00 0.11Ureter 6 0.18 0.10 0.20 0.09 0.28 1 0.03 - - 0.02 0.02Bladder 168 5.1 2.1 3.9 2.41 6.16 42 1.3 0.5 1 0.66 1.64Other Urinary organs 2 0.1 0 0 0.05 0.05 0 0.0 0 0 0.00 0.00Eye 21 0.6 0.3 0.3 0.13 0.34 15 0.5 0.2 0.2 0.12 0.22Brain, Nervous system 130 4.0 1.6 2.1 1.43 2.42 81 2.5 1 1.3 0.92 1.53Thyroid 85 2.6 1.1 1.7 1.19 2.17 343 10.5 4.3 5.7 4.36 6.04Adrenal gland 14 0.4 0.2 0.2 0.08 0.13 12 0.4 0.1 0.2 0.07 0.12Other Endocrine 4 0.12 - - 0.03 0.03 1.00 0.03 - - 0.01 0.01Hodgkin disease 139 4.3 1.7 1.8 1.11 1.72 104 3.2 1.3 1.4 0.96 1.40Non-Hodgkin lymphoma 303 9.3 3.8 5.9 3.15 8.73 218 6.7 2.7 4.5 2.59 6.49Immunoproliferative dis. 1.00 0.03 - - 0.03 0.03 - - - - 0.00 0.00Multiple Myeloma 34 1.0 0.4 0.8 0.50 1.28 12 0.4 0.1 0.3 0.22 0.50Lymphoid Leukaemia 150 4.6 1.9 2 1.23 1.67 84 2.6 1 1.1 0.64 0.80Myeloid Leukaemia 85 2.6 1.1 1.4 1.05 1.69 95 2.9 1.2 1.5 1.02 1.73Leukaemia unspec. 4 0.1 0 0.1 0.01 0.11 5 0.2 0.1 0 0.03 0.03Other & unspecified 138 4.2 1.7 3.2 1.85 5.08 155 4.8 1.9 3.7 2.31 5.62

MaleCumulative Rate

Female

Part002.indd 20 18-08-2007 11:55:14 AM

21

Between January and December 2003, the total number of adult cancer incidence cases reported was 8,165. Overall cancer was slightly more in males than in females. Cancer affected 4,182 (51.2%) males and 3,983 (48.8%) females, with a ratio of

Table 2.4 Distribution of Reported Adult Cancer Cases in Saudi Arabia by Nationality and Sex 2003


105:100. Of all cases, there were 6,102 Saudis, 1,809 of Non-Saudis and 247 of unknown nationalities. As shown on table 2.4, the total number of analysed cases were 7,748.

Adult Cancers in Saudi Arabia, 2003 (>14 years)

Saudis Non -Saudis Unknown Nationality All


Total 3025 3084 6109 1035 774 1809 122 125 247 8165

Invasive 2970 3033 6003 1017 747 1764 121 122 243 8010

In-Situ 55 51 106 18 27 45 1 3 4 155

ICD 10* 6 11 17 1 1 2 0 0 0 19

Analyzed** 2964 3022 5986 1016 746 1762 121 122 243 7748

315

265

246

183

178

172

167

156

145

94

10.6%

8.9%

8.3%

6.2%

6.0%

5.8%

5.6%

5.3%

4.9%

3.2%

Colo-rectal

NHL

Liver

Lung

Prostate

Stomach

Bladder

Skin

Leukemia

Hodgkin disease

3022Female2964Male

Breast

Thyroid

Colo-rectal

NHL

Skin

Corpus uteri

Leukemia

Liver

Ovary

Cervix uteri

676

336

249

194

112

112

112

107

103

87

22.4%

11.1%

8.2%

6.4%

3.7%

3.7%

3.7%

3.5%

3.4%

2.9%

Figure 2.6 Ten Most Common Cancers among Saudi Adults, 2003

Part002.indd 21 18-08-2007 11:55:14 AM

22

Primary Site Code Morphology Male % Female %Breast 8500 Infiltrating duct carcinoma, NOS 11 68.8 517 76.6

8520 Lobular carcinoma, NOS 0 0.0 33 4.98010 Carcinoma, NOS 1 6.3 20 3.08523 Infiltrating duct mixed with other types of carcinoma 2 12.5 17 2.58140 Adenocarcinoma, NOS 2 12.5 13 1.98522 Infiltrating duct and lobular carcinoma 0 0.0 14 2.18510 Medullary carcinoma, NOS 0 0.0 12 1.88541 Paget disease and infiltrating duct carcinoma of breast 0 0.0 10 1.58521 Infiltrating ductular carcinoma 0 0.0 7 1.0

All Others 0 0.0 32 4.7Colo-rectal 8140 Adenocarcinoma, NOS 227 70.9 181 72.6

8480 Mucinous adenocarcinoma 31 9.7 21 8.48490 Signet ring cell carcinoma 10 3.4 8 3.28261 Adenocarcinoma in villous adenoma 10 3.1 5 2.08481 Mucin-Producing adenocarcinoma 6 1.9 9 3.68263 Adenocarcinoma in tubulovillous adenoma 9 2.8 4 1.68210 Adenocarcinoma in adenomatous polyp 6 1.9 3 1.28010 Carcinoma, NOS 2 0.6 4 1.68144 Adenocarcinoma, intestinal type 3 1.0 3 1.2

All Others 11 3.5 11 4.4NHL 9680 Malignant lymphoma, large B-cell, diffuse, NOS 119 44.9 98 50.5

9591 Malignant lymphoma, non-Hodgkin, NOS 18 6.8 15 7.79590 Malignant lymphoma, NOS 13 4.9 13 6.79699 Marginal zone B-cell lymphoma, NOS 14 5.3 6 3.19698 Follicular lymphoma, grade 3 10 3.8 8 4.19675 Malignant lymphoma, mixed small and large cell, diffuse 10 3.8 5 2.69690 Follicular lymphoma, NOS 9 3.4 5 2.69670 Malignant lymphoma, small B lymphocytic, NOS 8 3.0 5 2.69714 Anaplastic large cell lymphoma, T cell and Null cell type 2 0.8 10 5.29695 Follicular lymphoma, grade 1 7 2.6 4 2.19691 Follicular lymphoma, grade 2 5 1.9 4 2.1

All Others 50 18.9 21 10.8Thyroid 8260 Papillary adenocarcinoma, NOS 50 60.2 200 59.7

8340 Papillary carcinoma, follicular variant 11 13.3 52 15.58341 Papillary microcarcinoma 6 7.2 30 9.08343 Papillary carcinoma, encapsulated 0 0.0 14 4.28050 Papillary carcinoma, NOS 3 3.6 7 2.18021 Carcinoma, anaplastic, NOS 3 3.6 6 1.88330 Follicular adenocarcinoma, NOS 1 1.2 7 2.18290 Oxyphilic adenocarcinoma 3 3.6 4 1.28510 Medullary carcinoma, NOS 3 3.6 4 1.2

All Others 3 3.6 11 3.3Liver 8170 Hepatocellular carcinoma, NOS 213 86.9 79 73.8

8160 Cholangiocarcinoma 7 2.9 13 12.18000 Neoplasm, malignant 6 2.4 2 1.98010 Carcinoma, NOS 3 1.2 2 1.98162 Klatskin tumor 3 1.2 2 1.98190 Trabecular adenocarcinoma 5 2.0 0 0.0

All Others 7 3.3 9 8.4Skin 8090 Basal cell carcinoma, NOS 83 53.2 53 47.3

8070 Squamous cell carcinoma, NOS 33 21.2 25 22.38071 Squamous cell carcinoma, keratinizing, NOS 10 6.4 7 6.38832 Dermatofibrosarcoma, NOS 6 3.8 7 6.38051 Verrucous carcinoma, NOS 4 2.6 3 2.78091 Multifocal superficial basal cell carcinoma 3 1.9 2 1.88094 Basosquamous carcinoma 3 1.9 2 1.88097 Basal cell carcinoma, nodular 3 1.9 2 1.88410 Sebaceous adenocarcinoma 1 0.6 4 3.68000 Neoplasm, malignant 1 0.6 3 2.7

All Others 8 5.8 4 3.6Leukemia 9863 Chronic myeloid leukemia, NOS 18 12.4 25 22.3

9835 Precursor cell lymphoblastic leukemia, NOS 25 17.2 9 8.09823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 21 14.5 8 7.19836 Precursor B-cell lymphoblastic leukemia 14 9.7 10 8.99861 Acute myeloid leukemia, NOS 7 4.8 13 11.69891 Acute monocytic leukemia 6 4.1 13 11.69866 Acute promyelocytic leukemia, t(15;17)(q22;q11-12) 8 5.5 8 7.19867 Acute myelomonocytic leukemia 5 3.4 9 8.09837 Precursor T-cell lymphoblastic leukemia 8 5.5 1 0.99874 Acute myeloid leukemia with maturation 5 3.4 4 3.6

All Others 27 19.3 12 10.7

Table 2.5 Number and Proportion of Morphological Types for the Most Common Types of Cancer among Saudi Adults, 2003

Part002.indd 22 18-08-2007 11:55:14 AM

23

Primary Site Code Morphology Male % Female %Stomach 8140 Adenocarcinoma, NOS 81 47.4 34 45.9

8490 Signet ring cell carcinoma 39 22.8 21 28.48144 Adenocarcinoma, intestinal type 12 7.0 3 4.18145 Carcinoma, diffuse type 12 7.0 1 1.48010 Carcinoma, NOS 4 2.3 4 5.48480 Mucinous adenocarcinoma 6 3.5 1 1.48936 Gastrointestinal stromal sarcoma 4 2.3 1 1.4

All Others 13 7.6 9 12.2Lung 8070 Squamous cell carcinoma, NOS 51 27.9 10 16.9

8140 Adenocarcinoma, NOS 36 19.7 19 32.28041 Small cell carcinoma, NOS 29 15.8 3 5.18010 Carcinoma, NOS 14 7.7 3 5.18046 Non-small cell carcinoma 12 6.6 1 1.78012 Large cell carcinoma, NOS 7 3.8 1 1.78250 Bronchiolo-alveolar adenocarcinoma, NOS 3 1.6 4 6.88071 Squamous cell carcinoma, keratinizing, NOS 5 2.7 0 0.0

All Others 26 14.2 18 30.5Bladder 8120 Transitional cell carcinoma, NOS 65 39.2 20 50.0

8130 Papillary transitional cell carcinoma 68 41.0 11 27.58070 Squamous cell carcinoma, NOS 10 6.0 3.00 7.58120 Transitional cell carcinoma in situ 11 6.6 - 0.08071 Squamous cell carcinoma, keratinizing, NOS 4 2.4 1.00 2.5

All Others 8 4.8 5.00 12.5Hodgkins 9663 Hodgkin lymphoma, nodular sclerosis, NOS 32 34.0 49 57.6Disease 9652 Hodgkin lymphoma, mixed cellularity, NOS 16 17.0 14 16.5

9667 Hodgkin lymphoma, nodular sclerosis, grade 2 13 13.8 5 5.99650 Hodgkin lymphoma, NOS 8 8.5 7 8.29665 Hodgkin lymphoma, nodular sclerosis, grade 1 8 8.5 5 5.99651 Hodgkin lymphoma, lymphocyte-rich 7 7.4 2 2.49659 Hodgkin lymphoma, nodular lymphocyte predominance 8 8.5 1 1.2

All Others 2 2.1 2 2.4Prostate 8140 Adenocarcinoma, NOS 166 93.8 - -

8010 Carcinoma, NOS 6 3.4 - -8000 Neoplasm, malignant 3 1.7 - -8070 Squamous cell carcinoma, NOS 1 0.6 - -8120 Transitional cell carcinoma, NOS 1 0.6 - -

Corpus Uteri 8380 Endometrioid adenocarcinoma, NOS - - 58 51.88140 Adenocarcinoma, NOS - - 23 20.58260 Papillary adenocarcinoma, NOS - - 4 3.68950 Mullerian mixed tumor - - 4 3.68890 Leiomyosarcoma, NOS - - 3 2.78930 Endometrial stromal sarcoma, NOS - - 3 2.7

All Others - - 17 15.2Ovary 8460 Papillary serous cystadenocarcinoma - - 24 23.3

8140 Adenocarcinoma, NOS - - 13 12.68480 Mucinous adenocarcinoma - - 9 8.78441 Serous cystadenocarcinoma, NOS - - 8 7.88461 Serous surface papillary carcinoma - - 8 7.89060 Dysgerminoma - - 6 5.88470 Mucinous cystadenocarcinoma, NOS - - 5 4.99080 Teratoma, malignant, NOS - - 5 4.98010 Carcinoma, NOS - - 4 3.98440 Cystadenocarcinoma, NOS - - 3 2.9

All Others - - 18 17.5Cervix uteri 8070 Squamous cell carcinoma, NOS - - 30 34.5

8072 Squamous cell carcinoma, large cell, nonkeratinizing, NOS - - 23 26.48071 Squamous cell carcinoma, keratinizing, NOS - - 12 13.88140 Adenocarcinoma, NOS - - 8 9.28560 Adenosquamous carcinoma - - 3 3.4

All Others 11 12.6

Table 2.5 continued .....

Part002.indd 23 18-08-2007 11:55:15 AM

24


The total incident cases reported among children (0-14 years) between January and December 2003 were 668. This represents 7.6 % of the total number of cancers in Saudi Arabia. The reported incidents show that cancer was more common among boys than girls. 379 (56.7%) cases were reported among boys and 289 (43.3%) among girls, with a male to female ratio of 131:100. Of all the

cases reported there were 533 Saudis, 104 non-Saudis and 31 of “unknown nationality”. Based on table 2-6, the total number of cases analyzed was 632 including 528 (83.5%) Saudis and 104 (16.5%) non-Saudis. Among Saudis, 298(56.4%) were male and 230 (43.6%) were female. The male to female ratio among s Saudis was 129:100.

Figure 2.7 Ten Most Common Cancers among Saudi Children by Sex, 2003

Childhood cancer is very important, not only because of the age of occurrence, but also because 41.7% of the Saudi population is under 15 years of age. In addition to this, recent years have shown a breakthrough for the cure of many childhood cancers. Childhood cancers accounted for 8.1% of all cancer among Saudis.

The leading cancer among Saudi children was leukemia, which accounted for 31.4%, followed by Brain (CNS) then Hodgkins disease and NHL. Figure 2-7 shows the top ten sites by sex and frequency, and table 2-7 shows the number and proportion of the morphological types for the most common types of cancer.

Saudis Non-Saudis Unknown Nationality All


Total 301 232 533 58 46 104 20 11 31 668

Invasive 300 232 532 58 46 104 20 11 31 667

In-Situ 1 0 1 0 0 0 0 0 0 1

ICD 10* 2 2 4 0 0 0 0 1 1 5

Analyzed** 298 230 528 58 46 104 20 10 30 632

94

45

44

38

14

13

11

10

7

5

5

31.5%

15.1%

14.8%

12.8%

4.7%

4.4%

3.7%

3.4%

2.3%

1.7%

1.7%

Leukemia

Hodgkin disease


NHL

Eye


Kidney

Adrenal gland

Bone

Liver

Testis

298Boys 230GirlsLeukemia


NHL

Hodgkin disease

Bone


Kidney

Eye

Adrenal gland

Other Thoracic organs

Ovary

Thyroid

72

29

24

18

15

15

10

10

8

6

6

6

31.3%

12.6%

10.4%

7.8%

6.5%

6.5%

4.3%

4.3%

3.5%

2.6%

2.6%

2.6%

Table 2.6 Distribution of Reported Childhood Cancer Cases in Saudi Arabia by Nationality and Sex, 2003

Childhood Cancers in Saudi Arabia, 2003 (≤ 14 years)

Part002.indd 24 18-08-2007 11:55:15 AM

25

Table 2.7 Number and Proportion of Morphological Types for the Most Common Types of Cancer among Saudi Children, 2003

Primary Site Code Morphology Male % Female %Leukemia 9836 Precursor B-cell lymphoblastic leukemia 41 43.6 30 41.7

9835 Precursor cell lymphoblastic leukemia, NOS 27 28.7 21 29.29837 Precursor T-cell lymphoblastic leukemia 8 8.5 3 4.29861 Acute myeloid leukemia, NOS 4 4.3 6 8.39805 Acute biphenotypic leukemia 2 2.1 2 2.89867 Acute myelomonocytic leukemia 2 2.1 1 1.49872 Acute myeloid leukemia, minimal differentiation 1 1.1 2 2.8

All Others 9 9.6 7 9.7Brain 9470 Medulloblastoma, NOS 14 31.8 12 41.4

9380 Glioma, malignant 9 20.5 3 10.39400 Astrocytoma, NOS 3 6.8 3 10.39391 Ependymoma, NOS 2 4.5 3 10.39500 Neuroblastoma, NOS 3 6.8 1 3.48963 Malignant rhabdoid tumor 2 4.5 1 3.4

All Others 11 25.0 6 20.7Hodgkins Disease 9663 Hodgkin lymphoma, nodular sclerosis, NOS 25 55.6 10 55.6

9652 Hodgkin lymphoma, mixed cellularity, NOS 5 11.1 2 11.19665 Hodgkin lymphoma, nodular sclerosis, grade 1 6 13.3 0 0.09651 Hodgkin lymphoma, lymphocyte-rich 4 8.9 1 5.69659 Hodgkin lymphoma, nodular lymphocyte predominance 4 8.9 1 5.69664 Hodgkin lymphoma, nodular sclerosis, cellular phase 1 2.2 1 5.6

All Others 0 0.0 3 16.7NHL 9687 Burkitt lymphoma, NOS 20 52.6 10 41.7

9680 Malignant lymphoma, large B-cell, diffuse, NOS 4 10.5 1 4.29729 Precursor T-cell lymphoblastic lymphoma 1 2.6 4 16.79590 Malignant lymphoma, NOS 2 5.3 2 8.39591 Malignant lymphoma, non-Hodgkin, NOS 3 7.9 1 4.29714 Anaplastic large cell lymphoma, T cell and Null cell type 3 7.9 1 4.29727 Precursor cell lymphoblastic lymphoma, NOS 1 2.6 2 8.3

All Others 4 10.5 3 12.5Connective tissue 9500 Neuroblastoma, NOS 3 23.1 6 40.0

8910 Embryonal rhabdomyosarcoma, NOS 2 15.4 2 13.38920 Alveolar rhabdomyosarcoma 2 15.4 0 0.08900 Rhabdomyosarcoma, NOS 1 7.7 1 6.79490 Ganglioneuroblastoma 0 0.0 2 13.3

All Others 5 38.5 3 26.7Eye 9512 Retinoblastoma, undifferentiated 8 57.1 7 70.0

9510 Retinoblastoma, NOS 5 35.7 2 20.08070 Squamous cell carcinoma, NOS 1 7.1 0 0.09513 Retinoblastoma, diffuse 0 0.0 1 10.0

Bone 9180 Osteosarcoma, NOS 2 28.6 7 46.79260 Ewing sarcoma 2 28.6 7 46.79181 Chondroblastic osteosarcoma 2 28.6 1 6.79473 Primitive neuroectodermal tumor, NOS 1 14.3 0 0.0

Kidney 8960 Nephroblastoma, NOS 11 100.0 9 90.08963 Malignant rhabdoid tumor 0 0.0 1 10.0

Adrenal gland 9500 Neuroblastoma, NOS 8 80.0 5 62.58370 Adrenal cortical carcinoma 1 10.0 2 25.09490 Ganglioneuroblastoma 1 10.0 1 12.5

Liver 8970 Hepatoblastoma 2 40.0 2 100.08170 Hepatocellular carcinoma, NOS 2 40.0 0 0.08910 Embryonal rhabdomyosarcoma, NOS 1 20.0 0 0.0

Thyroid 8260 Papillary adenocarcinoma, NOS 1 100.0 4 66.78330 Follicular adenocarcinoma, NOS 0 0.0 1 16.78340 Papillary carcinoma, follicular variant 0 0.0 1 16.7

Other Thoracic Organs 8002 Malignant tumor, small cell type - - 1 16.78581 Thymoma, type A, malignant - - 1 16.79490 Ganglioneuroblastoma - - 1 16.79500 Neuroblastoma, NOS - - 3 50.0

Ovary 9071 Yolk sac tumor - - 2 33.39085 Mixed germ cell tumor - - 4 66.7

Testis 8910 Embryonal rhabdomyosarcoma, NOS 1 20.0 - -9071 Yolk sac tumor 4 80.0 - -

Part002.indd 25 18-08-2007 11:55:15 AM

26

Figure 2.8.2 Najran Region, 2003 (Percentage Distribution)

Figure 2.8.1 Riyadh Region, 2003 (Percentage Distribution)

The following bar charts list the most common cancer sites in the 13 administrative regions of Saudi Arabia by sex. These sites are listed on the basis of the total number of cases for each site reported by permanent address (region) of the patient at the time of diagnosis. In most regions breast cancer was the leading cancer among women, while among men Colo-rectal, NHL, Liver and Leukemia

interchange. It is worth noting that the major regions such as Riyadh, Makkah and Eastern Province represent the majority of cases. This can be attributed to the increasing number of people seeking medical attention in these urbanized cities with modern hospital facilities but permanent addresses may not be documented in source records.

Cancer in the 13 Administrative Regions of the Kingdom

35.7

3.5

3.7

3.9

4.8

4.9

5.1

8.5

9.8

9.5

10.6

0 10 20 30 40

Other sites

Hodgkin disease

Skin

Stomach


Prostate

Bladder

Leukemia

NHL

Colo-rectal

Liver

Males (874)

29.2

3

3.7

3.9

4.1

5

5.5

6.5

7.3

14.7

17.1

0 10 20 30 40

Other sites


Hodgkin disease

Corpus Uteri

Skin

Liver

NHL

Leukemia

Colo-rectal

Thyroid

Breast

Females (894)

36.2

3.2

3.6

3.9

3.9

7.5

7.6

7.8

8.4

8.9

9

0 10 20 30 40

Other sites

Stomach

Hodgkin disease

Skin


Leukemia

NHL

Liver

Colo-rectal

Breast

Thyroid

All (1768)

16.34.14.14.14.14.14.1

6.16.16.1

8.210.210.2

12.2

0 10 20 30 40

Males (49)

20

4.4

4.4

4.4

6.7

6.7

6.7

8.9

8.9

8.9

20

0 10 20 30 40

Other sites

Pancreas

Bone

Leukemia

Stomach

Colo-rectal

Skin

Breast

Cervix Uteri

NHL

ThyroidLiverNHL

StomachProstate

Hodgkin diseaseBladder

Skin

LeukemiaBrain, Nervous systemConnective, Soft tissue

MesotheliomaBone

Colo-rectalOther sites

Females (45)

23.14.34.34.34.34.34.34.35.36.47.48.59.69.6

0 10 20 30 40

Other sitesBone

BreastCervix Uteri

ProstateBladder

Hodgkin diseaseLeukemia

Colo-rectalSkinLiver

StomachThyroid

NHL

All (94)

Part002.indd 26 18-08-2007 11:55:16 AM

27

Figure 2.8.5 Northern Region, 2003 (Percentage Distribution)

Figure 2.8.4 Makkah Region, 2003 (Percentage Distribution)


Figure 2.8.3 Eastern Region, 2003 (Percentage Distribution)

29.63.54.24.44.85.15.76.2

8.499.59.6

0 10 20 30 40Males (547)

24.42.22.22.82.83.545.46.76.9

10.428.7

0 10 20 30 40

Females (578)

323.23.33.94.14.15.85.86.87.88.2

15

0 10 20 30 40

All (1125)

Colo-rectalLung

NHLProstate

Leukemia

BladderLiverSkin

StomachHodgkin disease

Brain, Nervous systemOther sites

BreastThyroid

Colo-rectalNHL

LeukemiaHodgkin disease

OvaryCorpus Uteri

LiverLung

Gallbladder etc.Other sites

Breast

Colo-rectalNHL

ThyroidLeukemia

LungHodgin disease

ProstateLiver

Stomach

Other sites

36.13.83.955.55.96.47.37.98.6

12.3

0 10 20 30 40

Males (794)

302.82.833.73.94.1

7.38.19.1

25.2

0 10 20 30 40

Females (777)

37.53.43.444.45.15.15.6

810.8

12.7

0 10 20 30 40

All (1571)

Colo-rectalLungNHL

LiverLeukemia

Prostate

StomachBladder

SkinBrain, Nervous system

Other sites

BreastColo-rectal

NHLThyroid

Corpus UteriOvary

LeukemiaSkin

Cervix UteriLiver

Other sites

BreastColo-rectal

NHLLung

LeukemiaLiver

ThyroidStomachBladder

SkinOther sites

24.7

6.3

6.3

6.3

6.3

6.3

9.4

9.4

9.4

15.6

0 10 20 30 40Males (32)

18.3

5.3

5.3

5.3

5.3

5.3

7.9

10.5

10.5

26.3

0 10 20 30 40

Other sites

Skin

Connective,Soft tissue

Corpus Uteri

Hodgkin disease

Leukemia

NHL

Colo-rectal

Thyroid

Breast

Other sites

Colo-rectal

Pancreas

Larynx

Mesothelioma

Hodgkin disease

Lung

Bladder

Leukemia

NHL

Other sites

Bladder

Lung

Thyroid

Hodgkin disease

Leukemia

Colo-rectal

NHL

Breast

Females (38)

38.6

4.3

4.3

5.7

5.7

7.1

8.6

11.4

14.3

0 10 20 30 40All (70)

Part002.indd 27 18-08-2007 11:55:18 AM

28

Figure 2.8.7 Jazan Region, 2003 (Percentage Distribution)

Figure 2.8.8 Hail Region, 2003 (Percentage Distribution)


Figure 2.8.6 Qassim Region, 2003 (Percentage Distribution)

29.7

3.7

3.7

3.7

3.7

4.9

4.9

5.6

6.2

8

8

8

9.9

0 10 20 30 40

Other sites

Nasopharynx

Oesophagus

Prostate

Thyroid


NHL

Skin

Liver

Stomach

Colo-rectal

Hodgkin disease

LeukemiaBreast

Breast

Colo-rectal

Leukemia

NHL

Hodgkin disease

Thyroid

Liver

Skin

Stomach


Other sites

Colo-rectalLeukemia

ThyroidNHLSkinLiver

Hodgkin diseaseBrain, Nervous system

Corpus UteriCervix Uteri

Connective, Soft tissueBone

Gallbladder etc.Oesophagus

Other sites

Males (162)

16.32.32.32.32.32.32.32.32.33.93.9

6.278.610.1

25.6

0 10 20 30 40

Females (129)

35.1

3.8

4.8

4.8

5.2

5.2

5.5

5.5

9.3

9.1

11.7

0 10 20 30 40

All (291)

25.3

4.1

4.1

4.1

4.9

5.7

6.6

7.4

7.4

8.2

10.7

11.5

0 10 20 30 40

Males (122)

28.6

3.2

3.2

3.2

3.2

3.2

3.2

5.3

6.4

6.4

16

18.1

0 10 20 30 40

Females (94)

35.3

3.7

4.6

4.6

5.1

5.1

6

6.9

6.9

9.3

12.5

All (216)

NHL

Bladder

Mouth

Leukemia

Liver

Skin

Stomach

Colo-rectal

Hodgkin disease

MouthMouth

NHL

Bladder

Breast

Skin

Liver

Tongue

Leukemia

Stomach

Hodgkin disease

Other sites

Breast

NHL

Tongue

Skin

Hodgkin disease

Thyroid

Bone

Gallbladder etc.

Stomach

Lip

Other sites

Prostate

Tongue

Other sites

21.5

3.8

3.8

3.8

3.8

3.8

3.8

3.8

5.8

5.8

7.7

9.6

11.5

11.5

0 10 20 30 40

Males (52)

29.7

3.1

3.1

4.7

4.7

4.7

7.8

7.8

7.8

12.5

14.1

0 10 20 30 40

Females (64)

37.1

4.3

4.3

4.3

5.2

6

6.2

6.9

6.9

8.6

9.5

0 10 20 30 40

All (116)

NHL Thyroid

Breast

Leukemia

Nasopharynx

Cervix Uteri

Colo-rectal

Skin

Liver

Bladder

Stomach

Other sites

Thyroid

Leukemia

Breast

Stomach

Colo-rectal

NHL

Nasopharynx

Cervix Uteri

Skin

Liver

Other sites

StomachLeukemia

Hodgkin disease

Colo-rectal

Connective, Soft tissue


Thyroid

Kidney

SkinLung

Larynx

Liver

Other sites

Part002.indd 28 18-08-2007 11:55:20 AM

29

Figure 2.8.11 Asir Region, 2003 (Percentage Distribution)

Figure 2.8.10 Baha Region, 2003 (Percentage Distribution)

Figure 2.8.9 Madinah Region, 2003 (Percentage Distribution)


29

3.3

4.9

4.9

5.5

6

7.1

8.7

9.3

9.3

12

0 10 20 30 40

Males (183)

31.8

3.5

3.5

4.5

5.1

6.1

6.6

8.1

8.1

8.1

14.6

0 10 20 30 40

Females (198)

38.2

3.7

3.7

4.2

4.5

5.8

5.8

7.6

7.9

8.4

10.2

0 10 20 30 40

All (381)

Colo-rectal

NHL

Skin

Leukemia

Liver

Bladder

Stomach

Hodgkin disease

Lung


Other sites

Breast

Colo-rectal

Leukemia


Thyroid

NHL

Ovary

Oesophagus

Cervix Uteri

Nasopharynx

Other sites

Colo-rectal

Leukemia

Breast

NHL


Skin

Liver

Thyroid

Hodgkin disease

Stomach

Other sites

25.93.43.4

5.25.25.25.2

6.98.68.6

10.312.1

0 10 20 30 40Males (58)

16.73.33.33.35556.76.78.31011.7

15

0 10 20 30 40Females (60)

24.73.43.43.43.43.44.24.24.25.15.15.15.95.97.6

11

0 10 20 30 40

All (118)

NHLStomach

ProstateSkin

Colo-rectalLeukemia

Hodgkin diseaseBladder

Liver

LungTongue

Other sites

Colo-rectalBreast

ThyroidCervix Uteri

Corpus UteriPancreasLeukemia

OvaryConnective, Soft tissue

NHLBrain, Nervous system

Other sitesLung

Colo-rectalNHL

ThyroidBreast

LeukemiaSkin

StomachProstate

Cervix UteriPancreas

Hodgkin disease

Corpus UteriConnective, Soft tissue

LungOther sites

Bladder

34

4.2

4.6

5

5

5.4

6.3

7.1

7.5

9.2

11.7

0 10 20 30 40

Males (240)

32.6

3.1

3.5

4

5.3

5.7

6.2

6.6

10.1

11

11.9

0 10 20 30

Females (227)

38.33.6

3.6

4.9

5.1

5.8

6

6.6

7.5

7.7

10.9

0 10 20 30 40

All (467)

NHL

Colo-rectal

Stomach

Skin

Liver

Leukemia

Lung

Nasopharynx

Thyroid

Prostate

Other sites

BreastThyroid

NHL

Leukemia

SkinColo-rectal

Ovary

Hodgkin disease

Liver

Corpus UteriOther sites

NHL

ThyroidColo-rectal

SkinLeukemia

Breast

Stomach

Liver

Hodgkin disease

Lung

Other sites

Part002.indd 29 18-08-2007 11:55:22 AM

30

Figure 2.8.12 Tabuk Region, 2003 (Percentage Distribution)

Figure 2.8.13 Jouf Region, 2003 (Percentage Distribution)


33.13.14.14.16.1

8.29.210.210.210.2

0 10 20 30 40

Males (98)

25.23.83.83.83.85.15.16.36.37.6

12.716.5

0 10 20 30 40

Females (79)

32.23.43.44.04.55.66.87.37.97.98.58.5

0 10 20 30 40

All (177)

Leukemia

NHLHodgkin disease

Liver

Colo-rectal

Brain, Nervous systemBladder

Nasopharynx

Skin

Oesophagus

Other sites

BreastThyroid

Colo-rectal

Leukemia

Leukemia

NHLBreast

Colo-rectalHodgkin disease

ThyroidLiver


SkinOesophagus

Nasopharynx

Other sites

NHLCorpus Uteri

SkinHodgkin disease

Connective, Soft tissueOesophagus

TongueOther sites

27

6.1

6.1

6.1

6.1

6.1

6.1

6.1

9.1

9.1

12.1

0 10 20 30 40Males (33)

23.8

3.7

3.7

5.6

5.6

7.5

7.4

11.1

11.2

20.4

0 10 20 30 40Females (54)

38.1

3.4

4.6

4.6

4.6

5.7

5.7

9.2

10.3

13.8

0 10 20 30 40

All (87)

Prostate Breast Breast

Leukemia

Thyroid

NHL

Colo-rectal

Prostate

Corpus Uteri

Liver

Cervix Uteri

Other sites

Leukemia

Thyroid

Corpus Uteri

Colo-rectal

NHL

Cervix Uteri

Ovary

Connective, Soft tissue

Other sites

Leukemia

Liver

Multiple Myeloma

NHL

Thyroid


Testis

Skin

Melanoma of Skin

Other sites

Part002.indd 30 18-08-2007 11:55:22 AM

31

Worldwide, it is estimated that around 11 million people developed cancer in 2002. Of these, 53.7% were in developing countries and 46.5% were in developed countries. According to 2002 estimates, the most common cancer site among all men was lung cancer. However; in developed countries prostate was the leading cancer followed by lung,

Figure 2.9.A Comparison of ASR* for Saudi Males with Selected Countries**

Figure 2.9.B Comparison of ASR* for Saudi Females with Selected Countries**

* ASR Per 100,000 ** Source for this information is summarized on page 64

colo-rectal, and stomach. While in developing countries, lung cancer was first followed by stomach, liver, esophagus and colo-rectal cancers. Among women, breast cancer was the most common followed by colo-rectal, lung and corpus uteri cancers in developed countries. While in the developing countries breast cancer was followed by cancers of the cervix, stomach and lung.

International Comparison of Age-Standardized Incidence Rates

66.381.985.496.4107.2

136.7142.3154.2165.2

271.7366.3

395.5403.6

487.7

0 50 100 150 200 250 300 350 400 450 500 550

Saudi ArabiaUnited Arab Emirates

OmanLibya

PolandKuwait

BahrainMalaysia

QatarNorway

WalesCroatia

United States (All Races)Slovenia

68.770.1

99.1121.1132.6134.3

157.0158.7

201.3328.0

447.1456.3

514.2541.8

0 50 100 150 200 250 300 350 400 450 500 550

Saudi Arabia

United Arab Emirates

Oman

Libya

Kuwait

Malaysia

Qatar

Bahrain

Poland

Norway

Croatia

Wales

Slovenia

United States (All Races)

Part002.indd 31 18-08-2007 11:55:22 AM

32

Part002.indd 32 18-08-2007 11:55:23 AM

PART IIICANCER INCIDENCE FOR MOST COMMON SITES

2003

Part003.indd 33 18-08-2007 12:42:59 PM

34

Part003.indd 34 18-08-2007 12:43:00 PM

35

In this section, the incidence of the most common cancers among Saudi males and females are outlined in accordance to their

Table 3.1 Most Common Cancers among Saudis, 2003

relative frequencies. The relevant data incorporate details for all patients presented over the period of January through December 2003.

Cancer Incidence for Most Common Sites, 2003

Cancer Male Female All % Breast 16 676 692 10.6 Colo-rectal 317 249 566 8.7 Non-Hodgkin Lymphoma 303 218 521 8.0 Thyroid 85 343 428 6.6 Leukemia 239 184 423 6.5 Liver 251 109 360 5.5 Skin 158 113 271 4.2 Stomach 173 75 248 3.8 Hodgkin disease 139 104 243 3.7 Lung 183 59 242 3.7 Bladder 168 42 210 3.2 Prostate 178 - 178 2.7 Corpus Uteri - 112 112 1.7 Ovary - 109 109 1.7 Others 1117 924 1913 29.4 Total 3327 3317 6516 100

Part003.indd 35 18-08-2007 12:43:01 PM

36

Figure 3.1.2 Stage Distribution of Female Breast Cancer, 2003

Figure 3.1.1 Age-Specific Incidence Rate (AIR) for Female Breast Cancer in Saudi Arabia, 2003

Table 3.1.1 Morphological Distribution of Female Breast Cancer in Saudi Arabia, 2003

There were 676 female breast cancer cases for year 2003. Breast cancer ranked first amongfemales accounting for 20.8% of all newly diagnosed female cancers (3,253). The ASR was 13.9/100,000 for female population. The five regions with the

highest ASR were Eastern region at 27.6/100,000, Makkah region at 19.1/100,000, Riyadh region at 16.2/100,000, Northern region at 15.5/100,000 and Jouf region at 14.6/100,000. The mean age at diagnosis was 48 years (Range 19-98 years).

Female Breast (C 50)

05101520253035404550

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

AIR

(per

100

,000

)

Age Groups

female

ICD-O Code Morphology Total %

8500 Infiltrating duct carcinoma, NOS 518 76.6%

8520 Lobular carcinoma, NOS 33 4.9%

8010 Carcinoma, NOS 20 3.0%

8523 Infiltrating duct mixed with other types of carcinoma 17 2.5%

8522 Infiltrating duct and lobular carcinoma 14 2.1%

8140 Adenocarcinoma, NOS 13 1.9%

8510 Medullary carcinoma, NOS 12 1.8%

8541 Paget disease and infiltrating duct carcinoma of breast 10 1.5%

8521 Infiltrating ductular carcinoma 7 1.0%

All Others 32 4.7%

15.5%

22.8%

50.0%

11.7%

Distant

Localised

Regional

Unknown

Part003.indd 36 18-08-2007 12:43:02 PM

37

Figure 3.1.4 Comparison of ASR* for Female Breast Cancer among Saudi Females with ASR in Selected Countries**

Figure 3.1.3 ASR* Regional Distribution of Female Breast Cancer in Saudi Arabia, 2003


4.7

5.8

6.0

6.6

6.6

10.6

13.0

14.0

14.6

15.5

16.2

19.1

27.6

0 5 10 15 20 25 30

Jazan

Najran

Hail

Asir

Baha

Madinah

Qassim

Tabuk

Jouf

Northern

Riyadh

Makkah

Eastern

8.613.915.816.8

22.924.9

44.046.247.151.3

76.089.7

106.2118.0119.0120.8

0 20 40 60 80 100 120 140

WalesUnited States (All Races)

ScotlandSloveniaSwedenNorwayBahrain

QatarMalaysia

KuwaitUnited Arab Emirates

LibyaGreeceOman

Saudi ArabiaJapan

Part003.indd 37 18-08-2007 12:43:03 PM

38

Figure 3.2.1 Age-Specific Incidence Rate (AIR) for Colo-rectal Cancer in Saudi Arabia, 2003

Table 3.2.1 Morphological Distribution of Colo-rectal Cancer in Saudi Arabia, 2003

Figure 3.2.2 Stage Distribution of Colo-rectal Cancer, 2003

There were 566 cases of colo-rectal cancer accounting for 8.7% of all newly diagnosed cases in year 2003. This cancer ranked first among malepopulation and third among female population. It affected 317 (56%) males and 249 (44.%) females with a male to female ratio of 126:100. The overall ASR was 6.6/100,000. ASR for males was 7.3/100,000 and for females 5.9/100,000.

The five regions with the highest ASR wereNorthern region at 9.5/100,000, Riyadh region at 9.3/100,000, Eastern region at 9.2/100,000, Makkah region at 8.9/100,000 and Tabuk region at 7/100,000. The mean age at diagnosis was 57 years among males (range 11-90 years) and 57 years among females (range 22-99 years).

Colo-rectal (C18-C20)

21.5%

28.4%38.8%

11.4%

Male

21.0%

28.8%38.5%

11.7%

All

20.5%

29.3%38.2%

12.0%

Female

Distant

Localised

Regional

Unknown

ICD-O-3 Code Morphology Male

%

Female %

8140 Adenocarcinoma, NOS 227 40%

181 32%

8480 Mucinous adenocarcinoma 31 5.5% 21 3.7%

8490 Signet ring cell carcinoma 11 1.9% 8 1.4%

8261 Adenocarcinoma in villous adenoma 10 1.8% 5 0.9%

8281 Mucin-producing adenocarcinoma 6 1.1% 9 1.6%

8263 Adenocarcinoma in tubulovillous adenoma 9 1.6% 4 0.7%

8210 Adenocarcinoma in adenomatous polyp 6 1.1% 3 0.5%

8010 Carcinoma, NOS 2 0.4% 4 0.7%

All Others 15 2.7% 14 2.5%

05101520253035404550

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+

AIR

(per

100

,000

)

Age Groups

male female

Part003.indd 38 18-08-2007 12:43:04 PM

39

Figure 3.2.4 Comparison of ASR* for Colo-rectal Cancer among Saudis with ASR in Selected Countries**

Figure 3.2.3 ASR* Regional Distribution of Colo-rectal Cancer in Saudi Arabia, 2003

1.8

2.6

5.54.7

7.4

6.2

2.8

6.4

10.2

9.9

10.4

4.9

0.3

2.1

5.1

2.9

5.5

6.0

7.2

10.8

7.5

7.6

8.4

8.2

14.0

0 5 10 15

Jazan

Hail

Najran

Asir

Baha

Madinah

Qassim

Jouf

Tabuk

Makkah

Eastern

Riyadh

Northern

Female

Male

5.8

6.9

7.3

11.6

14.7

15.0

21.2

31.7

41.8

35.9

60.4

69.9

6.3

5.3

5.9

8.8

10.0

14.5

17.4

7.7

34.4

60.8

44.2

52.0

0 10 20 30 40 50 60 70 80


Oman

Saudi Arabia

Libya

Bahrain

Kuwait

Malaysia

Qatar

Norway

Wales


Slovenia

FemaleMale


Part003.indd 39 18-08-2007 12:43:06 PM

40

Figure 3.3.1 Age-Specific Incidence Rate (AIR) for NHL in Saudi Arabia, 2003

Table 3.3.1 Morphological Distribution of NHL in Saudi Arabia, 2003

There were 521 cases of Non-Hodgkin Lymphoma accounting for 8% of all newly diagnosed cancers in year 2003. This cancer ranked second among male population and fourth among female population. It affected 303(51.7%) males and 218(37.3%) females with a male to female ratio of 139:100. The overall ASR was 5.2/100,000. ASR for males was 5.9/100,000 and 4.5/100,000 for females.

The five regions with the highest ASR wereNorthern region at 12.3/100,000, Eastern region at 7.3/100,000, Riyadh region at 7.3/100,000, Makkah region at 6.1/100,000 and Asir regions at 5.3/100,000 each. The mean age at diagnosis was 49 years among males (range 2-95 years) and 49 years among females (range 1-93 years).

Non-Hodgkin Lymphoma (C82-C85; C96)

0

5

10

15

20

25

30

35

40

45

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male female

AIR

(per

100

,000

)

ICD-0-3 Code Morphology Male

%

Female %

9680 Malignant lymphoma, large B-cell, diffuse, NOS 123 23.6% 99 19.0%

9591 Malignant lymphoma, non-Hodgkin, NOS 21 4.0% 16 3.1%

9687 Burkitt lymphoma, NOS 26 5.0% 11 2.1%

9590 Malignant lymphoma, NOS 15 2.9% 15 2.9%

9699 Marginal zone B-cell lymphoma, NOS 14 2.7% 6 1.2%

9698 Follicular lymphoma, grade 3 10 1.9% 8 1.5%

9675 Malignant lymphoma, mixed small and large cell, diffuse 11 2.1% 5 1.0%

9714 Anaplastic large cell lymphoma, T cell and Null cell type 5 1.0% 11 2.1%

9670 Malignant lymphoma, small B lymphocytic, NOS 9 1.7% 5 1.0%

9690 Follicular lymphoma, NOS 9 1.7% 5 1.0%


9729 Precursor T-cell lymphoblastic lymphoma 4 0.8% 6 1.2%


9702 Mature T-cell lymphoma, NOS 8 1.5% 1 0.2%

9709 Cutaneous T-cell lymphoma, NOS 7 1.3% 1 0.2%

9700 Mycosis fungoides 3 0.6% 4 0.8%

9596 Composite Hodgkin and non-Hodgkin lymphoma 4 0.8% 2 0.4%

9671 Malignant lymphoma, lymphoplasmacytic 3 0.6% 3 0.6%

9673 Mantle cell lymphoma 2 0.4% 3 0.6%

9727 Precursor cell lymphoblastic lymphoma, NOS 3 0.6% 2 0.4%

All Others 14 2.7% 7 1.3%

Part003.indd 40 18-08-2007 12:43:07 PM

41

Figure 3.3.3 ASR* Regional Distribution of NHL Cancer in Saudi Arabia, 2003

Figure 3.3.4 Comparison of ASR* for NHL Cancer among Saudis with ASR in Selected Countries**

Figure 3.3.2 Stage Distribution of NHL Cancer, 2003

42.9%

15.5%

21.1%

20.5%

Male

41.5%

15.2%

22.5%

20.9%

All

39.4%

14.7%

24.3%

21.6%

Female

Distant

Localised

Regional

Unknown

3.3

3.62.7

6.0

4.7

4.0

2.8

6.5

5.5

5.6

8.8

7.911.1

0.8

1.7

3.6

1.5

3.35.1

6.5

3.6

5.06.5

5.7

6.613.5

0 2 4 6 8 10 12 14 16

Hail

Jazan

Jouf

Baha

Madinah

Qassim

Najran

Tabuk

Asir

Makkah

Riyadh

Eastern

Northern

Female

Male

5.95.3

8.85.8

7.7

11.49.5

11.3

16.3

16.714.0

22.2

4.5

5.4

3.77.3

9.1

5.9

9.2

7.9

11.2

11.517.4

15.8

0 5 10 15 20 25

Saudi Arabia

Libya

Bahrain


Qatar

Oman

Kuwait

Norway

Scotland

Wales

Slovenia


Female

Male


Part003.indd 41 18-08-2007 12:43:08 PM

42

There were 428 cases of thyroid cancer for year 2003. This cancer ranked second among female population and eleventh among male population. It affected 85 (19.9%) males and 343 (80.1%) females with a male to female ratio of 25:100. The over all ASR was 3.7/100,000. ASR was 1.7/100,000 for males and 5.7 /100,000 for females.

Figure 3.4.2 Stage Distribution of Thyroid Cancer, 2003

The five regions with the highest ASR wereRiyadh region at 6.4/100,000, Jouf region at 6.3/100,000, Najran region at 4.5/100,000, Eastern region at 4.5 /100,000 and Asir region at 3.9/100,000. The mean age at diagnosis was 50 years among males (range 21-80 years) and 39 years among females (range 11-91 years).

Table 3.4.1 Morphological Distribution of Thyroid Cancer in Saudi Arabia, 2003

Figure 3.4.1 Age-Specific Incidence Rate (AIR) forThyroid Cancer in Saudi Arabia, 2003

Thyroid (C 73)

0

2

4

6

8

10

12

14

16

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male female

AIR

(per

100

,000

)


%

Female %

8260 Papillary adenocarcinoma, NOS 51 11.9% 205 47.9%

8340 Papillary carcinoma, follicular variant 11 2.6% 54 12.6%

8341 Papillary microcarcinoma 6 1.4% 30 7.0%

8343 Papillary carcinoma, encapsulated 0 0.0% 14 3.3%

8050 Papillary carcinoma, NOS 3 0.7% 7 1.6%

8021 Carcinoma, anaplastic, NOS 3 0.7% 6 1.4%

8330 Follicular adenocarcinoma, NOS 1 0.2% 8 1.9%

8290 Oxyphilic adenocarcinoma 3 0.7% 4 0.9%

8510 Medullary carcinoma, NOS 3 0.7% 4 0.9%

All Others 4 0.9% 11 2.3%

11.8%

32.9%

35.3%

20.0%

Male

7.9%

47.2%

26.9%

18.0%

All

7.0%

50.7%

24.8%

17.5%

Female

Distant

Localised

Regional

Unknown

Part003.indd 42 18-08-2007 12:43:10 PM

43

Figure 3.4.3 ASR* Regional Distribution of Thyroid Cancer in Saudi Arabia, 2003

Figure 3.4.4 Comparison of ASR* for Thyroid Cancer among Saudis with ASR in Selected Countries**

0.4

0.0

0.7

1.2

2.7

1.2

1.5

1.2

2.5

1.9

0.0

3.5

2.7

0.9

4.6

3.9

2.6

4.9

5.9

6.4

5.2

7.1

9.0

9.1

10.1

0 2 4 6 8 10 12

Jazan

Northern

Baha

Madinah

Qassim

Makkah

Tabuk

Hail

Asir

Eastern

Najran

Jouf

Riyadh

Female

Male

0.21.7

1.0

1.5

1.61.7

1.3

3.0

1.6

2.4

2.4

4.3

2.8

3.4

2.43.4

3.44.1

5.7

8.5

6.9

8.3

8.7

9.0

12.7

21.1

0 5 10 15 20 25

LibyaWales

SwedenScotlandNorway


OmanKuwait

BahrainSlovenia

United States (All Races)Qatar

Female

Male


Part003.indd 43 18-08-2007 12:43:11 PM

44

Figure 3.5.1 Age-Specific Incidence Rate (AIR) for Leukemia in Saudi Arabia, 2003

Table 3.5.1 Morphological Distribution of Leukemia in Saudi Arabia, 2003

There were 423 cases of leukemia accounting for 6.5% of all newly diagnosed cancers in year 2003. This cancer ranked fourth for males and fifthamong females and affected 239(56.5%) males and 184(43.5%) females with a male to female ratio of 130:100. The overall ASR was 3/100,000. ASR for males was 3.5/100,000 and 2.6/100,000 for females.

The five regions with the highest ASR were Riyadhregion at 4.7/100,000, Qassim region at 4.6/100,000, Tabuk region at 4.2/100,000, Jouf region at 3.9/100,000 and Eastern region at 3.8/100,000. The mean age at diagnosis is 27 years among males (range 0-98 years) and 27 years among females (range 0-91 years).

Leukemia (C91-C95)

0

2

4

6

8

10

12

14

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male female

AIR

(per

100

,000

)


%

Female %

9836 Precursor B-cell lymphoblastic leukemia 55 13.0% 40 9.5% 9835 Precursor cell lymphoblastic leukemia, NOS 52 12.3% 30 7.1% 9863 Chronic myeloid leukemia, NOS 18 4.3% 26 6.1% 9861 Acute myeloid leukemia, NOS 11 2.6% 19 4.5% 9823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 21 5.0% 8 1.9% 9837 Precursor T-cell lymphoblastic leukemia 16 3.8% 4 0.9% 9891 Acute monocytic leukemia 7 1.7% 13 3.1% 9867 Acute myelomonocytic leukemia 7 1.7% 10 2.4% 9866 Acute promyelocytic leukemia, t(15;17) (q22;q11-12) 8 1.9% 8 1.9% 9874 Acute myeloid leukemia with maturation 7 1.7% 4 0.9% 9871 Acute myeloid leukemia with abnormal marrow eosinophils 5 1.2% 1 0.2% 9872 Acute myeloid leukemia, minimal differentiation 3 0.7% 3 0.7% 9873 Acute myeloid leukemia without maturation 4 0.9% 1 0.2%

All Others 25 5.9% 17 4.0%

Part003.indd 44 18-08-2007 12:43:12 PM

45

Figure 3.5.3 Comparison of ASR* for Leukemia among Saudis with ASR in Selected Countries**

Figure 3.5.2 ASR* Regional Distribution of Leukemia in Saudi Arabia, 2003

1.9

2.4

1.6

2.4

3.1

3.1

3.4

4.3

3.5

3.7

6.6

5.1

5.0

0.2

0.9

2.2

2.2

1.6

1.8

1.9

2.9

4.1

4.0

1.8

4.0

4.3

0 1 2 3 4 5 6 7

Jazan

Najran

Northern

Asir

Makkah

Baha

Hail

Madinah

Eastern

Jouf

Tabuk

Qassim

Riyadh

Female

Male

3.5

3.5

6.1

4.0

6.1

7.0

9.3

8.2

10.3

14.8

14.9

2.6

3.8

1.6

4.6

4.6

5.0

6.0

9.0

7.1

8.3

9.1

0 2 4 6 8 10 12 14 16

Saudi Arabia

Libya

Bahrain


Qatar

Kuwait

Norway

Oman

Slovenia

Wales


Female

Male


Part003.indd 45 18-08-2007 12:43:12 PM

46

Figure 3.6.1 Age-Specific Incidence Rate (AIR) for Liver Cancer in Saudi Arabia, 2003

Figure 3.6.2 Stage Distribution of Liver Cancer, 2003

Table 3.6.1 Morphological Distribution of Liver Cancer in Saudi Arabia, 2003

There were 360 cases of liver cancer accounting for 5.5% of all newly diagnosed cases in year 2003. This cancer ranked third in males, and eighth in females and affected 251 (69.7%) males and 109 (30.7%) females with a male to female ratio of 227:100. The overall ASR was 4.5/100,000. ASR was 6.2/100,000 for males and 2.8/100,000 for females.

The five regions with the highest ASR were Riyadhregion at 9.4/100,000, Najran region at 6.4/100,000, Eastern region at 5.4/100,000, Tabuk region at 4.5/100,000 and Makkah region at 4.2/100,000. The mean age at diagnosis was 64 years in males (range 0-98 years) and 62 years in female (range 1-92 years).

Liver (C 22)

0

10

20

30

40

50

60

70

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male female

AIR

(per

100

,000

)

20.7%

25.1%

10.4%

43.8%

Male

20.8%

26.1%

12.5%

40.6%

All

21.1%

28.4%

17.4%

33.0%

Female

Distant

Localised

Regional

Unknown


%

Female %

8170 Hepatocellular carcinoma, NOS 216 60.0% 79 21.9%

8160 Cholangiocarcinoma 7 1.9% 13 3.6% 8000 Neoplasm, malignant 6 1.7% 2 0.6%

8010 Carcinoma, NOS 3 0.8% 2 0.6%

8162 Klatskin tumor 3 0.8% 2 0.6% 8190 Trabecular adenocarcinoma 5 1.4% 0 0.0%

8970 Hepatoblastoma 2 0.6% 2 0.6%

All Others 9 2.5% 9 2.5%

Part003.indd 46 18-08-2007 12:43:14 PM

47

Figure 3.6.4 Comparison of ASR* for Liver Cancer among Saudis with ASR in Selected Countries*

Figure 3.6.3 ASR* Regional Distribution of Liver Cancer in Saudi Arabia, 2003

2.4

3.0

1.8

3.7

1.6

4.6

4.5

5.3

6.1

8.1

6.4

10.0

12.0

0.0

0.7

2.3

1.8

4.0

1.6

2.4

2.9

2.3

0.8

4.3

2.7

6.7

0 2 4 6 8 10 12 14

Baha

Jazan

Northern

Asir

Hail

Madinah

Jouf

Qassim

Makkah

Tabuk

Eastern

Najran

Riyadh

Female

Male

1.9

1.1

3.3

5.5

5.8

4.2

5.8

6.2

5.5

8.2

8.1

21.6

0.8

1.8

3.1

2.1

2.2

4.3

2.7

2.8

3.5

3.0

5.4

5.1

0 5 10 15 20 25

Norway


Libya

Malaysia

Oman

Bahrain

Scotland

Saudi Arabia

Kuwait


Slovenia

Qatar

Female

Male


Part003.indd 47 18-08-2007 12:43:15 PM

48

Skin (Non-Melanoma) (C 44)

There were 271 cases of skin cancer accounting for 4.2% of all newly diagnosed cases in year 2003. This cancer ranked ninth for males and sixth for females. It affected 158(58.3%) males and 113(41.7%) females with a male to female ratio of 140:100. The overall ASR was 3.1/100,000. ASR was 3.6/100,000 for males and 2.6/100,000 for females.

Figure 3.7.2 Stage Distribution of Skin Cancer in Saudi Arabia, 2003

The five regions with the highest ASR wereNorthern region at 6.1/100,000, Najran region at 4.7/100,000, Riyadh region at 4.3/100,000, Madinah region at 4.1/100,000 and Eastern region at 3.8/100,000. The mean age at diagnosis was 64 years among males (range 7-98 years) and 62 years among female (range 1-97 years).

Figure 3.7.1 Age-Specific Incidence Rate (AIR) for Skin Cancer in Saudi Arabia, 2003

Table 3.7.1 Morphological Distribution of Skin Cancer in Saudi Arabia, 2003

0

5

10

15

20

25

30

35

40

45

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male female

AIR

(per

100

,000

)

ICD-O-3 Code Morphology

Male

% Female %

8090 Basal cell carcinoma, NOS 83 30.6% 53 19.6%

8070 Squamous cell carcinoma, NOS 33 12.2% 25 9.2%

8071 Squamous cell carcinoma, keratinizing, NOS 10 3.7% 7 2.6%

8832 Dermatofibrosarcoma, NOS 8 3.0% 8 3.0%

8051 Verrucous carcinoma, NOS 4 1.5% 3 1.1%

8091 Multifocal superficial basal cell carcinoma 3 1.1% 2 0.7%

8094 Basosquamous carcinoma 3 1.1% 2 0.7%

8097 Basal cell carcinoma, nodular 3 1.1% 2 0.7%

8410 Sebaceous adenocarcinoma 1 0.4% 4 1.5%

8000 Neoplasm, malignant 1 0.4% 3 1.1%

All Others 9 3.3% 4 1.5%

3.8%

51.3%

7.6%

37.3%

Male

3.0%

56.8%

7.0%

33.2%

All

1.8%

64.6%6.2%

27.4%

Female

Distant

Localised

Regional

Unknown

Part003.indd 48 18-08-2007 12:43:17 PM

49

Figure 3.7.4 Comparison of ASR* for Skin Cancer among Saudis with ASR in Selected Countries**

Figure 3.7.3 ASR* Regional Distribution of Skin Cancer in Saudi Arabia, 2003

1.0

1.7

3.6

4.4

3.2

3.9

5.2

2.0

5.1

6.2

3.6

5.7

0.0

2.2

1.7

0.5

0.0

2.3

2.9

2.2

5.4

2.4

1.9

5.0

3.6

12.2

0 2 4 6 8 10 12 14

Hail

Jazan

Baha

Jouf

Makkah

Asir

Qassim

Tabuk

Eastern

Madinah

Riyadh

Najran

Northern

Female

Male

1.0

3.5

4.6

3.6

4.3

6.4

5.9

11.6

13.3

22.374.6

1.8

1.4

1.5

2.6

2.5

1.5

4.5

3.0

8.2

14.4

81.8

0 10 20 30 40 50 60 70 80 90

Kuwait

Libya

Bahrain

Saudi Arabia

Oman


Malaysia

Qatar

Norway


Slovenia

Female

Male


Part003.indd 49 18-08-2007 12:43:18 PM

50

Table 3.8.1 Morphological Distribution of Stomach Cancer in Saudi Arabia, 2003

Figure 3.8.2 Stage Distribution of Stomach Cancer, 2003

There were 248 cases of stomach cancer accounting for 3.8% of all newly diagnosed cases in year 2003. This cancer ranked seventh among male population and thirteenth among female population. It affected 173 (69.8%) males and 75 (30.2%) females with a male to female ratio of 231:100. The overall ASR was 2.9/100,000. ASR was 4/100,000 for male and 1.8/100,000 for for females.

The five regions with the highest ASR were Najranregion at 5.8/100,000, Eastern region at 3.6/100,000, Makkah region at 3.5/100,000, Riyadh region at 3.5/100,000 and Qassim region at 3.2/100,000. The mean age at diagnosis was 64 years among males (range 4-103 years) and 60 years among female (range 0-83 years).

Figure 3.8.1 Age-Specific Incidence Rate (AIR) for Stomach Cancer in Saudi Arabia, 2003

Stomach (C 16)

05101520253035404550

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male female

AIR

(per

100

,000

)


%

Female %

8140 Adenocarcinoma, NOS 83 33.5% 34 13.7% 8490 Signet ring cell carcinoma 39 15.7% 22 8.9% 8144 Adenocarcinoma, intestinal type 12 4.8% 3 1.2% 8145 Carcinoma, diffuse type 12 4.8% 1 0.4% 8010 Carcinoma, NOS 4 1.6% 4 1.6% 8480 Mucinous adenocarcinoma 6 2.4% 1 0.4% 8936 Gastrointestinal stromal sarcoma 4 1.6% 1 0.4% 8481 Mucin-producing adenocarcinoma 3 1.2% 1 0.4% 8070 Squamous cell carcinoma, NOS 1 0.4% 2 0.8% 8211 Tubular adenocarcinoma 2 0.8% 1 0.4%

All Others 7 2.8% 5 2.0%

20.2%

24.3%

34.1%

21.4%

Male

22.2%

23.8%

33.1%

21.0%

All

26.7%

22.7%

30.7%

20.0%

Female

Distant

Localised

Regional

Unknown

Part003.indd 50 18-08-2007 12:43:20 PM

51

Figure 3.8.4 Comparison of ASR* for Stomach Cancer among Saudis with ASR in Selected Countries**

Figure 3.8.3 ASR* Regional Distribution of Stomach Cancer in Saudi Arabia, 2003

1.5

0.0

2.3

4.3

3.6

4.1

3.8

4.3

5.9

3.8

4.5

4.7

7.3

0.0

2.4

0.9

0.0

1.7

1.3

1.6

1.5

0.5

3.2

2.5

2.4

4.2

0 1 2 3 4 5 6 7 8

Tabuk

Jouf

Jazan

Baha

Northern

Asir

Madinah

Hail

Qassim

Riyadh

Makkah

Eastern

Najran

Female

Male

3.5

4.0

4.4

5.5

6.7

7.45.8

8.5

7.2

9.2

10.0

17.0

19.6

29.1

2.0

1.8

3.4

2.7

3.3

3.96.1

3.8

5.3

4.3

4.9

7.6

8.0

18.7

0 5 10 15 20 25 30 35

KuwaitSaudi Arabia

LibyaQatar

SwedenUnited Arab Emirates

BahrainNorway

MalaysiaOman

United States (All Races)Scotland

WalesSlovenia

Female

Male


Part003.indd 51 18-08-2007 12:43:21 PM

52

There were 243 cases of hodgkin disease cancer accounting for 3.7% of all newly diagnosed cases in year 2003. This cancer ranked tenth among male and female population. It affected 139 (57.2%) males and 104 (42.8%) females with a male to female ratio of 134:100. The overall ASR was 1.6/100,000. ASR was 1.8/100,000 for males and 1.4/100,000 for females.

The five regions with highest ASR were Easternregion at 2.4/100,000, Qassim region at 2.1/100,000, Riyadh region at 2.1/100,000, Tabuk region at 1.9/100,000 and Makkah region at 1.5/100,000. The mean age at diagnosis was 27 years (range 2-82 years) in males and 29 year in females (range 5-87).

Table 3.9.1 Morphological Distribution of Hodgkins disease in Saudi Arabia, 2003

Figure 3.9.2 Stage Distribution of Hodgkins disease, 2003

Figure 3.9.1 Age-Specific Incidence Rate (AIR) for Hodgkins disease in Saudi Arabia, 2003

Hodgkins disease (C 81)

0

1

2

3

4

5

6

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male female

AIR

(per

100

,000

)

ICD-0-3 Code Morphology Male

%

Female %

9663 Hodgkin lymphoma, nodular sclerosis, NOS 57 23.5% 60 24.7%

9652 Hodgkin lymphoma, mixed cellularity, NOS 21 8.6% 16 6.6%

9667 Hodgkin lymphoma, nodular sclerosis, grade 2 13 5.3% 7 2.9%

9665 Hodgkin lymphoma, nodular sclerosis, grade 1 14 5.8% 5 2.1%

9650 Hodgkin lymphoma, NOS 8 3.3% 8 3.3%

9651 Hodgkin lymphoma, lymphocyte-rich 11 4.5% 3 1.2%

9659 Hodgkin lymphoma, nodular lymphocyte predominance 12 4.9% 2 0.8%

9664 Hodgkin lymphoma, nodular sclerosis, cellular phase 1 0.4% 2 0.8%

All Others 2 0.8% 1 0.4%

26.6%

16.5%38.1%

18.7%

Male

28.4%

15.2%38.3%

18.1%

All

30.8%

13.5%38.5%

17.3%

Female

Distant

Localised

Regional

Unknown

Part003.indd 52 18-08-2007 12:43:23 PM

53

Figure 3.9.3 ASR* Regional Distribution of Hodgkins disease in Saudi Arabia, 2003

Figure 3.9.4 Comparison of ASR* for Hodgkins disease among Saudis with ASR in Selected Countries**

0.5

1.4

1.4

1.6

1.3

1.5

1.4

1.6

1.8

2.4

1.9

3.4

2.4

0.6

0.5

0.5

0.5

1

1

1.3

1.4

1.2

1.4

2.2

0.7

2.3

0 1 2 3 4

Jouf

Baha

Najran

Jazan

Hail

Madinah

Northern

Asir

Makkah

Tabuk

Riyadh

Qassim

Eastern

Female

Male

1.1

1.2

1.2

1.8

4.0

2.9

3.3

3.1

3.1

6.1

16.7

11.3

0.6

1.0

1.3

1.4

0.6

2.0

2.2

2.45.9

3.5

2.0

7.9

0 2 4 6 8 10 12 14 16 18


Libya

Bahrain

Saudi Arabia

Kuwait

Scotland

Slovenia


Oman

Qatar

Wales

Norway

Female

Male


Part003.indd 53 18-08-2007 12:43:24 PM

54

Figure 3.10.1 Age-Specific Incidence Rate (AIR) for Lung Cancer in Saudi Arabia, 2003

Table 3.10.1 Morphological Distribution of Lung Cancer in Saudi Arabia, 2003

There were 242 cases of lung cancer accounting for 3.7% of all diagnosed cases in year 2003. Lung cancer ranked fifth among male population andfifteenth among female population. It affected 183(75.6%) males and 59 (24.4%) females with a male to female ratio of 310:100. The overall ASR was 3.1/100,000. ASR was 4.7/100,000 for males and 1.4/100,000 for females.

The five regions with the highest ASR were Easternregion at 8.2/100,000, Makkah region at 4.9/100,000, Northern region at 3.7/100,000, Riyadh region at 3/100,000 and Madinah region at 2.6 /100,000. The mean age at diagnosis was 64 years among males (range 24-98 years) and 61 years among females (range 24-89 years).

Lung (C33-C34)

0

5

10

15

20

25

30

35

40

45

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male female

AIR

(per

100

,000

)

ICD-O-3 Code Morphology Male %

Female

%

8070 Squamous cell carcinoma, NOS 51 21.1% 10 4.1%

8140 Adenocarcinoma, NOS 36 14.9% 19 7.9%

8041 Small cell carcinoma, NOS 29 12.0% 3 1.2%

8010 Carcinoma, NOS 14 5.8% 3 1.2%

8046 Non-small cell carcinoma 12 5.0% 1 0.4%

8012 Large cell carcinoma, NOS 7 2.9% 1 0.4%

8250 Bronchiolo-alveolar adenocarcinoma, NOS 3 1.2% 4 1.7%

8071 Squamous cell carcinoma, keratinizing, NOS 5 2.1% 0 0.0%

8020 Carcinoma, undifferentiated, NOS 3 1.2% 1 0.4%

8240 Carcinoid tumor, NOS 0 0.0% 4 1.7%

8000 Neoplasm, malignant 1 0.4% 2 0.8%

8033 Pseudosarcomatous carcinoma 1 0.4% 2 0.8%

8249 A typical carcinoid tumor 1 0.4% 2 0.8%

8481 Mucin-producing adenocarcinoma 2 0.8% 1 0.4%

All Others 18 7.4% 6 2.5%

Part003.indd 54 18-08-2007 12:43:25 PM

55

Figure 3-10-2 Stage Distribution of Lung Cancer, 2003

Figure 3.10.4 Comparison of ASR* for Lung Cancer among Saudis with ASR in Selected Countries**

Figure 3.10.3 ASR* Regional Distribution of Lung Cancer in Saudi Arabia, 2003

55.7%

9.8%

13.7%

20.8%

Male

54.5%

13.6%

14.5%

17.4%

All

50.8%

25.4%

16.9%

6.8%

Female

Distant

Localised

Regional

Unknown

0.0

0.2

1.6

1.8

0.9

2.4

3.4

4.3

4.1

7.3

7.6

13.4

0.0

0.0

0.0

1.0

2.0

0.7

1.5

1.0

0.8

1.8

0.0

2.2

2.9

0 2 4 6 8 10 12 14 16

Tabuk

Jazan

Qassim

Hail

Najran

Jouf

Baha

Asir

Madinah

Riyadh

Northern

Makkah

Eastern

Female

Male

4.79.4

9.1

12.919.5

24.8

21.20

29.9

36.720.3

68.1

89.8

82.7

87.1

1.4

0.52.6

2.7

6.92.0

15.610.2

21.546.2

35.9

27.5

50.8

54.4

0 10 20 30 40 50 60 70 80 90 100

Female

Male


OmanQatar

KuwaitLibya

SwedenBahrainNorway

MalaysiaWales

SloveniaScotland



Part003.indd 55 18-08-2007 12:43:27 PM

56

Figure 3.11.1 Age-Specific Incidence Rate (AIR) for Bladder Cancer in Saudi Arabia, 2003

Table 3.11.1 Morphological Distribution of Bladder Cancer in Saudi Arabia, 2003

Figure 3.11.2 Stage Distribution of Bladder Cancer, 2003

There were 210 cases of bladder cancer accounting for 3.2% of all newly diagnosed cases in year 2003. This cancer ranked eighth among male population and ninteenth among female population. It affected 168 (80%) males and 42 (20%) females with a male to female ratio of 400:100. The overall ASR was 2.5/100,000. ASR was 3.9/100,000 for males

and 1/100,000 for females .The five regions with thehighest ASR were Northern region at 3.9/100,000, Eastern region at 3.8/100,000, Najran region at 3.5/100,000, Tabuk region at 3.3 /100,000 and Riyadh region at 3.3 /100,000. The mean age at diagnosis was 66 among males (range 22-92 years) and 64 among females (range 13-100 years).

Bladder (C 67)

0

5

10

15

20

25

30

35

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male female

AIR

(per

100

,000

)

ICD-O-3 Code Morphology

Male

% Female %

8120 Transitional cell carcinoma, NOS 65 31.0% 21 10.0% 8130 Papillary transitional cell carcinoma 70 33.3% 11 5.2% 8070 Squamous cell carcinoma, NOS 10 4.8% 3 1.4% 8120 Transitional cell carcinoma in situ 11 5.2% 0 0.0% 8071 Squamous cell carcinoma, keratinizing, NOS 4 1.9% 1 0.5% 8000 Neoplasm, malignant 1 0.5% 2 1.0% 8010 Carcinoma, NOS 2 1.0% 0 0.0% 8130 Papillary transitional cell carcinoma, non-invasive 2 1.0% 0 0.0% 8140 Adenocarcinoma, NOS 1 0.5% 1 0.5%

All Others 2 1.0% 3 1.4%

10.1%

64.3%

13.7%

11.9%

Male

10.5%

60.0%

13.8%

15.7%

All

11.9%

42.9%14.3%

31.0%

Female

Distant

Localised

Regional

Unknown

Part003.indd 56 18-08-2007 12:43:29 PM

57

Figure 3.11.4 Comparison of ASR* for Bladder Cancer among Saudis with ASR in Selected Countries**

Figure 3.11.3 ASR* Regional Distribution of Bladder Cancer in Saudi Arabia, 2003

1.8

1.9

3.3

0.7

0.8

4.0

4.2

4.0

5.2

5.5

4.2

6.8

7.7

0.3

0.4

0.6

3.2

3.6

0.8

0.8

1.5

1.4

1.1

2.7

0.7

0.0

0 2 4 6 8 10

Qassim

Asir

Jazan

Jouf

Hail

Baha

Madinah

Makkah

Riyadh

Tabuk

Najran

Eastern

Northern

Female

Male

3.9

4.7

6.0

6.1

5.7

9.5

11.7

11.7

16.9

16.8

21.2

33.8

36.9

1.0

1.3

2.0

2.7

3.8

0.0

1.3

1.6

5.7

6.2

5.6

10.0

9.5

0 5 10 15 20 25 30 35 40

Saudi Arabia


Kuwait

Oman

Malaysia

Qatar

Libya

Bahrain

Scotland

Slovenia

Norway

Wales

United States(All Races)

Female

Male


Part003.indd 57 18-08-2007 12:43:31 PM

58

Figure 3.12.1 Age-Specific Incidence Rate (AIR) for Prostate Cancer in Saudi Arabia, 2003

Figure 3.12.2 Stage Distribution of Prostate Cancer, 2003

Table 3.12.1 Morphological Distribution of Prostate Cancer in Saudi Arabia, 2003

There were 178 cases of prostate cancer accounting for 5.5% of all newly diagnosed cases among males in year 2003. The ASR was 4.2/100,000 among male population. This cancer ranked eighth among males. The five regions

with the highest ASR were Eastern region at 11.4/100,000, Jouf region at 7.3 /100,000, Makkah region at 4.9100,000, Riyadh region at 4.7/100,000 and Najran region at 4.2/100,000. The mean age at diagnosis was 72 years (range 44-98 years) .

Prostate (C 61)

0

10

20

30

40

50

60

70

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male

AIR

(per

100

,000

)

ICD-O Code Morphology Total %


8010 Carcinoma, NOS 6 3.4%

8000 Neoplasm, malignant 3 1.7%

8070 Squamous cell carcinoma, NOS 1 0.6%

8120 Transitional cell carcinoma, NOS 1 0.6%

32.0%

36.0%

9.6%

22.5%Distant

Localised

Regional

Unknown

Part003.indd 58 18-08-2007 12:43:31 PM

59

Figure 3.12.4 Comparison of ASR* for Prostate Cancer among Saudi Males with ASR in Selected Countries**

Figure 3.12.3 ASR* Regional Distribution of Prostate Cancer in Saudi Arabia, 2003

0.6

1.0

1.3

1.5

1.8

2.1

2.3

2.9

4.2

4.7

4.9

7.3

11.4

0 2 4 6 8 10 12

Hail

Jazan

Northern

Tabuk

Madinah

Baha

Asir

Qassim

Najran

Riyadh

Makkah

Jouf

Eastern

4.2

6.5

7.9

10.2

10.3

11.4

11.8

16.0

57.1

78.4

85.5

103.7

104.5

150.0

0 20 40 60 80 100 120 140 160


OmanQatar

MalaysiaLibya

BahrainKuwait

SloveniaScotlandNorway

SwedenWales

United States(All Races)


Part003.indd 59 18-08-2007 12:43:31 PM

60

There were112 cases of corpus uterine cancer among females accounting for 3.4 % of all newly diagnosed cases for females in year 2003. This cancer ranked seventh among female population. The ASR was 2.8/100,000 for female population. The five

regions with the highest ASR were Jouf region at 7.1/100,000, Riyadh region at 5/100,000, Makkah region at 4/100,000, Tabuk region at 3.9/100,000 and Northern region at 3.8/100,000. The mean age at diagnosis was 60 years (range 35-94 years).

Figure 3.13.1 Age-Specific Incidence Rate (AIR) for Corpus uterine Cancer in Saudi Arabia, 2003

Table 3.13.1 Morphological Distribution of Corpus uterine Cancer in Saudi Arabia, 2003

Figure 3.13.2 Stage Distribution of Corpus uterine Cancer, 2003

Corpus uteri (C 54)

02468101214161820

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

female

AIR

(per

100

,000

)

ICD-O-3 Code Morphology Total %

8380 Endometrioid adenocarcinoma, NOS 58 51.8%


8260 Papillary adenocarcinoma, NOS 4 3.6%

8950 Mullerian mixed tumor 4 3.6%

8890 Leiomyosarcoma, NOS 3 2.7%

8930 Endometrial stromal sarcoma, NOS 3 2.7%

8143 Superficial spreading adenocarcinoma 2 1.8%

8460 Papillary serous cystadenocarcinoma 2 1.8%

8560 Adenosquamous carcinoma 2 1.8%

9100 Choriocarcinoma, NOS 2 1.8%

All Others 9 8.0%

11.6%

57.1%

16.1%

15.2%

Distant

Localised

Regional

Unknown

Part003.indd 60 18-08-2007 12:43:33 PM

61

Figure 3.13.4 Comparison of ASR* for Corpus uterine Cancer among Saudi Females with ASR in Selected Countries**

Figure 3.13.3 ASR* Regional Distribution of Corpus uterine Cancer in Saudi Arabia, 2003

0.0

0.0

1.3

1.5

1.5

1.8

3.0

3.6

3.8

3.9

4.0

5.0

7.1

0 1 2 3 4 5 6 7 8

Jazan

Hail

Madinah

Najran

Qassim

Asir

Baha

Eastern

Northern

Tabuk

Makkah

Riyadh

Jouf

1.7

2.8

4.0

5.3

5.7

6.9

7.4

9.1

13.4

14.1

15.8

16.2

22.1

28.0

0 5 10 15 20 25 30

OmanSaudi Arabia

QatarLibya

United Arab EmiratesMalaysia

KuwaitBahrain

ScotlandSwedenNorwayWales

United States (All Races)Slovenia


Part003.indd 61 18-08-2007 12:43:34 PM

62

Figure 3.14.1 Age-Specific Incidence Rate (AIR) for Ovarian Cancer in Saudi Arabia, 2003

Figure 3.14.2 Stage Distribution of Ovarian Cancer, 2003

Table 3.14.1 Morphological Distribution of Ovarian Cancer in Saudi Arabia, 2003

There were 109 cases of ovarian cancer among females accounting for 3.4% of all newly diagnosed cases among females in year 2003. This cancer ranked ninth among female population. The ASR was 2/100,000 for females. The five regions with

the highest ASR were Makkah region at 3/100,000, Madinah region at 2.8/100,000, Eastern region at 2.7/100,000, Asir region at 2.4 /100,000 and Riyadh region at 2.3/100,000. The mean age at diagnosis was 45 years (range 4-86 years).

Ovary (C 56)

0

2

4

6

8

10

12

14

16

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

female

AIR

(per

100

,000

)

ICD-O Code Morphology Total % 8460 Papillary serous cystadenocarcinoma 24 22.0% 8140 Adenocarcinoma, NOS 13 11.9% 8480 Mucinous adenocarcinoma 9 8.3% 8441 Serous cystadenocarcinoma, NOS 8 7.3% 8461 Serous surface papillary carcinoma 8 7.3% 9060 Dysgerminoma 6 5.5% 8470 Mucinous cystadenocarcinoma, NOS 5 4.6% 9080 Teratoma, malignant, NOS 5 4.6% 8010 Carcinoma, NOS 4 3.7% 9071 Yolk sac tumor 4 3.7% 9085 Mixed germ cell tumor 4 3.7% 8440 Cystadenocarcinoma, NOS 3 2.8% 8450 Papillary cystadenocarcinoma, NOS 2 1.8% 8471 Papillary mucinous cystadenocarcinoma 2 1.8% 9364 Peripheral neuroectodermal tumor 2 1.8%

All Others 10 9.2%

60.6%24.8%

7.3%7.3%

Distant

Localised

Regional

Unknown

Part003.indd 62 18-08-2007 12:43:36 PM

63

Figure 3.14.4 Comparison of ASR* for Ovarian Cancer among Saudi Females with ASR in Selected Countries**

Figure 3.14.3 ASR* Regional Distribution of Ovarian Cancer in Saudi Arabia, 2003

0.0

0.0

0.3

0.9

1.2

1.7

1.9

2.1

2.3

2.4

2.7

2.8

3.0

0 1 2 3 4

Northern

Jazan

Hail

Najran

Qassim

Tabuk

Baha

Jouf

Riyadh

Asir

Eastern

Madinah

Makkah

2.0

3.6

3.6

4.0

4.5

6.1

10.7

10.8

10.8

11.4

12.9

17.9

18.3

20.8

0 5 10 15 20 25


OmanLibya

KuwaitMalaysia

BahrainQatar

SwedenNorway

United States (All Races)SloveniaScotland

Wales


Part003.indd 63 18-08-2007 12:43:38 PM

64

*References: 1. Gulf Center for Cancer Registration. 1998-2002 Report. 2006 2. National Cancer Registry. Cancer Incidence in Malaysia 2003. Available from: http://www.acrm.org.my/ncr/documents/NCR_2nd_Report/Chapter1.pdf 3. Croatian National Cancer Registry. Cancer Incidence in Croatia 2003. Available from: http://www.hzjz.hr/cancer/biten03.htm 4. Benghazi Cancer Registry. Cancer Incidence in Eastern Libya. 2003 5. Cancer Registry of Slovenia. Cancer Incidence in Slovenia. 2003. Ljubljana 2006. 6. Cancer Registry of Norway. Institute of Population Based Cancer Research. Cancer in Norway 2003. Oslo. 2005 7. Cancer Incidence in Malaysia 2003. Available from: http://www.acrm.org.my/ncr/documents/NCR_2nd_Report/Chapter1.pdf 8. Welsh Cancer Intelligence & Surveillance Unit. Cancer Incidence 2003 Report. Available from: http://www.wales.nhs.uk/sites3/Documents/242/CANCER/INCIDENCE/2003/5F281105/2Epdf 9. United States Cancer Statistics: 2003 Incidence and Mortality. Available from: http://www/cdc.gov/cancer/npcr/npcrpdfs/US_Cancer_Statistics_2003_Incidence_and_Mortality.pdf 10. Descriptive Epidemiology Group, IARC. Globocan, 2002. Available from: http://www.dep.iarc.fr/ 11. NationalMaster.com. http://www.nationalmaster.com/graph/hea_bre_can_inc-health-breast-cancer-incidence. 12. Cancer Incidence in Sweden 2003. http://www.socialstyrelsen.se/NR/rdon1yres/86E6C7D0-4650-43DA-82DF-FAC11CDB54C5/3019/20044210.pdf 13. Cancer Incidence and Mortality: 1994-2003 http://www.isdscotland.org/isd/servlet/FileBuffer?namedFile=cancer_incandmort_summary.xls&pContentDispositionType=inline 14. Cancer Research UK. http://info.cancerresearchuk.org/cancerstats/types/lung/incidence/

Part003.indd 64 18-08-2007 12:43:39 PM

PART IVCANCER AMONG NON-SAUDIS

2003

Part004.indd 65 13-06-2007 7:13:09 PM

66

Part004.indd 66 13-06-2007 7:13:09 PM

67

Between January and December 2003, a total of 1,913 cancer cases were reported among the Non-Saudi population. Forty seven cases were excluded from the analysis including 45 in situ cases and 2 cases that could not be converted from ICD-O-3 to ICD-10. As a result, the total number of cases analyzed were 1866 out of this 1074(57.6%) were males and 792 (42.4%) were females. The male to female ratio was 136:100. Taking into consideration the population structure of non-Saudis and the fact that cancer is primarily a disease of the elderly,

the pattern of cancer had some significantdifferences. Those over 60 years represented only 1.8 % and the 20 to 54 age-group represented 72.4% of non-Saudi population. During 2003, approximately 5.6% of all cancers occurred before the age of 15, 28 % occurred between the ages 15 to 40 years, 54.6% were between the ages 41-64, and 12% occured after the age of 64. The mean age at diagnosis was 47 years in males (range 0-98 years) and 44 years in females (range 0-87 years).

Table 4.1 Ten Most common Cancers among non-Saudis, 2003

Table 4.2 Distribution of Cancer Cases among Different Nationalities in Order of Relative Frequency

Cancer Among Non- Saudi Population 2003

CANCER All % Breast 254 13.6% Colo-rectal 178 9.5% Skin 128 6.9% Leukemia 117 6.3% Non-Hodgkin lymphoma 111 5.9% Thyroid 83 4.4% Lung 80 4.3% Stomach 72 3.9% Bladder 72 3.9% Brain, Nervous system 55 2.9%

Nationality Male Female Total % Yemen 213 172 385 20.1 Sudan 132 60 192 10.0 Egypt 100 76 176 9.2 Philippines 59 93 152 7.9 Pakistan 98 43 141 7.4 Gaza Strip (Palestine) 40 45 85 4.4 Bangladesh 80 4 84 4.4 India 61 19 80 4.2 Syrian Arab Republic 48 29 77 4.0 Jordan 30 22 52 2.7 Indonesia 16 27 43 2.2 United States of America 22 17 39 2.0 Bahrain 17 18 35 1.8 Somalia 16 16 32 1.7 United Kingdom 20 11 31 1.6 Other Nationalities 141 168 309 16.2 Total 1093 820 1913 100

Part004.indd 67 13-06-2007 7:13:09 PM

68

Figure 4.2 Age-Specific Incidence Rate (AIR) for All Cancers among non-Saudis in Saudi Arabia, 2003

Figure 4.1 Ten Most Common Cancer among non-Saudis, 2003

128

81

78

76

65

63

61

47

45

40

11.9%

7.5%

7.3%

7.2%

6.1%

5.9%

5.7%

4.4%

4.2%

3.7%

Colo-rectal

Skin

NHL

Leukemia

Lung

Stomach

Bladder

Prostate

Liver


Breast

Thyroid

Colo-rectal

Skin

Leukemia

Cervix uteri

Ovary

NHL

Corpus uteri


246

58

50

47

41

36

36

33

24

17

31.1%

7.3%

6.4%

5.9%

5.2%

4.5%

4.5%

4.2%

3.0%

2.1%

792Female1074Male

0

100

200

300

400

500

600

0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75+Age Groups

male female

AIR

(per

100

,000

)

Part004.indd 68 13-06-2007 7:13:10 PM

PART VTABLES

Part005.indd 69 14-06-2007 12:57:17 PM

70

Tabl

e 5.

1.1

Age

Dis

trib

utio

n of

Can

cer

Cas

es a

mon

g Sa

udi M

ales

, 200

3

ICD

10SI

TETo

t U

NK

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

+C

rude

R

ate

ASR

W

orld

C00

Lip

4

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.0

0.0

0.0

0.0

0.8

0.0

1.3

0.9

0.0

0.1

C01

-C02

Tong

ue

2

8 0.

00.

00.

00.

00.

00.

10.

00.

20.

40.

50.

72.

81.

42.

44.

01.

33.

60.

30.

6C

03-C

06M

outh

24

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.2

0.0

0.7

0.5

1.4

4.1

3.0

5.3

4.4

0.3

0.6

C07

-C08

Sal

ivar

y G

land

s

1

3 0.

00.

00.

00.

00.

10.

10.

10.

50.

40.

00.

00.

50.

70.

80.

00.

01.

80.

20.

2C

9To

nsil

5

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.7

0.0

1.0

0.0

2.7

0.1

0.1

C10

Oth

er o

roph

aryn

x

-

0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C

11N

asop

hary

nx

8

4 0.

00.

00.

00.

00.

60.

10.

40.

72.

32.

05.

25.

17.

04.

94.

02.

71.

81.

01.

7C

12-C

13H

ypop

hary

nx

7 0.

00.

00.

00.

00.

00.

00.

10.

00.

00.

00.

70.

00.

00.

80.

00.

02.

70.

10.

1C

14P

hary

nx u

nspe

c.3

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.7

0.8

0.0

1.3

0.0

0.0

0.1

C15

Oes

opha

gus

61

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.0

0.0

0.2

1.6

1.8

3.5

6.5

6.0

10.6

20.4

0.8

1.4

C16

Sto

mac

h

173

0.

00.

10.

00.

00.

00.

10.

10.

51.

51.

72.

67.

912

.713

.823

.925

.244

.42.

14.

0C

17S

mal

l int

estin

e

1

3 0.

00.

00.

00.

00.

00.

00.

00.

00.

40.

70.

00.

00.

71.

62.

02.

70.

90.

20.

3C

18C

olon

1

74

0.0

0.0

0.0

0.1

0.1

0.4

0.7

0.5

2.1

3.2

4.9

7.9

11.2

22.7

24.9

18.6

20.4

2.2

4.0

C19

-C20

Rec

tum

1

43

0.0

0.0

0.0

0.1

0.1

0.3

0.3

0.9

0.8

3.0

5.2

6.5

16.2

13.0

13.9

25.2

12.4

1.8

3.3

C21

Anu

s

1

0 0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

20.

30.

01.

43.

21.

00.

00.

90.

10.

3C

22Li

ver

2

51

0.0

0.3

0.0

0.2

0.1

0.0

0.3

0.4

1.0

1.2

4.6

6.0

17.6

34.9

37.8

62.4

45.3

3.1

6.2

C23

-C24

Gal

l bla

dder

etc

.

3

5 0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

71.

03.

22.

83.

27.

04.

03.

60.

40.

9C

25P

ancr

eas

65

0.0

0.0

0.0

0.0

0.0

0.1

0.0

0.2

0.4

0.2

1.3

3.2

7.0

6.5

8.9

10.6

12.4

0.8

1.6

C30

-C31

Nos

e, s

inus

es, e

tc.

10

0.0

0.0

0.0

0.1

0.1

0.0

0.1

0.0

0.2

0.0

0.0

0.9

0.0

0.8

1.0

0.0

1.8

0.1

0.2

C32

Lary

nx

5

5 0.

00.

00.

00.

10.

00.

00.

00.

00.

41.

50.

74.

25.

64.

96.

012

.05.

30.

71.

3C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g

183

0.

00.

00.

00.

00.

00.

10.

00.

01.

01.

53.

96.

912

.730

.833

.839

.921

.32.

34.

7C

37-C

38O

ther

Tho

raci

c O

rgan

s

1

2 0.

00.

00.

00.

00.

10.

30.

00.

20.

00.

00.

00.

02.

10.

83.

00.

00.

90.

10.

3C

40-C

41B

one

41

0.0

0.0

0.3

0.4

1.0

1.2

0.4

0.4

0.8

0.0

0.0

0.9

0.7

0.8

0.0

2.7

0.9

0.5

0.5

C43

Mel

anom

a of

Ski

n

1

0 0.

00.

00.

00.

00.

10.

10.

00.

00.

00.

00.

30.

00.

70.

00.

01.

34.

40.

10.

2C

44O

ther

Ski

n

158

0.

00.

00.

20.

00.

20.

30.

40.

91.

51.

02.

03.

27.

716

.219

.930

.640

.82.

03.

6C

45M

esot

helio

ma

5

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.3

0.5

0.0

0.8

0.0

0.0

0.9

0.1

0.1

C46

Kap

osi s

arco

ma

26

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.4

0.5

0.0

2.3

2.1

3.2

3.0

1.3

4.4

0.3

0.6

C47

; C49

Con

nect

ive,

Sof

t Tis

sue

66

0.0

0.8

0.4

0.1

0.2

0.7

0.4

0.5

0.6

2.5

1.3

2.8

2.8

2.4

2.0

2.7

5.3

0.8

1.1

C50

Bre

ast

16

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.7

0.3

0.0

2.1

1.6

3.0

1.3

2.7

0.2

0.4

C60

Pen

is

1 0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

50.

00.

00.

00.

00.

00.

00.

0C

61P

rost

ate

1

78

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

1.6

4.2

4.9

8.9

36.8

53.1

60.4

2.2

4.2

C62

Test

is

3

8 0.

00.

50.

00.

00.

20.

41.

30.

91.

31.

20.

70.

00.

70.

00.

00.

00.

00.

50.

5C

63O

ther

mal

e ge

nita

l

4 0.

00.

00.

00.

00.

00.

00.

00.

00.

40.

00.

00.

50.

00.

00.

00.

00.

90.

00.

1C

64K

idne

y

7

7 0.

00.

70.

40.

00.

10.

00.

40.

90.

60.

51.

01.

84.

98.

95.

014

.69.

81.

01.

6C

65R

enal

pel

vis

6

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.5

0.0

2.4

1.0

1.3

0.0

0.1

0.2

C66

Ure

ter

60.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

00.

70.

81.

02.

70.

00.

10.

2C

67B

ladd

er

168

1.

00.

00.

00.

00.

00.

10.

10.

92.

33.

04.

34.

614

.118

.716

.930

.627

.52.

13.

9C

68O

ther

urin

ary

orga

ns

2 0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

90.

00.

00.

00.

00.

00.

00.

0C

69E

ye

2

1 0.

01.

20.

10.

10.

00.

00.

00.

20.

20.

00.

00.

00.

00.

81.

01.

31.

80.

30.

3C

70-C

72B

rain

, Ner

vous

Sys

tem

1

30

0.0

1.8

1.3

1.0

0.6

1.2

1.4

1.4

0.6

0.7

1.6

3.2

5.6

8.1

6.0

12.0

1.8

1.6

2.1

C73

Thyr

oid

85

0.0

0.0

0.0

0.1

0.0

0.4

0.4

1.6

2.5

2.2

2.3

4.2

3.5

6.5

9.9

5.3

4.4

1.1

1.7

C74

Adr

enal

gla

nd

1

4 0.

00.

80.

20.

00.

00.

00.

10.

00.

00.

20.

30.

00.

00.

00.

00.

00.

90.

20.

2C

75O

ther

End

ocrin

e

4 0.

00.

00.

00.

10.

00.

40.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C

81H

odgk

in D

isea

se

139

0.

00.

81.

52.

02.

21.

91.

12.

71.

90.

71.

01.

82.

12.

43.

04.

05.

31.

71.

8C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

3

03

0.0

0.8

1.5

1.2

1.4

1.4

2.7

1.8

3.5

3.0

6.2

6.9

14.8

17.8

31.8

39.9

39.9

3.8

5.9

C88

Imm

unop

rolif

erat

ive

dis.

10.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

50.

00.

00.

00.

00.

00.

00.

0C

90M

ultip

le M

yelo

ma

34

0.0

0.0

0.0

0.0

0.1

0.0

0.0

0.2

0.4

0.2

0.7

2.3

2.8

3.2

4.0

8.0

3.6

0.4

0.8

C91

Lym

phoi

d Le

ukae

mia

1

50

0.0

3.7

1.8

1.8

1.9

1.8

1.0

0.5

0.6

0.7

1.6

1.4

2.1

5.7

2.0

4.0

2.7

1.9

2.0

C92

-C94

Mye

loid

Leu

kaem

ia

8

5 0.

00.

50.

30.

71.

11.

10.

60.

71.

01.

21.

62.

34.

94.

93.

08.

01.

81.

11.

4C

95Le

ukae

mia

uns

pec.

4

0.0

0.0

0.1

0.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.0

0.0

0.9

0.0

0.1

Oth

erO

ther

& u

nspe

cifie

d

138

0.

00.

20.

00.

10.

00.

10.

30.

41.

52.

51.

65.

19.

815

.417

.917

.329

.31.

73.

2A

llA

ll A

ges

Tota

l32

631.

012

.28.

18.

310

.312

.712

.818

.531

.437

.862

.410

7.8

192.

428

6.8

349.

446

5.1

458.

340

.568

.7N

ot C

44A

ll si

tes

but C

4431

051.

012

.27.

98.

310

.112

.412

.417

.629

.936

.860

.410

4.6

184.

727

0.6

329.

543

4.5

417.

538

.565

.1

Part005.indd 70 14-06-2007 12:57:18 PM

71

Tabl

e 5.

1.2

Age

Dis

trib

utio

n of

Can

cer

Cas

es a

mon

g Sa

udi F

emal

es, 2

003

Part005.indd 71 14-06-2007 12:57:20 PM

72

Tabl

e 5.

1.3

Can

cer

Inci

denc

e C

ases

am

ong

Saud

i Mal

es b

y A

ge G

roup

(pe

r 10

0,00

0), 2

003

ICD

10SI

TETo

t U

NK

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

+C

rude

R

ate

ASR

W

orld

C00

Lip

4

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.0

0.0

0.0

0.0

0.8

0.0

1.3

0.9

0.0

0.1

C01

-C02

Tong

ue

28

0.0

0.0

0.0

0.0

0.0

0.1

0.0

0.2

0.4

0.5

0.7

2.8

1.4

2.4

4.0

1.3

3.6

0.3

0.6

C03

-C06

Mou

th

24

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.2

0.0

0.7

0.5

1.4

4.1

3.0

5.3

4.4

0.3

0.6

C07

-C08

Sal

ivar

y G

land

s

13

0.0

0.0

0.0

0.0

0.1

0.1

0.1

0.5

0.4

0.0

0.0

0.5

0.7

0.8

0.0

0.0

1.8

0.2

0.2

C9

Tons

il

5

0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

01.

00.

02.

70.

10.

1C

10O

ther

oro

phar

ynx

-

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C11

Nas

opha

rynx

8

4 0.

00.

00.

00.

00.

60.

10.

40.

72.

32.

05.

25.

17.

04.

94.

02.

71.

81.

01.

7C

12-C

13H

ypop

hary

nx

7

0.

00.

00.

00.

00.

00.

00.

10.

00.

00.

00.

70.

00.

00.

80.

00.

02.

70.

10.

1C

14P

hary

nx u

nspe

c.3

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.7

0.8

0.0

1.3

0.0

0.0

0.1

C15

Oes

opha

gus

6

1 0.

00.

00.

00.

00.

00.

00.

10.

00.

00.

21.

61.

83.

56.

56.

010

.620

.40.

81.

4C

16S

tom

ach

17

3 0.

00.

10.

00.

00.

00.

10.

10.

51.

51.

72.

67.

912

.713

.823

.925

.244

.42.

14.

0C

17S

mal

l int

estin

e

13

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.4

0.7

0.0

0.0

0.7

1.6

2.0

2.7

0.9

0.2

0.3

C18

Col

on

174

0.0

0.0

0.0

0.1

0.1

0.4

0.7

0.5

2.1

3.2

4.9

7.9

11.2

22.7

24.9

18.6

20.4

2.2

4.0

C19

-C20

Rec

tum

14

3 0.

00.

00.

00.

10.

10.

30.

30.

90.

83.

05.

26.

516

.213

.013

.925

.212

.41.

83.

3C

21A

nus

1

0 0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

20.

30.

01.

43.

21.

00.

00.

90.

10.

3C

22Li

ver

25

1 0.

00.

30.

00.

20.

10.

00.

30.

41.

01.

24.

66.

017

.634

.937

.862

.445

.33.

16.

2C

23-C

24G

all b

ladd

er e

tc.

3

5 0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

71.

03.

22.

83.

27.

04.

03.

60.

40.

9C

25P

ancr

eas

6

5 0.

00.

00.

00.

00.

00.

10.

00.

20.

40.

21.

33.

27.

06.

58.

910

.612

.40.

81.

6C

30-C

31N

ose,

sin

uses

, etc

.

10

0.0

0.0

0.0

0.1

0.1

0.0

0.1

0.0

0.2

0.0

0.0

0.9

0.0

0.8

1.0

0.0

1.8

0.1

0.2

C32

Lary

nx

55

0.0

0.0

0.0

0.1

0.0

0.0

0.0

0.0

0.4

1.5

0.7

4.2

5.6

4.9

6.0

12.0

5.3

0.7

1.3

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

18

3 0.

00.

00.

00.

00.

00.

10.

00.

01.

01.

53.

96.

912

.730

.833

.839

.921

.32.

34.

7C

37-C

38O

ther

Tho

raci

c O

rgan

s

12

0.0

0.0

0.0

0.0

0.1

0.3

0.0

0.2

0.0

0.0

0.0

0.0

2.1

0.8

3.0

0.0

0.9

0.1

0.3

C40

-C41

Bon

e

41

0.0

0.0

0.3

0.4

1.0

1.2

0.4

0.4

0.8

0.0

0.0

0.9

0.7

0.8

0.0

2.7

0.9

0.5

0.5

C43

Mel

anom

a of

Ski

n

10

0.0

0.0

0.0

0.0

0.1

0.1

0.0

0.0

0.0

0.0

0.3

0.0

0.7

0.0

0.0

1.3

4.4

0.1

0.2

C44

Oth

er S

kin

15

8 0.

00.

00.

20.

00.

20.

30.

40.

91.

51.

02.

03.

27.

716

.219

.930

.640

.82.

03.

6C

45M

esot

helio

ma

5

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.3

0.5

0.0

0.8

0.0

0.0

0.9

0.1

0.1

C46

Kap

osi s

arco

ma

2

6 0.

00.

00.

00.

00.

00.

00.

00.

20.

40.

50.

02.

32.

13.

23.

01.

34.

40.

30.

6C

47; C

49C

onne

ctiv

e, S

oft T

issu

e

66

0.0

0.8

0.4

0.1

0.2

0.7

0.4

0.5

0.6

2.5

1.3

2.8

2.8

2.4

2.0

2.7

5.3

0.8

1.1

C50

Bre

ast

1

6 0.

00.

00.

00.

00.

00.

00.

00.

00.

00.

70.

30.

02.

11.

63.

01.

32.

70.

20.

4C

60P

enis

1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.5

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C61

Pro

stat

e

178

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

1.6

4.2

4.9

8.9

36.8

53.1

60.4

2.2

4.2

C62

Test

is

38

0.0

0.5

0.0

0.0

0.2

0.4

1.3

0.9

1.3

1.2

0.7

0.0

0.7

0.0

0.0

0.0

0.0

0.5

0.5

C63

Oth

er m

ale

geni

tal

4

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

0.5

0.0

0.0

0.0

0.0

0.9

0.0

0.1

C64

Kid

ney

7

7 0.

00.

70.

40.

00.

10.

00.

40.

90.

60.

51.

01.

84.

98.

95.

014

.69.

81.

01.

6C

65R

enal

pel

vis

6

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.5

0.0

2.4

1.0

1.3

0.0

0.1

0.2

C66

Ure

ter

60.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

30.

00.

70.

81.

02.

70.

00.

10.

2C

67B

ladd

er

168

1.0

0.0

0.0

0.0

0.0

0.1

0.1

0.9

2.3

3.0

4.3

4.6

14.1

18.7

16.9

30.6

27.5

2.1

3.9

C68

Oth

er u

rinar

y or

gans

2

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.9

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C69

Eye

2

1 0.

01.

20.

10.

10.

00.

00.

00.

20.

20.

00.

00.

00.

00.

81.

01.

31.

80.

30.

3C

70-C

72B

rain

, Ner

vous

Sys

tem

13

0 0.

01.

81.

31.

00.

61.

21.

41.

40.

60.

71.

63.

25.

68.

16.

012

.01.

81.

62.

1C

73Th

yroi

d

85

0.0

0.0

0.0

0.1

0.0

0.4

0.4

1.6

2.5

2.2

2.3

4.2

3.5

6.5

9.9

5.3

4.4

1.1

1.7

C74

Adr

enal

gla

nd

14

0.0

0.8

0.2

0.0

0.0

0.0

0.1

0.0

0.0

0.2

0.3

0.0

0.0

0.0

0.0

0.0

0.9

0.2

0.2

C75

Oth

er E

ndoc

rine

4

0.0

0.0

0.0

0.1

0.0

0.4

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C81

Hod

gkin

Dis

ease

13

9 0.

00.

81.

52.

02.

21.

91.

12.

71.

90.

71.

01.

82.

12.

43.

04.

05.

31.

71.

8C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

30

3 0.

00.

81.

51.

21.

41.

42.

71.

83.

53.

06.

26.

914

.817

.831

.839

.939

.93.

85.

9C

88Im

mun

opro

lifer

ativ

e di

s.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.5

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C90

Mul

tiple

Mye

lom

a

34

0.0

0.0

0.0

0.0

0.1

0.0

0.0

0.2

0.4

0.2

0.7

2.3

2.8

3.2

4.0

8.0

3.6

0.4

0.8

C91

Lym

phoi

d Le

ukae

mia

15

0 0.

03.

71.

81.

81.

91.

81.

00.

50.

60.

71.

61.

42.

15.

72.

04.

02.

71.

92.

0C

92-C

94M

yelo

id L

euka

emia

8

5 0.

00.

50.

30.

71.

11.

10.

60.

71.

01.

21.

62.

34.

94.

93.

08.

01.

81.

11.

4C

95Le

ukae

mia

uns

pec.

4

0.0

0.0

0.1

0.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.0

0.0

0.9

0.0

0.1

Oth

erO

ther

& u

nspe

cifie

d

138

0.0

0.2

0.0

0.1

0.0

0.1

0.3

0.4

1.5

2.5

1.6

5.1

9.8

15.4

17.9

17.3

29.3

1.7

3.2

All

All

Age

s To

tal

3263

1.0

12.2

8.1

8.3

10.3

12.7

12.8

18.5

31.4

37.8

62.4

107.

819

2.4

286.

834

9.4

465.

145

8.3

40.5

68.7

Not

C44

All

site

s bu

t C44

3105

1.0

12.2

7.9

8.3

10.1

12.4

12.4

17.6

29.9

36.8

60.4

104.

618

4.7

270.

632

9.5

434.

541

7.5

38.5

65.1

Part005.indd 72 14-06-2007 12:57:30 PM

73

Tabl

e 5.

1.4

Can

cer

Inci

denc

e C

ases

am

ong

Saud

i Fem

ales

by

Age

Gro

up (

per

100,

000)

, 200

3

Part005.indd 73 14-06-2007 12:57:31 PM

74

Tabl

e 5.

2.1

Num

ber,

Rel

ativ

e Fr

eque

ncie

s, A

ge S

tand

ardi

zed

and

Cru

de R

ates

for

All

Can

cer

Cas

es A

mon

g Sa

udi M

ales

by

Site

and

Adm

inis

trat

ive

Reg

ion,

200

3

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRC

00Li

p1

0.4

0.1

0.2

00.

00.

00.

00

0.0

0.0

0.0

C01

-C02

Tong

ue3

1.25

0.4

0.8

23.

41.

31.

55

4.1

1.1

1.8

C03

-C06

Mou

th1

0.4

0.1

0.2

00.

00.

00.

010

8.2

2.1

3.1

C07

-C08

Sal

ivar

y G

land

s0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C9

Tons

il1

0.4

0.1

0.1

00.

00.

00.

00

0.0

0.0

0.0

C10

Oth

er o

roph

aryn

x0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C11

Nas

opha

rynx

125.

01.

83.

10

0.0

0.0

0.0

00.

00.

00.

0C

12-C

13H

ypop

hary

nx0

0.0

0.0

0.0

00.

00.

00.

02

1.6

0.4

0.3

C14

Pha

rynx

uns

pec.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

15O

esop

hagu

s4

1.7

0.6

1.0

11.

70.

70.

42

1.6

0.4

0.6

C16

Sto

mac

h18

7.5

2.6

4.1

610

.34.

04.

37

5.7

1.5

2.3

C17

Sm

all i

ntes

tine

10.

40.

10.

10

0.0

0.0

0.0

10.

80.

20.

4C

18C

olon

145.

82.

13.

62

3.4

1.3

2.3

21.

60.

40.

5C

19-C

20R

ectu

m8

3.3

1.2

1.9

23.

41.

32.

44

3.3

0.8

1.3

C21

Anu

s0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C22

Live

r15

6.3

2.2

3.7

35.

22.

02.

49

7.4

1.9

3.0

C23

-C24

Gal

l bla

dder

etc

.4

1.7

0.6

1.1

00.

00.

00.

01

0.8

0.2

0.4

C25

Pan

crea

s7

2.9

1.0

1.8

11.

70.

71.

11

0.8

0.2

0.2

C30

-C31

Nos

e, s

inus

es, e

tc.

00.

00.

00.

00

0.0

0.0

0.0

10.

80.

20.

4C

32La

rynx

20.

80.

30.

41

1.7

0.7

0.4

32.

50.

60.

9C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g12

5.0

1.8

3.4

23.

41.

32.

41

0.8

0.2

0.2

C37

-C38

Oth

er T

hora

cic

Org

ans

00.

00.

00.

01

1.7

0.7

1.1

00.

00.

00.

0C

40-C

41B

one

52.

10.

70.

91

1.7

0.7

0.6

10.

80.

20.

3C

43M

elan

oma

of S

kin

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

44O

ther

Ski

n17

7.1

2.5

3.9

58.

63.

43.

68

6.6

1.7

1.7

C45

Mes

othe

liom

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C46

Kap

osi s

arco

ma

41.

70.

61.

00

0.0

0.0

0.0

00.

00.

00.

0C

47; C

49C

onne

ctiv

e, S

oft T

issu

e3

1.3

0.4

0.7

11.

70.

71.

62

1.6

0.4

0.5

C50

Bre

ast

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

60P

enis

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

61P

rost

ate

104.

21.

52.

35

8.6

3.4

2.1

54.

11.

11.

0C

62Te

stis

31.

30.

40.

60

0.0

0.0

0.0

00.

00.

00.

0C

63O

ther

mal

e ge

nita

l1

0.4

0.1

0.1

00.

00.

00.

01

0.8

0.2

0.3

C64

Kid

ney

72.

91.

01.

71

1.7

0.7

0.7

00.

00.

00.

0C

65R

enal

pel

vis

00.

00.

00.

00

0.0

0.0

0.0

10.

80.

20.

4C

66U

rete

r0

0.0

0.0

0.0

00.

00.

00.

02

1.6

0.4

0.8

C67

Bla

dder

93.

81.

31.

93

5.2

2.0

4.0

1310

.72.

83.

3C

68O

ther

urin

ary

orga

ns0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C69

Eye

00.

00.

00.

00

0.0

0.0

0.0

10.

80.

20.

2C

70-C

72B

rain

, Ner

vous

Sys

tem

104.

21.

51.

50

0.0

0.0

0.0

32.

50.

60.

8C

73Th

yroi

d11

4.6

1.6

2.5

11.

70.

70.

71

0.8

0.2

0.4

C74

Adr

enal

gla

nd0

0.0

0.0

0.0

11.

70.

70.

51

0.8

0.2

0.2

C75

Oth

er E

ndoc

rine

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

81H

odgk

in D

isea

se8

3.3

1.2

1.6

35.

22.

01.

45

4.1

1.1

1.6

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a28

11.7

4.1

5.5

712

.14.

76.

014

11.5

3.0

3.6

C88

Imm

unop

rolif

erat

ive

dis.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

90M

ultip

le M

yelo

ma

00.

00.

00.

00

0.0

0.0

0.0

32.

50.

61.

0C

91Ly

mph

oid

Leuk

aem

ia8

3.3

1.2

1.4

35.

22.

03.

18

6.6

1.7

1.7

C92

-C94

Mye

loid

Leu

kaem

ia5

2.1

0.7

1.0

00.

00.

00.

01

0.8

0.2

0.2

C95

Leuk

aem

ia u

nspe

c.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

Oth

erO

ther

& u

nspe

cifie

d8

3.3

1.2

1.9

610

.34.

05.

33

2.5

0.6

0.9

All

All

Site

s

240

100.

035

.054

.058

100.

039

.047

.912

210

0.0

25.6

34.3

All

but C

44A

ll Si

tes

but C

4422

392

.932

.550

.153

91.4

35.6

44.3

114

93.4

23.9

32.6

Asi

r B

aha

Jaza

n

Part005.indd 74 14-06-2007 12:57:41 PM

75

Tabl

e 5.

2.1

cont

inue

d ...

......

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRC

00Li

p0

0.0

0.0

0.0

11.

90.

50.

40

0.0

0.0

0.0

C01

-C02

Tong

ue0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C03

-C06

Mou

th1

0.5

0.2

0.2

00.

00.

00.

00

0.0

0.0

0.0

C07

-C08

Sal

ivar

y G

land

s1

0.5

0.2

0.2

11.

90.

50.

60

0.0

0.0

0.0

C9

Tons

il0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C10

Oth

er o

roph

aryn

x0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C11

Nas

opha

rynx

42.

20.

71.

31

1.9

0.5

0.6

63.

71.

53.

4C

12-C

13H

ypop

hary

nx0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C14

Pha

rynx

uns

pec.

00.

00.

00.

00

0.0

0.0

0.0

10.

60.

30.

7C

15O

esop

hagu

s2

1.1

0.4

0.6

11.

90.

50.

66

3.7

1.5

2.0

C16

Sto

mac

h10

5.5

1.8

3.8

611

.52.

84.

313

8.0

3.3

5.9

C17

Sm

all i

ntes

tine

10.

50.

20.

20

0.0

0.0

0.0

00.

00.

00.

0C

18C

olon

116.

02.

03.

44

7.7

1.9

3.5

84.

92.

03.

6C

19-C

20R

ectu

m11

6.0

2.0

4.0

00.

00.

00.

05

3.1

1.3

2.6

C21

Anu

s3

1.6

0.5

1.1

00.

00.

00.

00

0.0

0.0

0.0

C22

Live

r13

7.1

2.4

4.6

23.

80.

91.

610

6.2

2.5

5.3

C23

-C24

Gal

l bla

dder

etc

.1

0.5

0.2

0.5

00.

00.

00.

04

2.5

1.0

1.7

C25

Pan

crea

s4

2.2

0.7

1.2

11.

90.

50.

82

1.2

0.5

0.6

C30

-C31

Nos

e, s

inus

es, e

tc.

10.

50.

20.

40

0.0

0.0

0.0

21.

20.

50.

8C

32La

rynx

00.

00.

00.

02

3.8

0.9

1.4

31.

90.

81.

6C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g9

4.9

1.6

4.3

23.

80.

91.

83

1.9

0.8

1.6

C37

-C38

Oth

er T

hora

cic

Org

ans

00.

00.

00.

00

0.0

0.0

0.0

10.

60.

30.

6C

40-C

41B

one

31.

60.

50.

51

1.9

0.5

0.3

21.

20.

50.

5C

43M

elan

oma

of S

kin

00.

00.

00.

00

0.0

0.0

0.0

10.

60.

30.

3C

44O

ther

Ski

n17

9.3

3.1

6.2

23.

80.

91.

09

5.6

2.3

5.2

C45

Mes

othe

liom

a1

0.5

0.2

0.5

00.

00.

00.

00

0.0

0.0

0.0

C46

Kap

osi s

arco

ma

00.

00.

00.

00

0.0

0.0

0.0

10.

60.

30.

6C

47; C

49C

onne

ctiv

e, S

oft T

issu

e4

2.2

0.7

1.0

35.

81.

41.

34

2.5

1.0

0.8

C50

Bre

ast

10.

50.

20.

40

0.0

0.0

0.0

10.

60.

30.

5C

60P

enis

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

61P

rost

ate

31.

60.

51.

81

1.9

0.5

0.6

63.

71.

52.

9C

62Te

stis

42.

20.

70.

90

0.0

0.0

0.0

21.

20.

50.

4C

63O

ther

mal

e ge

nita

l0

0.0

0.0

0.0

11.

90.

50.

60

0.0

0.0

0.0

C64

Kid

ney

52.

70.

91.

32

3.8

0.9

1.5

53.

11.

32.

2C

65R

enal

pel

vis

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

66U

rete

r1

0.5

0.2

0.4

00.

00.

00.

00

0.0

0.0

0.0

C67

Bla

dder

116.

02.

04.

21

1.9

0.5

0.8

42.

51.

01.

8C

68O

ther

urin

ary

orga

ns1

0.5

0.2

0.4

00.

00.

00.

00

0.0

0.0

0.0

C69

Eye

21.

10.

40.

20

0.0

0.0

0.0

00.

00.

00.

0C

70-C

72B

rain

, Ner

vous

Sys

tem

63.

31.

11.

52

3.8

0.9

0.9

84.

92.

03.

4C

73Th

yroi

d3

1.6

0.5

1.2

23.

80.

91.

26

3.7

1.5

2.7

C74

Adr

enal

gla

nd0

0.0

0.0

0.0

11.

90.

50.

60

0.0

0.0

0.0

C75

Oth

er E

ndoc

rine

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

81H

odgk

in D

isea

se9

4.9

1.6

1.5

35.

81.

41.

313

8.0

3.3

3.4

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a17

9.3

3.1

4.7

611

.52.

83.

38

4.9

2.0

4.0

C88

Imm

unop

rolif

erat

ive

dis.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

90M

ultip

le M

yelo

ma

00.

00.

00.

00

0.0

0.0

0.0

53.

11.

31.

9C

91Ly

mph

oid

Leuk

aem

ia10

5.5

1.8

2.8

47.

71.

93.

112

7.4

3.0

3.4

C92

-C94

Mye

loid

Leu

kaem

ia5

2.7

0.9

1.4

11.

90.

50.

34

2.5

1.0

1.7

C95

Leuk

aem

ia u

nspe

c.1

0.5

0.2

0.1

00.

00.

00.

00

0.0

0.0

0.0

Oth

erO

ther

& u

nspe

cifie

d7

3.8

1.3

1.8

11.

90.

50.

47

4.3

1.8

2.4

All

All

Site

s

183

100.

033

.258

.652

100.

024

.532

.816

210

0.0

41.2

68.5

All

but C

44A

ll Si

tes

but C

4416

690

.730

.152

.450

96.2

23.6

31.8

153

94.4

38.9

63.3

Mad

inah

H

ail

Qas

sim

Part005.indd 75 14-06-2007 12:57:42 PM

76

Tabl

e 5.

2.1

cont

inue

d ...

......

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

C00

Lip

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C01

-C02

Tong

ue1

2.0

0.6

1.8

13.

00.

72.

80

0.0

0.0

0.0

13.

10.

91.

6C

03-C

06M

outh

00.

00.

00.

00

0.0

0.0

0.0

22.

00.

71.

50

0.0

0.0

0.0

C07

-C08

Sal

ivar

y G

land

s0

0.0

0.0

0.0

00.

00.

00.

02

2.0

0.7

1.2

00.

00.

00.

0C

9To

nsil

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C10

Oth

er o

roph

aryn

x0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

11N

asop

hary

nx0

0.0

0.0

0.0

00.

00.

00.

04

4.1

1.3

2.5

00.

00.

00.

0C

12-C

13H

ypop

hary

nx0

0.0

0.0

0.0

00.

00.

00.

02

2.0

0.7

2.2

00.

00.

00.

0C

14P

hary

nx u

nspe

c.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

15O

esop

hagu

s1

2.0

0.6

0.8

00.

00.

00.

03

3.1

1.0

2.3

00.

00.

00.

0C

16S

tom

ach

510

.23.

07.

30

0.0

0.0

0.0

22.

00.

71.

51

3.1

0.9

3.6

C17

Sm

all i

ntes

tine

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C18

Col

on2

4.1

1.2

2.6

13.

00.

72.

81

1.0

0.3

0.7

26.

31.

74.

9C

19-C

20R

ectu

m0

0.0

0.0

0.0

00.

00.

00.

07

7.1

2.4

5.7

00.

00.

00.

0C

21A

nus

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C22

Live

r6

12.2

3.6

10.0

39.

12.

04.

59

9.2

3.0

8.1

13.

10.

91.

8C

23-C

24G

all b

ladd

er, e

tc.

12.

00.

61.

70

0.0

0.0

0.0

11.

00.

30.

81

3.1

0.9

3.6

C25

Pan

crea

s0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

26.

31.

72.

7C

30-C

31N

ose,

sin

uses

, etc

.0

0.0

0.0

0.0

00.

00.

00.

02

2.0

0.7

1.1

00.

00.

00.

0C

32La

rynx

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

02

6.3

1.7

3.8

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

12.

00.

60.

91

3.0

0.7

2.2

00.

00.

00.

03

9.4

2.6

7.3

C37

-C38

Oth

er T

hora

cic

Org

ans

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C40

-C41

Bon

e2

4.1

1.2

0.8

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

43M

elan

oma

of S

kin

12.

00.

60.

82

6.1

1.3

3.1

11.

00.

30.

30

0.0

0.0

0.0

C44

Oth

er S

kin

36.

11.

85.

72

6.1

1.3

4.4

33.

11.

02.

00

0.0

0.0

0.0

C45

Mes

othe

liom

a2

4.1

1.2

2.7

00.

00.

00.

00

0.0

0.0

0.0

26.

31.

73.

1C

46K

apos

i sar

com

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

47; C

49C

onne

ctiv

e, S

oft T

issu

e2

4.1

1.2

4.9

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

50B

reas

t0

0.0

0.0

0.0

13.

00.

70.

91

1.0

0.3

0.7

00.

00.

00.

0C

60P

enis

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C61

Pro

stat

e4

8.2

2.4

4.2

412

.12.

77.

32

2.0

0.7

1.5

13.

10.

91.

3C

62Te

stis

12.

00.

60.

42

6.1

1.3

1.7

11.

00.

30.

30

0.0

0.0

0.0

C63

Oth

er m

ale

geni

tal

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C64

Kid

ney

12.

00.

63.

10

0.0

0.0

0.0

11.

00.

31.

61

3.1

0.9

1.4

C65

Ren

al p

elvi

s0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

66U

rete

r0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

67B

ladd

er3

6.1

1.8

4.2

13.

00.

70.

74

4.1

1.3

5.5

39.

42.

67.

7C

68O

ther

urin

ary

orga

ns0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

69E

ye0

0.0

0.0

0.0

13.

00.

70.

51

1.0

0.3

0.2

00.

00.

00.

0C

70-C

72B

rain

, Ner

vous

Sys

tem

24.

11.

21.

02

6.1

1.3

1.3

66.

12.

02.

50

0.0

0.0

0.0

C73

Thyr

oid

00.

00.

00.

02

6.1

1.3

3.5

22.

00.

71.

50

0.0

0.0

0.0

C74

Adr

enal

gla

nd0

0.0

0.0

0.0

00.

00.

00.

02

2.0

0.7

0.4

13.

10.

91.

8C

75O

ther

End

ocrin

e0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

81H

odgk

in D

isea

se3

6.1

1.8

1.4

13.

00.

70.

510

10.2

3.4

2.4

26.

31.

71.

4C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

510

.23.

02.

82

6.1

1.3

2.7

1010

.23.

46.

55

15.6

4.3

11.1

C88

Imm

unop

rolif

erat

ive

dis.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C90

Mul

tiple

Mye

lom

a1

2.0

0.6

1.0

26.

11.

33.

81

1.0

0.3

0.8

00.

00.

00.

0C

91Ly

mph

oid

Leuk

aem

ia2

4.1

1.2

2.4

00.

00.

00.

08

8.2

2.7

4.7

26.

31.

71.

1C

92-C

94M

yelo

id L

euka

emia

00.

00.

00.

03

9.1

2.0

3.7

22.

00.

71.

91

3.1

0.9

0.5

C95

Leuk

aem

ia u

nspe

c.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0O

ther

Oth

er &

uns

peci

fied

00.

00.

00.

02

6.1

1.3

1.3

88.

22.

76.

41

3.1

0.9

1.9

All

All

Site

s

4910

0.0

29.4

60.5

3310

0.0

22.0

47.7

9810

0.0

32.9

66.8

3210

0.0

27.8

60.6

All

but C

44A

ll Si

tes

but C

4446

93.9

27.6

54.8

3193

.920

.743

.395

96.9

31.9

64.8

3210

0.0

27.8

60.6

Naj

ran

Jouf

Ta

buk

Nor

ther

n

Part005.indd 76 14-06-2007 12:57:43 PM

77

Tabl

e 5.

2.1

cont

inue

d ...

......

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRC

00Li

p1

0.1

0.1

0.1

00.

00.

00.

01

0.2

0.1

0.4

C01

-C02

Tong

ue7

0.8

0.4

0.8

50.

60.

30.

53

0.5

0.2

0.5

C03

-C06

Mou

th5

0.6

0.3

0.6

30.

40.

20.

32

0.4

0.2

0.5

C07

-C08

Sal

ivar

y G

land

s1

0.1

0.1

0.0

20.

30.

10.

16

1.1

0.5

1.0

C9

Tons

il1

0.1

0.1

0.1

00.

00.

00.

03

0.5

0.2

0.8

C10

Oth

er o

roph

aryn

x0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C11

Nas

opha

rynx

283.

21.

52.

521

2.6

1.2

2.0

81.

50.

61.

2C

12-C

13H

ypop

hary

nx0

0.0

0.0

0.0

30.

40.

20.

30

0.0

0.0

0.0

C14

Pha

rynx

uns

pec.

00.

00.

00.

01

0.1

0.1

0.2

10.

20.

10.

3C

15O

esop

hagu

s18

2.1

1.0

2.3

202.

51.

12.

03

0.5

0.2

0.7

C16

Sto

mac

h34

3.9

1.8

3.8

445.

52.

54.

524

4.4

1.9

4.7

C17

Sm

all i

ntes

tine

20.

20.

10.

25

0.6

0.3

0.5

30.

50.

20.

5C

18C

olon

424.

82.

35.

259

7.4

3.4

6.2

264.

82.

05.

2C

19-C

20R

ectu

m41

4.7

2.2

5.2

394.

92.

24.

026

4.8

2.0

4.7

C21

Anu

s4

0.5

0.2

0.7

10.

10.

10.

12

0.4

0.2

0.5

C22

Live

r93

10.6

5.0

12.0

587.

33.

36.

128

5.1

2.2

6.4

C23

-C24

Gal

l bla

dder

, etc

.9

1.0

0.5

0.9

81.

00.

50.

94

0.7

0.3

0.8

C25

Pan

crea

s17

1.9

0.9

2.1

212.

61.

22.

29

1.6

0.7

2.3

C30

-C31

Nos

e, s

inus

es, e

tc.

10.

10.

10.

12

0.3

0.1

0.1

10.

20.

10.

2C

32La

rynx

171.

90.

92.

016

2.0

0.9

1.8

91.

60.

71.

9C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g29

3.3

1.6

4.1

688.

63.

97.

652

9.5

4.1

13.4

C37

-C38

Oth

er T

hora

cic

Org

ans

20.

20.

10.

23

0.4

0.2

0.3

50.

90.

41.

0C

40-C

41B

one

70.

80.

40.

49

1.1

0.5

0.7

101.

80.

80.

7C

43M

elan

oma

of S

kin

20.

20.

10.

22

0.3

0.1

0.2

10.

20.

10.

2C

44O

ther

Ski

n32

3.7

1.7

3.6

313.

91.

83.

226

4.8

2.0

5.1

C45

Mes

othe

liom

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C46

Kap

osi s

arco

ma

111.

30.

61.

36

0.8

0.3

0.6

40.

70.

30.

9C

47; C

49C

onne

ctiv

e, S

oft T

issu

e13

1.5

0.7

1.2

172.

11.

01.

516

2.9

1.3

1.5

C50

Bre

ast

50.

60.

30.

64

0.5

0.2

0.4

30.

50.

20.

6C

60P

enis

00.

00.

00.

01

0.1

0.1

0.1

00.

00.

00.

0C

61P

rost

ate

434.

92.

34.

747

5.9

2.7

4.9

468.

43.

611

.4C

62Te

stis

141.

60.

80.

97

0.9

0.4

0.4

40.

70.

30.

3C

63O

ther

mal

e ge

nita

l0

0.0

0.0

0.0

00.

00.

00.

01

0.2

0.1

0.2

C64

Kid

ney

242.

71.

32.

318

2.3

1.0

1.8

101.

80.

81.

8C

65R

enal

pel

vis

30.

30.

20.

60

0.0

0.0

0.0

20.

40.

20.

4C

66U

rete

r0

0.0

0.0

0.0

20.

30.

10.

21

0.2

0.1

0.3

C67

Bla

dder

455.

12.

45.

240

5.0

2.3

4.0

315.

72.

46.

8C

68O

ther

urin

ary

orga

ns0

0.0

0.0

0.0

10.

10.

10.

10

0.0

0.0

0.0

C69

Eye

40.

50.

20.

26

0.8

0.3

0.3

30.

50.

20.

6C

70-C

72B

rain

, Ner

vous

Sys

tem

424.

82.

33.

530

3.8

1.7

2.4

193.

51.

52.

5C

73Th

yroi

d28

3.2

1.5

2.7

121.

50.

71.

217

3.1

1.3

1.9

C74

Adr

enal

gla

nd5

0.6

0.3

0.2

20.

30.

10.

11

0.2

0.1

0.1

C75

Oth

er E

ndoc

rine

40.

50.

20.

20

0.0

0.0

0.0

00.

00.

00.

0C

81H

odgk

in D

isea

se31

3.5

1.7

1.9

273.

41.

51.

823

4.2

1.8

2.4

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a86

9.8

4.6

8.8

637.

93.

65.

649

9.0

3.8

7.9

C88

Imm

unop

rolif

erat

ive

dis.

10.

10.

10.

10

0.0

0.0

0.0

00.

00.

00.

0C

90M

ultip

le M

yelo

ma

111.

30.

61.

55

0.6

0.3

0.6

61.

10.

51.

1C

91Ly

mph

oid

Leuk

aem

ia40

4.6

2.2

2.1

324.

01.

81.

821

3.8

1.6

1.7

C92

-C94

Mye

loid

Leu

kaem

ia32

3.7

1.7

2.7

182.

31.

01.

313

2.4

1.0

1.8

C95

Leuk

aem

ia u

nspe

c.2

0.2

0.1

0.2

10.

10.

10.

00

0.0

0.0

0.0

Oth

erO

ther

& u

nspe

cifie

d37

4.2

2.0

4.5

344.

31.

93.

624

4.4

1.9

5.1

All

All

Site

s

874

100.

047

.592

.579

410

0.0

45.4

76.5

547

100.

042

.810

2.3

All

but C

44A

ll Si

tes

but C

4484

296

.345

.888

.976

396

.143

.673

.352

195

.240

.897

.2

Riy

adh

M

akka

h

East

ern

Prov

ince

Part005.indd 77 14-06-2007 12:57:43 PM

78

Tabl

e 5.

2.2

Num

ber,

Rel

ativ

e Fr

eque

ncie

s, A

ge S

tand

ardi

zed

and

Cru

de R

ates

for

All

Can

cer

Cas

es A

mon

g Sa

udi F

emal

es b

y Si

te a

nd R

egio

n, 2

003

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRC

00Li

p0

0.0

0.0

0.0

00.

00.

00.

03

3.2

0.6

0.9

C01

-C02

Tong

ue2

0.9

0.3

0.6

00.

00.

00.

06

6.4

1.2

1.8

C03

-C06

Mou

th3

1.3

0.4

0.6

00.

00.

00.

017

18.1

3.4

5.8

C07

-C08

Sal

ivar

y G

land

s1

0.4

0.1

0.1

00.

00.

00.

01

1.1

0.2

0.1

C9

Tons

il0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C10

Oth

er o

roph

aryn

x0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C11

Nas

opha

rynx

20.

90.

30.

40

0.0

0.0

0.0

22.

10.

40.

6C

12-C

13H

ypop

hary

nx1

0.4

0.1

0.1

00.

00.

00.

00

0.0

0.0

0.0

C14

Pha

rynx

uns

pec.

10.

40.

10.

30

0.0

0.0

0.0

00.

00.

00.

0C

15O

esop

hagu

s2

0.9

0.3

0.5

11.

70.

60.

92

2.1

0.4

0.6

C16

Sto

mac

h6

2.6

0.8

1.3

00.

00.

00.

03

3.2

0.6

0.9

C17

Sm

all i

ntes

tine

10.

40.

10.

30

0.0

0.0

0.0

11.

10.

20.

3C

18C

olon

73.

11.

01.

63

5.0

1.8

1.6

11.

10.

20.

3C

19-C

20R

ectu

m6

2.6

0.8

1.3

610

.03.

53.

90

0.0

0.0

0.0

C21

Anu

s0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C22

Live

r8

3.5

1.1

1.8

00.

00.

00.

02

2.1

0.4

0.7

C23

-C24

Gal

l bla

dder

, etc

.2

0.9

0.3

0.6

11.

70.

60.

73

3.2

0.6

0.9

C25

Pan

crea

s2

0.9

0.3

0.5

46.

72.

32.

62

2.1

0.4

0.6

C30

-C31

Nos

e, s

inus

es, e

tc.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

32La

rynx

10.

40.

10.

20

0.0

0.0

0.0

22.

10.

40.

5C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g5

2.2

0.7

1.0

23.

31.

21.

50

0.0

0.0

0.0

C37

-C38

Oth

er T

hora

cic

Org

ans

10.

40.

10.

20

0.0

0.0

0.0

00.

00.

00.

0C

40-C

41B

one

31.

30.

40.

31

1.7

0.6

0.4

33.

20.

60.

6C

43M

elan

oma

of S

kin

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

44O

ther

Ski

n14

6.2

2.0

2.9

11.

70.

60.

55

5.3

1.0

1.7

C45

Mes

othe

liom

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C46

Kap

osi s

arco

ma

00.

00.

00.

00

0.0

0.0

0.0

22.

10.

40.

5C

47; C

49C

onne

ctiv

e, S

oft T

issu

e4

1.8

0.6

0.7

35.

01.

81.

40

0.0

0.0

0.0

C51

Fem

ale

Bre

ast

2711

.93.

86.

67

11.7

4.1

6.6

1516

.03.

04.

7C

52V

ulva

10.

40.

10.

20

0.0

0.0

0.0

00.

00.

00.

0C

53V

agin

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C54

Cer

vix

Ute

ri5

2.2

0.7

1.2

58.

32.

93.

71

1.1

0.2

0.3

C55

Cor

pus

Ute

ri7

3.1

1.0

1.8

46.

72.

33.

00

0.0

0.0

0.0

C56

Ute

rus

Uns

pec.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

57O

vary

.12

5.3

1.7

2.4

35.

01.

81.

90

0.0

0.0

0.0

C58

Oth

er F

emal

e G

enita

l0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C64

Pla

cent

a1

0.4

0.1

0.2

00.

00.

00.

02

2.1

0.4

0.6

C64

Kid

ney

10.

40.

10.

21

1.7

0.6

0.6

11.

10.

20.

3C

65R

enal

pel

vis

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

66U

rete

r0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C67

Bla

dder

20.

90.

30.

41

1.7

0.6

0.8

22.

10.

40.

6C

68O

ther

urin

ary

orga

ns0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C69

Eye

31.

30.

40.

30

0.0

0.0

0.0

11.

10.

20.

4C

70-C

72B

rain

, Ner

vous

Sys

tem

62.

60.

80.

92

3.3

1.2

0.8

11.

10.

20.

3C

73Th

yroi

d25

11.0

3.5

5.2

610

.03.

54.

03

3.2

0.6

0.9

C74

Adr

enal

gla

nd0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C75

Oth

er E

ndoc

rine

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

81H

odgk

in D

isea

se9

4.0

1.3

1.4

11.

70.

60.

53

3.2

0.6

0.5

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a23

10.1

3.2

5.0

23.

31.

21.

56

6.4

1.2

1.7

C88

Imm

unop

rolif

erat

ive

dis.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

90M

ultip

le M

yelo

ma

10.

40.

10.

30

0.0

0.0

0.0

00.

00.

00.

0C

91Ly

mph

oid

Leuk

aem

ia8

3.5

1.1

1.1

23.

31.

21.

31

1.1

0.2

0.2

C92

-C94

Mye

loid

Leu

kaem

ia7

3.1

1.0

1.1

11.

70.

60.

50

0.0

0.0

0.0

C95

Leuk

aem

ia u

nspe

c.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

Oth

erO

ther

& u

nspe

cifie

d17

7.5

2.4

3.3

35.

01.

82.

03

3.2

0.6

1.0

All

All

Site

s

227

100.

031

.546

.960

100.

035

.440

.794

100.

018

.828

.3A

ll bu

t C44

All

Site

s bu

t C44

213

93.8

29.5

44.0

5998

.334

.840

.289

94.7

17.8

26.6

Asi

r

Bah

a

Jaza

n

Part005.indd 78 14-06-2007 12:57:44 PM

79

Tabl

e 5.

2.2

cont

inue

d ...

......

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRC

00Li

p0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C01

-C02

Tong

ue4

2.0

0.7

1.4

00.

00.

00.

00

0.0

0.0

0.0

C03

-C06

Mou

th0

0.0

0.0

0.0

11.

60.

40.

31

0.8

0.3

0.2

C07

-C08

Sal

ivar

y G

land

s0

0.0

0.0

0.0

11.

60.

40.

70

0.0

0.0

0.0

C9

Tons

il0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C10

Oth

er o

roph

aryn

x0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C11

Nas

opha

rynx

73.

51.

21.

75

7.8

2.2

6.0

10.

80.

30.

4C

12-C

13H

ypop

hary

nx1

0.5

0.2

0.3

00.

00.

00.

00

0.0

0.0

0.0

C14

Pha

rynx

uns

pec.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

15O

esop

hagu

s9

4.5

1.6

3.2

00.

00.

00.

03

2.3

0.8

1.5

C16

Sto

mac

h4

2.0

0.7

1.6

23.

10.

91.

51

0.8

0.3

0.5

C17

Sm

all i

ntes

tine

00.

00.

00.

00

0.0

0.0

0.0

10.

80.

31.

3C

18C

olon

105.

11.

83.

62

3.1

0.9

1.3

53.

91.

32.

3C

19-C

20R

ectu

m6

3.0

1.1

2.4

11.

60.

40.

88

6.2

2.0

4.9

C21

Anu

s1

0.5

0.2

0.3

11.

60.

40.

72

1.6

0.5

1.7

C22

Live

r4

2.0

0.7

1.6

34.

71.

34.

05

3.9

1.3

2.9

C23

-C24

Gal

l bla

dder

, etc

.3

1.5

0.5

1.1

11.

60.

40.

83

2.3

0.8

1.6

C25

Pan

crea

s3

1.5

0.5

1.1

11.

60.

40.

41

0.8

0.3

1.3

C30

-C31

Nos

e, s

inus

es, e

tc.

00.

00.

00.

01

1.6

0.4

0.4

00.

00.

00.

0C

32La

rynx

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g2

1.0

0.4

0.8

11.

60.

41.

00

0.0

0.0

0.0

C37

-C38

Oth

er T

hora

cic

Org

ans

42.

00.

70.

60

0.0

0.0

0.0

00.

00.

00.

0C

40-C

41B

one

31.

50.

50.

80

0.0

0.0

0.0

32.

30.

80.

6C

43M

elan

oma

of S

kin

00.

00.

00.

01

1.6

0.4

0.7

21.

60.

52.

1C

44O

ther

Ski

n5

2.5

0.9

1.9

34.

71.

32.

25

3.9

1.3

2.2

C45

Mes

othe

liom

a2

1.0

0.4

0.7

00.

00.

00.

00

0.0

0.0

0.0

C46

Kap

osi s

arco

ma

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

47; C

49C

onne

ctiv

e, S

oft T

issu

e3

1.5

0.5

0.7

11.

60.

40.

33

2.3

0.8

0.9

C51

Fem

ale

Bre

ast

2914

.65.

110

.68

12.5

3.5

6.0

3325

.68.

313

.0C

52V

ulva

10.

50.

20.

41

1.6

0.4

1.0

00.

00.

00.

0C

53V

agin

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C54

Cer

vix

Ute

ri7

3.5

1.2

2.3

57.

82.

23.

73

2.3

0.8

1.4

C55

Cor

pus

Ute

ri4

2.0

0.7

1.3

00.

00.

00.

03

2.3

0.8

1.5

C56

Ute

rus

Uns

pec.

00.

00.

00.

01

1.6

0.4

0.7

00.

00.

00.

0C

57O

vary

.10

5.1

1.8

2.8

11.

60.

40.

32

1.6

0.5

1.2

C58

Oth

er F

emal

e G

enita

l0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C64

Pla

cent

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C64

Kid

ney

31.

50.

51.

01

1.6

0.4

0.7

21.

60.

50.

4C

65R

enal

pel

vis

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

66U

rete

r0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C67

Bla

dder

21.

00.

40.

82

3.1

0.9

3.6

10.

80.

30.

3C

68O

ther

urin

ary

orga

ns0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C69

Eye

10.

50.

20.

11

1.6

0.4

0.4

10.

80.

30.

2C

70-C

72B

rain

, Ner

vous

Sys

tem

168.

12.

83.

51

1.6

0.4

0.7

32.

30.

80.

5C

73Th

yroi

d13

6.6

2.3

3.9

914

.14.

06.

49

7.0

2.3

2.6

C74

Adr

enal

gla

nd0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C75

Oth

er E

ndoc

rine

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

81H

odgk

in D

isea

se5

2.5

0.9

1.0

11.

60.

41.

03

2.3

0.8

0.7

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a12

6.1

2.1

3.3

11.

60.

40.

88

6.2

2.0

5.1

C88

Imm

unop

rolif

erat

ive

dis.

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

90M

ultip

le M

yelo

ma

00.

00.

00.

00

0.0

0.0

0.0

10.

80.

30.

5C

91Ly

mph

oid

Leuk

aem

ia8

4.0

1.4

1.4

34.

71.

31.

25

3.9

1.3

1.6

C92

-C94

Mye

loid

Leu

kaem

ia8

4.0

1.4

1.5

23.

10.

90.

76

4.7

1.5

2.4

C95

Leuk

aem

ia u

nspe

c.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

Oth

erO

ther

& u

nspe

cifie

d8

4.0

1.4

2.5

23.

10.

91.

15

3.9

1.3

3.8

All

All

Site

s

198

100.

035

.060

.264

100.

027

.549

.412

910

0.0

33.4

59.6

All

but C

44A

ll Si

tes

but C

4419

397

.534

.158

.361

95.3

26.2

47.2

124

96.1

32.1

57.4

Mad

inah

H

ail

Q

assi

m

Part005.indd 79 14-06-2007 12:57:44 PM

80

Tabl

e 5.

2.2

cont

inue

d ...

......

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

C00

Lip

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C01

-C02

Tong

ue1

2.2

0.6

1.0

00.

00.

00.

03

3.8

1.1

3.5

12.

60.

92.

3C

03-C

06M

outh

00.

00.

00.

00

0.0

0.0

0.0

11.

30.

40.

30

0.0

0.0

0.0

C07

-C08

Sal

ivar

y G

land

s0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

9To

nsil

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C10

Oth

er o

roph

aryn

x0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

11N

asop

hary

nx1

2.2

0.6

1.0

11.

90.

70.

82

2.5

0.7

1.2

00.

00.

00.

0C

12-C

13H

ypop

hary

nx0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

14P

hary

nx u

nspe

c.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

15O

esop

hagu

s0

0.0

0.0

0.0

00.

00.

00.

03

3.8

1.1

1.3

00.

00.

00.

0C

16S

tom

ach

36.

71.

84.

21

1.9

0.7

2.4

00.

00.

00.

01

2.6

0.9

1.7

C17

Sm

all i

ntes

tine

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C18

Col

on1

2.2

0.6

2.7

11.

90.

72.

44

5.1

1.4

4.8

00.

00.

00.

0C

19-C

20R

ectu

m2

4.4

1.2

2.4

35.

62.

08.

42

2.5

0.7

2.7

410

.53.

414

.0C

21A

nus

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C22

Live

r1

2.2

0.6

2.7

11.

90.

72.

41

1.3

0.4

0.8

12.

60.

92.

3C

23-C

24G

all b

ladd

er e

tc1

2.2

0.6

2.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

25P

ancr

eas

24.

41.

22.

10

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C30

-C31

Nos

e, s

inus

es, e

tc.

00.

00.

00.

01

1.9

0.7

0.6

00.

00.

00.

00

0.0

0.0

0.0

C32

Lary

nx0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g1

2.2

0.6

2.0

11.

90.

70.

70

0.0

0.0

0.0

00.

00.

00.

0C

37-C

38O

ther

Tho

raci

c O

rgan

s0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

40-C

41B

one

24.

41.

20.

91

1.9

0.7

0.6

11.

30.

40.

40

0.0

0.0

0.0

C43

Mel

anom

a of

Ski

n0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

44O

ther

Ski

n3

6.7

1.8

3.6

00.

00.

00.

04

5.1

1.4

5.4

25.

31.

712

.2C

45M

esot

helio

ma

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C46

Kap

osi s

arco

ma

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C47

; C49

Con

nect

ive,

Sof

t Tis

sue

00.

00.

00.

02

3.7

1.3

1.0

33.

81.

12.

12

5.3

1.7

1.5

C51

Fem

ale

Bre

ast

48.

92.

35.

811

20.4

7.3

14.6

1316

.54.

614

.010

26.3

8.6

15.5

C52

Vul

va0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

53V

agin

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

54C

ervi

x U

teri

48.

92.

36.

43

5.6

2.0

5.2

11.

30.

41.

40

0.0

0.0

0.0

C55

Cor

pus

Ute

ri1

2.2

0.6

1.5

47.

42.

77.

14

5.1

1.4

3.9

25.

31.

73.

8C

56U

teru

s U

nspe

c.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

57O

vary

.1

2.2

0.6

0.9

23.

71.

32.

12

2.5

0.7

1.7

00.

00.

00.

0C

58O

ther

Fem

ale

Gen

ital

00.

00.

00.

01

1.9

0.7

1.5

00.

00.

00.

00

0.0

0.0

0.0

C64

Pla

cent

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

64K

idne

y0

0.0

0.0

0.0

00.

00.

00.

01

1.3

0.4

0.4

12.

60.

91.

1C

65R

enal

pel

vis

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C66

Ure

ter

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C67

Bla

dder

12.

20.

62.

71

1.9

0.7

3.2

11.

30.

41.

10

0.0

0.0

0.0

C68

Oth

er u

rinar

y or

gans

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C69

Eye

00.

00.

00.

01

1.9

0.7

2.4

22.

50.

70.

40

0.0

0.0

0.0

C70

-C72

Bra

in, N

ervo

us S

yste

m0

0.0

0.0

0.0

00.

00.

00.

02

2.5

0.7

2.6

00.

00.

00.

0C

73Th

yroi

d9

20.0

5.3

9.0

611

.14.

09.

110

12.7

3.6

5.9

410

.53.

44.

6C

74A

dren

al g

land

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

01

2.6

0.9

0.6

C75

Oth

er E

ndoc

rine

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C81

Hod

gkin

Dis

ease

12.

20.

60.

51

1.9

0.7

0.6

33.

81.

11.

42

5.3

1.7

1.3

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a4

8.9

2.3

6.5

35.

62.

03.

65

6.3

1.8

3.6

37.

92.

613

.5C

88Im

mun

opro

lifer

ativ

e di

s.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

90M

ultip

le M

yelo

ma

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

01

2.6

0.9

3.7

C91

Lym

phoi

d Le

ukae

mia

12.

20.

60.

42

3.7

1.3

0.9

22.

50.

70.

62

5.3

1.7

2.2

C92

-C94

Mye

loid

Leu

kaem

ia1

2.2

0.6

0.5

35.

62.

02.

73

3.8

1.1

1.2

00.

00.

00.

0C

95Le

ukae

mia

uns

pec.

00.

00.

00.

01

1.9

0.7

0.4

00.

00.

00.

00

0.0

0.0

0.0

Oth

erO

ther

& u

nspe

cifie

d0

0.0

0.0

0.0

35.

62.

07.

06

7.6

2.1

5.9

12.

60.

91.

7A

llA

ll Si

tes

45

100

26.6

58.8

5410

036

.379

.779

100

28.4

66.6

3810

032

.882

.0A

ll bu

t C44

All

Site

s bu

t C44

4293

.333

24.8

55.2

5410

036

.379

.775

94.9

27.0

61.2

3694

.731

.169

.8

Naj

ran

Jo

uf

Tabu

k

Nor

ther

n R

egio

n

Part005.indd 80 14-06-2007 12:57:45 PM

81

Tabl

e 5.

2.2

cont

inue

d ...

......

ICD

(10t

h)A

LL S

ITES

Tot.

%

Cru

deA

SRTo

t.%

C

rude

ASR

Tot.

%

Cru

de

ASR

C00

Lip

00.

00.

00.

02

0.3

0.1

0.2

00.

00.

00.

0C

01-C

02To

ngue

10.

10.

10.

212

1.5

0.7

1.4

20.

30.

20.

4C

03-C

06M

outh

40.

40.

20.

51

0.1

0.1

0.1

00.

00.

00.

0C

07-C

08S

aliv

ary

Gla

nds

20.

20.

10.

21

0.1

0.1

0.1

30.

50.

20.

5C

9To

nsil

10.

10.

10.

21

0.1

0.1

0.1

10.

20.

10.

3C

10O

ther

oro

phar

ynx

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

11N

asop

hary

nx6

0.7

0.3

0.8

70.

90.

40.

65

0.9

0.4

0.4

C12

-C13

Hyp

opha

rynx

00.

00.

00.

00

0.0

0.0

0.0

00.

00.

00.

0C

14P

hary

nx u

nspe

c.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C15

Oes

opha

gus

121.

30.

71.

79

1.2

0.5

1.0

61.

00.

51.

5C

16S

tom

ach

232.

61.

33.

219

2.4

1.1

2.5

122.

11.

02.

4C

17S

mal

l int

estin

e0

0.0

0.0

0.0

50.

60.

30.

52

0.3

0.2

0.5

C18

Col

on43

4.8

2.4

5.2

425.

42.

44.

625

4.3

2.1

5.1

C19

-C20

Rec

tum

222.

51.

23.

029

3.7

1.7

3.0

152.

61.

23.

3C

21A

nus

30.

30.

20.

52

0.3

0.1

0.2

10.

20.

10.

1C

22Li

ver

455.

02.

56.

722

2.8

1.3

2.3

162.

81.

34.

3C

23-C

24G

all b

ladd

er e

tc.

161.

80.

92.

313

1.7

0.7

1.5

132.

21.

13.

3C

25P

ancr

eas

111.

20.

61.

44

0.5

0.2

0.3

61.

00.

51.

4C

30-C

31N

ose,

sin

uses

, etc

.1

0.1

0.1

0.2

00.

00.

00.

00

0.0

0.0

0.0

C32

Lary

nx1

0.1

0.1

0.1

00.

00.

00.

00

0.0

0.0

0.0

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

131.

50.

71.

820

2.6

1.1

2.2

132.

21.

12.

9C

37-C

38O

ther

Tho

raci

c O

rgan

s2

0.2

0.1

0.1

20.

30.

10.

11

0.2

0.1

0.1

C40

-C41

Bon

e9

1.0

0.5

0.7

60.

80.

30.

25

0.9

0.4

0.3

C43

Mel

anom

a of

Ski

n2

0.2

0.1

0.2

20.

30.

10.

20

0.0

0.0

0.0

C44

Oth

er S

kin

374.

12.

15.

023

3.0

1.3

2.3

111.

90.

92.

4C

45M

esot

helio

ma

10.

10.

10.

12

0.3

0.1

0.3

20.

30.

20.

5C

46K

apos

i sar

com

a2

0.2

0.1

0.3

00.

00.

00.

01

0.2

0.1

0.3

C47

; C49

Con

nect

ive,

Sof

t Tis

sue

182.

01.

01.

47

0.9

0.4

0.5

71.

20.

60.

7C

51Fe

mal

e B

reas

t15

317

.18.

616

.219

625

.211

.219

.116

628

.713

.727

.6C

52V

ulva

10.

10.

10.

11

0.1

0.1

0.1

10.

20.

10.

2C

53V

agin

a0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C54

Cer

vix

Ute

ri19

2.1

1.1

2.1

222.

81.

32.

412

2.1

1.0

1.7

C55

Cor

pus

Ute

ri35

3.9

2.0

5.0

324.

11.

84.

016

2.8

1.3

3.6

C56

Ute

rus

Uns

pec.

20.

20.

10.

25

0.6

0.3

0.5

10.

20.

10.

2C

57O

vary

.26

2.9

1.5

2.3

303.

91.

73.

020

3.5

1.6

2.7

C58

Oth

er F

emal

e G

enita

l2

0.2

0.1

0.3

20.

30.

10.

20

0.0

0.0

0.0

C64

Pla

cent

a1

0.1

0.1

0.1

10.

10.

10.

11

0.2

0.1

0.1

C64

Kid

ney

212.

31.

22.

516

2.1

0.9

1.5

101.

70.

81.

8C

65R

enal

pel

vis

10.

10.

10.

21

0.1

0.1

0.1

00.

00.

00.

0C

66U

rete

r0

0.0

0.0

0.0

10.

10.

10.

10

0.0

0.0

0.0

C67

Bla

dder

111.

20.

61.

414

1.8

0.8

1.5

30.

50.

20.

7C

68O

ther

urin

ary

orga

ns0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C69

Eye

40.

40.

20.

31

0.1

0.1

0.0

00.

00.

00.

0C

70-C

72B

rain

, Ner

vous

Sys

tem

273.

01.

52.

411

1.4

0.6

1.1

122.

11.

01.

5C

73Th

yroi

d13

114

.77.

410

.157

7.3

3.3

4.9

6010

.44.

97.

1C

74A

dren

al g

land

40.

40.

20.

33

0.4

0.2

0.2

40.

70.

30.

2C

75O

ther

End

ocrin

e1

0.1

0.1

0.1

00.

00.

00.

00

0.0

0.0

0.0

C81

Hod

gkin

Dis

ease

333.

71.

92.

218

2.3

1.0

1.2

234.

01.

92.

3C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

495.

52.

85.

763

8.1

3.6

6.5

396.

73.

26.

6C

88Im

mun

opro

lifer

ativ

e di

s.0

0.0

0.0

0.0

00.

00.

00.

00

0.0

0.0

0.0

C90

Mul

tiple

Mye

lom

a2

0.2

0.1

0.3

40.

50.

20.

43

0.5

0.2

0.9

C91

Lym

phoi

d Le

ukae

mia

262.

91.

51.

412

1.5

0.7

0.5

122.

11.

01.

3C

92-C

94M

yelo

id L

euka

emia

313.

51.

72.

916

2.1

0.9

1.1

172.

91.

42.

7C

95Le

ukae

mia

uns

pec.

10.

10.

10.

01

0.1

0.1

0.0

20.

30.

20.

1O

ther

Oth

er &

uns

peci

fied

384.

32.

15.

139

5.0

2.2

4.8

295.

02.

47.

3A

llA

ll Si

tes

89

410

0.0

50.6

97.0

777

100.

044

.677

.557

810

0.0

47.7

99.3

All

but C

44A

ll Si

tes

but C

4485

795

.948

.592

.075

497

.043

.375

.256

798

.146

.896

.9

Riy

adh

M

akka

h

East

ern

Prov

ince

Part005.indd 81 14-06-2007 12:57:46 PM

82

Tabl

e 5.

3.1

Age

Dis

trib

utio

n of

Can

cer

Cas

es a

mon

g no

n-Sa

udi M

ales

, 200

3

ICD

10SI

TETo

t U

NK

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

+C

rude

R

ate

ASR

W

orld

C00

Lip

20

00

00

00

00

0.2

00

00

00

11.4

00.

2C

01-C

02To

ngue

140

00

00

0.3

00

0.6

0.4

0.6

1.1

2.4

2.6

00

00.

30.

4C

03-C

06M

outh

80

0.5

00

00

00

0.3

00

02.

42.

66.

10

11.4

0.2

0.7

C07

-C08

Sal

ivar

y G

land

s6

00

00

00

0.2

00.

20.

40

01.

22.

60

00

0.1

0.2

C9

Tons

il1

00

00

00

00

00

00

02.

60

00

00.

1C

10O

ther

oro

phar

ynx

00

00

00

00

00

00

00

00

00

00

C11

Nas

opha

rynx

250

00

01.

40.

30

0.1

0.3

0.6

3.3

0.5

1.2

7.8

00

00.

60.

8C

12-C

13H

ypop

hary

nx5

00

00

00

00.

10

0.2

0.6

01.

20

00

00.

10.

1C

14P

hary

nx u

nspe

c.1

00

00

00

00

00

0.3

00

00

00

00

C15

Oes

opha

gus

140

00

00

00

0.6

00.

20.

90

2.4

5.2

020

.80

0.3

0.8

C16

Sto

mac

h63

00

00

00.

30

1.2

1.2

1.2

3.6

4.8

610

.46.

183

.311

.41.

53.

4C

17S

mal

l int

estin

e4

00

00

00

00.

10

0.4

00

1.2

00

00

0.1

0.1

C18

Col

on70

00

00

00.

30.

50.

61.

71.

84.

84.

87.

27.

818

.410

.445

.61.

73.

1C

19-C

20R

ectu

m58

00

00

00.

70.

30.

70.

51.

83

3.7

9.7

12.9

36.8

10.4

01.

42.

8C

21A

nus

100

00

00

00

0.1

0.2

00.

60.

52.

40

6.1

022

.80.

20.

8C

22Li

ver

450

00

00

00

00.

81.

42.

42.

70

18.1

4352

.111

.41.

13.

7C

23-C

24G

all b

ladd

er e

ct.

60

00

00

00

00

0.2

0.6

0.5

00

6.1

011

.40.

10.

5C

25P

ancr

eas

110

00

00

00

00

0.2

0.6

0.5

2.4

2.6

6.1

10.4

22.8

0.3

1.1

C30

-C31

Nos

e, s

inus

es, e

tc.

50

00

00

00

00

0.2

0.9

00

00

011

.40.

10.

3C

32La

rynx

300

00

00

0.3

0.2

00.

30.

61.

21.

610

.910

.40

10.4

22.8

0.7

1.8

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

650

00

00

00

0.1

0.8

12.

76.

414

.531

.16.

131

.257

1.6

4.4

C37

-C38

Oth

er T

hora

cic

Org

ans

110

00

00

00.

20.

40

10.

30

02.

60

00

0.3

0.2

C40

-C41

Bon

e16

00

10

4.1

10.

20.

10

00.

30

02.

60

011

.40.

40.

9C

43M

elan

oma

of S

kin

40

00

00

00.

20

00

01.

60

00

00

0.1

0.1

C44

Oth

er S

kin

810

00

00

0.3

00.

30.

61.

45.

16.

420

.518

.149

.131

.234

.21.

95.

1C

45M

esot

helio

ma

50

00

00

00

0.1

00

00

1.2

2.6

6.1

011

.40.

10.

6C

46K

apos

i sar

com

a4

00

00

00

00

00.

20.

30.

50

00

10.4

00.

10.

3C

47; C

49C

onne

ctiv

e, S

oft T

issu

e25

01.

40.

50.

60.

70

00.

40.

20.

23.

30.

51.

20

00

11.4

0.6

0.9

C50

Bre

ast

80

00

00

0.3

00

00.

40.

31.

10

2.6

6.1

00

0.2

0.4

C60

Pen

is0

00

00

00

00

00

00

00

00

00

0C

61P

rost

ate

470

00

00

00

00

00.

33.

214

.528

.555

.341

.645

.61.

15.

3C

62Te

stis

210

00

00.

70.

70.

51

0.6

0.6

00

1.2

00

00

0.5

0.3

C63

Oth

er m

ale

geni

tal

00

00

00

00

00

00

00

00

00

00

C64

Kid

ney

270

00

00

00.

20

0.3

12.

12.

14.

85.

26.

10

11.4

0.6

1.1

C65

Ren

al p

elvi

s0

00

00

00

00

00

00

00

00

00

0C

66U

rete

r1

00

00

00

00

00

00

02.

60

00

00.

1C

67B

ladd

er61

00

0.5

00

0.3

00

0.5

1.2

2.1

10.1

620

.724

.631

.245

.61.

54.

2C

68O

ther

urin

ary

orga

ns0

00

00

00

00

00

00

00

00

00

0C

69E

ye10

01.

40

00

00.

20.

10.

50.

20

00

2.6

00

00.

20.

3C

70-C

72B

rain

, Ner

vous

Sys

tem

400

02.

51.

20.

70.

30.

20.

90.

21.

22.

41.

62.

42.

66.

120

.80

11.

6C

73Th

yroi

d25

00

0.5

01.

40.

70.

20.

30.

51.

40.

61.

61.

20

6.1

00

0.6

0.7

C74

Adr

enal

gla

nd4

01.

40

00

00

00.

20

00

00

00

00.

10.

2C

75O

ther

End

ocrin

e1

00

00

00

00.

10

00

00

00

00

00

C81

Hod

gkin

Dis

ease

310

0.9

2.5

0.6

00.

30.

50.

70.

60.

80.

61.

12.

40

00

00.

70.

8C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

780

1.8

10.

62.

71.

40.

50.

91.

22.

21.

24.

815

.77.

830

.70

11.4

1.9

3.4

C88

Imm

unop

rolif

erat

ive

dis.

10

00

00

00

00

00

00

06.

10

00

0.2

C90

Mul

tiple

Mye

lom

a8

00

00

00

00

00.

20.

30.

51.

25.

212

.30

00.

20.

7C

91Ly

mph

oid

Leuk

aem

ia36

03.

71.

52.

34.

10.

30.

50.

10.

30.

20.

31.

62.

42.

60

00

0.9

1.6

C92

-C94

Mye

loid

Leu

kaem

ia35

00

0.5

1.2

01.

70.

31.

30.

50.

21.

51.

61.

25.

26.

10

00.

81

C95

Leuk

aem

ia u

nspe

c.5

00

00.

60

0.3

00

00

0.9

00

00

00

0.1

0.1

Oth

erO

ther

& u

nspe

cifie

d46

00

00.

60.

70.

30

0.3

0.8

11.

54.

86

18.1

12.3

10.4

22.8

1.1

2.6

All

All

Age

s To

tal

1074

0.0

11.1

10.5

7.7

16.5

10.1

4.9

10.6

13.9

24.2

49.5

70.2

147.

024

6.3

361.

837

4.6

444.

625

.458

.0N

ot C

44A

ll si

tes

but C

4499

30.

011

.110

.57.

716

.59.

84.

910

.313

.322

.844

.463

.812

6.5

228.

231

2.7

343.

441

0.4

23.5

52.9

Part005.indd 82 14-06-2007 12:57:46 PM

83

Tabl

e 5.

3.2

Age

Dis

trib

utio

n of

Can

cer

Cas

es a

mon

g no

n-Sa

udi F

emal

es, 2

003

ICD

10SI

TETo

t U

NK

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

+C

rude

Rat

eA

SR

Wor

ldC

00Li

p2

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

02.

40.

00.

00.

00.

014

.20.

10.

4C

01-C

02To

ngue

30

0.0

0.0

0.0

0.0

0.6

0.0

0.0

0.0

0.8

1.4

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.2

C03

-C06

Mou

th7

00.

00.

00.

00.

00.

00.

00.

00.

50.

02.

82.

44.

70.

013

.10.

014

.20.

41.

2C

07-C

08S

aliv

ary

Gla

nds

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.4

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.1

C9

Tons

il0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00

0C

10O

ther

oro

phar

ynx

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

4.7

0.0

0.0

0.0

0.0

0.1

0.2

C11

Nas

opha

rynx

80

0.0

0.0

0.0

0.0

1.3

0.4

0.4

1.1

1.7

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.4

0.3

C12

-C13

Hyp

opha

rynx

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.4

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.1

C14

Pha

rynx

uns

pec.

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

00

C15

Oes

opha

gus

80

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.5

0.8

0.0

2.4

0.0

6.8

0.0

0.0

56.7

0.4

1.6

C16

Sto

mac

h9

00.

00.

00.

00.

00.

00.

00.

00.

01.

71.

47.

14.

70.

026

.10.

00.

00.

51.

5C

17S

mal

l int

estin

e3

00.

00.

00.

00.

00.

00.

00.

40.

00.

01.

42.

40.

00.

00.

00.

00.

00.

20.

2C

18C

olon

290

0.0

0.0

0.0

0.0

0.6

0.9

0.4

0.5

2.5

1.4

14.1

47.3

6.8

26.1

0.0

14.2

1.6

4.3

C19

-C20

Rec

tum

210

0.0

0.0

0.0

0.0

0.0

0.9

0.8

1.1

3.4

7.0

7.1

9.5

0.0

0.0

16.1

0.0

1.1

1.9

C21

Anu

s5

00.

00.

00.

00.

00.

00.

00.

00.

00.

04.

22.

40.

00.

013

.10.

00.

00.

30.

8C

22Li

ver

60

0.0

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

1.4

0.0

9.5

6.8

13.1

0.0

0.0

0.3

1.2

C23

-C24

Gal

l bla

dder

ect

.6

00.

00.

00.

00.

00.

00.

00.

00.

00.

80.

00.

04.

713

.713

.10.

014

.20.

31.

5C

25P

ancr

eas

100

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

1.4

2.4

14.2

0.0

39.2

0.0

14.2

0.5

2.3

C30

-C31

Nos

e, s

inus

es, e

tc.

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.5

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0C

32La

rynx

40

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.1

0.0

0.0

0.0

4.7

6.8

0.0

0.0

0.0

0.2

0.5

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

150

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

0.8

1.4

2.4

9.5

0.0

52.2

32.1

42.5

0.8

3.7

C37

-C38

Oth

er T

hora

cic

Org

ans

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.1

C40

-C41

Bon

e7

00.

00.

50.

01.

40.

00.

00.

40.

50.

01.

42.

40.

00.

00.

00.

00.

00.

40.

4C

43M

elan

oma

of S

kin

60

0.5

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

0.0

0.0

14.2

6.8

0.0

0.0

0.0

0.3

0.9

C44

Oth

er S

kin

470

0.0

0.5

0.0

0.0

0.6

1.3

2.3

1.6

5.0

7.0

16.5

14.2

13.7

39.2

80.3

28.3

2.6

6.4

C45

Mes

othe

liom

a2

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

04.

70.

00.

00.

00.

00.

00.

10.

2C

46K

apos

i sar

com

a1

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

04.

70.

00.

00.

00.

00.

10.

2C

47; C

49C

onne

ctiv

e, S

oft T

issu

e17

00.

50.

00.

02.

21.

90.

90.

80.

51.

71.

40.

00.

06.

80.

00.

014

.20.

91.

3C

50B

reas

t24

60

0.0

0.0

0.0

0.0

1.9

3.0

9.8

21.6

29.4

61.9

96.5

75.7

88.9

143.

632

.111

3.3

13.4

26.4

C51

Vul

va2

00.

00.

00.

00.

00.

00.

00.

00.

50.

00.

00.

04.

70.

00.

00.

00.

00.

10.

2C

52V

agin

a1

00.

00.

00.

00.

00.

60.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

10.

1C

53C

ervi

x U

teri

360

0.0

0.0

0.0

0.0

0.6

0.9

0.8

2.7

10.9

5.6

7.1

18.9

0.0

26.1

0.0

0.0

23.

2C

54C

orpu

s U

teri

240

0.0

0.0

0.0

0.0

0.0

0.4

0.4

1.1

2.5

1.4

9.4

28.4

20.5

13.1

32.1

0.0

1.3

3.8

C55

Ute

rus

Uns

pec.

50

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

2.8

2.4

0.0

0.0

13.1

0.0

0.0

0.3

0.7

C56

Ova

ry.

360

0.9

0.0

0.0

1.4

1.3

0.4

1.5

2.2

2.5

1.4

21.2

9.5

13.7

13.1

32.1

14.2

24.

1C

57O

ther

Fem

ale

Gen

ital

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

00

C58

Pla

cent

a0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00

0C

64K

idne

y6

00.

00.

00.

00.

00.

60.

00.

00.

00.

80.

00.

00.

027

.40.

00.

00.

00.

31.

2C

65R

enal

pel

vis

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C66

Ure

ter

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C67

Bla

dder

110

0.0

0.0

0.0

0.0

0.0

0.0

0.4

2.2

0.0

0.0

7.1

0.0

6.8

13.1

16.1

0.0

0.6

1.5

C68

Oth

er u

rinar

y or

gans

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C69

Eye

50

1.9

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

4.7

0.0

0.0

0.0

0.0

0.3

0.4

C70

-C72

Bra

in, N

ervo

us S

yste

m15

00.

90.

50.

60.

00.

60.

00.

40.

02.

51.

44.

79.

50.

013

.10.

00.

00.

81.

5C

73Th

yroi

d58

00.

00.

00.

61.

40.

04.

33.

47.

08.

45.

64.

79.

520

.513

.10.

014

.23.

24.

1C

74A

dren

al g

land

40

1.9

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.2

C75

Oth

er E

ndoc

rine

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

00

C81

Hod

gkin

Dis

ease

160

0.0

0.0

0.6

3.6

0.6

1.3

0.4

0.0

0.0

1.4

0.0

9.5

6.8

0.0

16.1

0.0

0.9

1.6

C82

-C85

; C96

Non

Hod

gkin

lym

phom

a33

00.

50.

51.

82.

20.

60.

00.

81.

10.

84.

216

.59.

513

.713

.148

.214

.21.

84.

3C

88Im

mun

opro

lifer

ativ

e di

s.0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C

90M

ultip

le M

yelo

ma

50

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.5

0.0

1.4

0.0

9.5

6.8

0.0

0.0

0.0

0.3

0.8

C91

Lym

phoi

d Le

ukae

mia

230

5.7

2.1

0.6

1.4

0.0

0.0

0.0

0.0

1.7

0.0

0.0

4.7

0.0

0.0

0.0

14.2

1.3

1.6

C92

-C94

Mye

loid

Leu

kaem

ia18

00.

50.

01.

20.

00.

61.

30.

81.

61.

70.

04.

70.

00.

00.

032

.10.

01

1.4

C95

Leuk

aem

ia u

nspe

c.0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00

0O

ther

Oth

er &

uns

peci

fied

270

0.5

0.0

0.0

0.0

0.0

0.9

0.8

1.6

3.4

4.2

4.7

23.7

0.0

26.1

32.1

14.2

1.5

3.6

All

All

Age

s To

tal

792

013

.84.

15.

413

.612

.417

.325

.450

.087

.012

7.7

247.

736

4.4

273.

352

2.7

369.

439

7.0

43.6

92.2

Not

C44

All

site

s bu

t C44

745

013

.83.

65.

413

.611

.816

.023

.148

.482

.012

0.7

231.

235

0.2

259.

648

3.5

289.

136

8.7

41.0

85.8

Part005.indd 83 14-06-2007 12:57:47 PM

84

Tabl

e 5.

3.3

Inci

denc

e R

ates

for

Can

cer

Cas

es a

mon

g no

n- S

audi

Mal

es b

y A

ge G

roup

(pe

r 10

0,00

0), 2

003

ICD

10SI

TETo

t U

NK

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

+C

rude

Rat

eA

SRW

orld

C00

Lip

20

00

00

00

00

0.2

00

00

00

11.4

00.

2C

01-C

02To

ngue

140

00

00

0.3

00

0.6

0.4

0.6

1.1

2.4

2.6

00

00.

30.

4C

03-C

06M

outh

80

0.5

00

00

00

0.3

00

02.

42.

66.

10

11.4

0.2

0.7

C07

-C08

Sal

ivar

y G

land

s6

00

00

00

0.2

00.

20.

40

01.

22.

60

00

0.1

0.2

C9

Tons

il1

00

00

00

00

00

00

02.

60

00

00.

1C

10O

ther

oro

phar

ynx

00

00

00

00

00

00

00

00

00

00

C11

Nas

opha

rynx

250

00

01.

40.

30

0.1

0.3

0.6

3.3

0.5

1.2

7.8

00

00.

60.

8C

12-C

13H

ypop

hary

nx5

00

00

00

00.

10

0.2

0.6

01.

20

00

00.

10.

1C

14P

hary

nx u

nspe

c.1

00

00

00

00

00

0.3

00

00

00

00

C15

Oes

opha

gus

140

00

00

00

0.6

00.

20.

90

2.4

5.2

020

.80

0.3

0.8

C16

Sto

mac

h63

00

00

00.

30

1.2

1.2

1.2

3.6

4.8

610

.46.

183

.311

.41.

53.

4C

17S

mal

l int

estin

e4

00

00

00

00.

10

0.4

00

1.2

00

00

0.1

0.1

C18

Col

on70

00

00

00.

30.

50.

61.

71.

84.

84.

87.

27.

818

.410

.445

.61.

73.

1C

19-C

20R

ectu

m58

00

00

00.

70.

30.

70.

51.

83

3.7

9.7

12.9

36.8

10.4

01.

42.

8C

21A

nus

100

00

00

00

0.1

0.2

00.

60.

52.

40

6.1

022

.80.

20.

8C

22Li

ver

450

00

00

00

00.

81.

42.

42.

70

18.1

4352

.111

.41.

13.

7C

23-C

24G

all b

ladd

er e

ct.

60

00

00

00

00

0.2

0.6

0.5

00

6.1

011

.40.

10.

5C

25P

ancr

eas

110

00

00

00

00

0.2

0.6

0.5

2.4

2.6

6.1

10.4

22.8

0.3

1.1

C30

-C31

Nos

e, s

inus

es, e

tc.

50

00

00

00

00

0.2

0.9

00

00

011

.40.

10.

3C

32La

rynx

300

00

00

0.3

0.2

00.

30.

61.

21.

610

.910

.40

10.4

22.8

0.7

1.8

C33

-C34

Trac

hea,

Bro

nchu

s, L

ung

650

00

00

00

0.1

0.8

12.

76.

414

.531

.16.

131

.257

1.6

4.4

C37

-C38

Oth

er T

hora

cic

Org

ans

110

00

00

00.

20.

40

10.

30

02.

60

00

0.3

0.2

C40

-C41

Bon

e16

00

10

4.1

10.

20.

10

00.

30

02.

60

011

.40.

40.

9C

43M

elan

oma

of S

kin

40

00

00

00.

20

00

01.

60

00

00

0.1

0.1

C44

Oth

er S

kin

810

00

00

0.3

00.

30.

61.

45.

16.

420

.518

.149

.131

.234

.21.

95.

1C

45M

esot

helio

ma

50

00

00

00

0.1

00

00

1.2

2.6

6.1

011

.40.

10.

6C

46K

apos

i sar

com

a4

00

00

00

00

00.

20.

30.

50

00

10.4

00.

10.

3C

47; C

49C

onne

ctiv

e, S

oft T

issu

e25

01.

40.

50.

60.

70

00.

40.

20.

23.

30.

51.

20

00

11.4

0.6

0.9

C50

Bre

ast

80

00

00

0.3

00

00.

40.

31.

10

2.6

6.1

00

0.2

0.4

C60

Pen

is0

00

00

00

00

00

00

00

00

00

0C

61P

rost

ate

470

00

00

00

00

00.

33.

214

.528

.555

.341

.645

.61.

15.

3C

62Te

stis

210

00

00.

70.

70.

51

0.6

0.6

00

1.2

00

00

0.5

0.3

C63

Oth

er m

ale

geni

tal

00

00

00

00

00

00

00

00

00

00

C64

Kid

ney

270

00

00

00.

20

0.3

12.

12.

14.

85.

26.

10

11.4

0.6

1.1

C65

Ren

al p

elvi

s0

00

00

00

00

00

00

00

00

00

0C

66U

rete

r1

00

00

00

00

00

00

02.

60

00

00.

1C

67B

ladd

er61

00

0.5

00

0.3

00

0.5

1.2

2.1

10.1

620

.724

.631

.245

.61.

54.

2C

68O

ther

urin

ary

orga

ns0

00

00

00

00

00

00

00

00

00

0C

69E

ye10

01.

40

00

00.

20.

10.

50.

20

00

2.6

00

00.

20.

3C

70-C

72B

rain

, Ner

vous

Sys

tem

400

02.

51.

20.

70.

30.

20.

90.

21.

22.

41.

62.

42.

66.

120

.80

11.

6C

73Th

yroi

d25

00

0.5

01.

40.

70.

20.

30.

51.

40.

61.

61.

20

6.1

00

0.6

0.7

C74

Adr

enal

gla

nd4

01.

40

00

00

00.

20

00

00

00

00.

10.

2C

75O

ther

End

ocrin

e1

00

00

00

00.

10

00

00

00

00

00

C81

Hod

gkin

Dis

ease

310

0.9

2.5

0.6

00.

30.

50.

70.

60.

80.

61.

12.

40

00

00.

70.

8C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

780

1.8

10.

62.

71.

40.

50.

91.

22.

21.

24.

815

.77.

830

.70

11.4

1.9

3.4

C88

Imm

unop

rolif

erat

ive

dis.

10

00

00

00

00

00

00

06.

10

00

0.2

C90

Mul

tiple

Mye

lom

a8

00

00

00

00

00.

20.

30.

51.

25.

212

.30

00.

20.

7C

91Ly

mph

oid

Leuk

aem

ia36

03.

71.

52.

34.

10.

30.

50.

10.

30.

20.

31.

62.

42.

60

00

0.9

1.6

C92

-C94

Mye

loid

Leu

kaem

ia35

00

0.5

1.2

01.

70.

31.

30.

50.

21.

51.

61.

25.

26.

10

00.

81

C95

Leuk

aem

ia u

nspe

c.5

00

00.

60

0.3

00

00

0.9

00

00

00

0.1

0.1

Oth

erO

ther

& u

nspe

cifie

d46

00

00.

60.

70.

30

0.3

0.8

11.

54.

86

18.1

12.3

10.4

22.8

1.1

2.6

All

All

site

s 10

740.

011

.110

.57.

716

.510

.14.

910

.613

.924

.249

.570

.214

7.0

246.

336

1.8

374.

644

4.6

25.4

58.0

All

but C

44A

ll si

tes

but C

4499

30.

011

.110

.57.

716

.59.

84.

910

.313

.322

.844

.463

.812

6.5

228.

231

2.7

343.

441

0.4

23.5

52.9

Part005.indd 84 14-06-2007 12:57:48 PM

85

Tabl

e 5.

3.4

Inci

denc

e R

ates

for

Can

cer

Cas

es a

mon

g no

n-Sa

udi F

emal

es b

y A

ge G

roup

(pe

r 10

0,00

0), 2

003

ICD

10SI

TETo

t U

NK

0-4

5-9

10-1

415

-19

20-2

425

-29

30-3

435

-39

40-4

445

-49

50-5

455

-59

60-6

465

-69

70-7

475

+C

rude

R

ate

ASR

W

orld

C00

Lip

20

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.4

0.0

0.0

0.0

0.0

14.2

0.1

0.4

C01

-C02

Tong

ue3

00.

00.

00.

00.

00.

60.

00.

00.

00.

81.

40.

00.

00.

00.

00.

00.

00.

20.

2C

03-C

06M

outh

70

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.5

0.0

2.8

2.4

4.7

0.0

13.1

0.0

14.2

0.4

1.2

C07

-C08

Sal

ivar

y G

land

s1

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

40.

00.

00.

00.

00.

00.

00.

10.

1C

9To

nsil

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

00

C10

Oth

er o

roph

aryn

x1

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

04.

70.

00.

00.

00.

00.

10.

2C

11N

asop

hary

nx8

00.

00.

00.

00.

01.

30.

40.

41.

11.

70.

00.

00.

00.

00.

00.

00.

00.

40.

3C

12-C

13H

ypop

hary

nx1

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

40.

00.

00.

00.

00.

00.

00.

10.

1C

14P

hary

nx u

nspe

c.0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00

0C

15O

esop

hagu

s8

00.

00.

00.

00.

00.

00.

00.

00.

50.

80.

02.

40.

06.

80.

00.

056

.70.

41.

6C

16S

tom

ach

90

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.7

1.4

7.1

4.7

0.0

26.1

0.0

0.0

0.5

1.5

C17

Sm

all i

ntes

tine

30

0.0

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

1.4

2.4

0.0

0.0

0.0

0.0

0.0

0.2

0.2

C18

Col

on29

00.

00.

00.

00.

00.

60.

90.

40.

52.

51.

414

.147

.36.

826

.10.

014

.21.

64.

3C

19-C

20R

ectu

m21

00.

00.

00.

00.

00.

00.

90.

81.

13.

47.

07.

19.

50.

00.

016

.10.

01.

11.

9C

21A

nus

50

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

4.2

2.4

0.0

0.0

13.1

0.0

0.0

0.3

0.8

C22

Live

r6

00.

00.

00.

00.

00.

00.

00.

40.

00.

01.

40.

09.

56.

813

.10.

00.

00.

31.

2C

23-C

24G

all b

ladd

er e

ct.

60

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.8

0.0

0.0

4.7

13.7

13.1

0.0

14.2

0.3

1.5

C25

Pan

crea

s10

00.

00.

00.

00.

00.

00.

00.

00.

00.

81.

42.

414

.20.

039

.20.

014

.20.

52.

3C

30-C

31N

ose,

sin

uses

, etc

.1

00.

00.

00.

00.

00.

00.

00.

00.

50.

00.

00.

00.

00.

00.

00.

00.

00.

10

C32

Lary

nx4

00.

00.

00.

00.

00.

00.

00.

01.

10.

00.

00.

04.

76.

80.

00.

00.

00.

20.

5C

33-C

34Tr

ache

a, B

ronc

hus,

Lun

g15

00.

00.

00.

00.

00.

00.

40.

00.

00.

81.

42.

49.

50.

052

.232

.142

.50.

83.

7C

37-C

38O

ther

Tho

raci

c O

rgan

s1

00.

00.

00.

00.

00.

00.

00.

00.

00.

80.

00.

00.

00.

00.

00.

00.

00.

10.

1C

40-C

41B

one

70

0.0

0.5

0.0

1.4

0.0

0.0

0.4

0.5

0.0

1.4

2.4

0.0

0.0

0.0

0.0

0.0

0.4

0.4

C43

Mel

anom

a of

Ski

n6

00.

50.

00.

00.

00.

00.

00.

00.

00.

80.

00.

014

.26.

80.

00.

00.

00.

30.

9C

44O

ther

Ski

n47

00.

00.

50.

00.

00.

61.

32.

31.

65.

07.

016

.514

.213

.739

.280

.328

.32.

66.

4C

45M

esot

helio

ma

20

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

4.7

0.0

0.0

0.0

0.0

0.0

0.1

0.2

C46

Kap

osi s

arco

ma

10

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

4.7

0.0

0.0

0.0

0.0

0.1

0.2

C47

; C49

Con

nect

ive,

Sof

t Tis

sue

170

0.5

0.0

0.0

2.2

1.9

0.9

0.8

0.5

1.7

1.4

0.0

0.0

6.8

0.0

0.0

14.2

0.9

1.3

C50

Bre

ast

246

00.

00.

00.

00.

01.

93.

09.

821

.629

.461

.996

.575

.788

.914

3.6

32.1

113.

313

.426

.4C

51V

ulva

20

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.5

0.0

0.0

0.0

4.7

0.0

0.0

0.0

0.0

0.1

0.2

C52

Vag

ina

10

0.0

0.0

0.0

0.0

0.6

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.1

0.1

C53

Cer

vix

Ute

ri36

00.

00.

00.

00.

00.

60.

90.

82.

710

.95.

67.

118

.90.

026

.10.

00.

02

3.2

C54

Cor

pus

Ute

ri24

00.

00.

00.

00.

00.

00.

40.

41.

12.

51.

49.

428

.420

.513

.132

.10.

01.

33.

8C

55U

teru

s U

nspe

c.5

00.

00.

00.

00.

00.

00.

00.

00.

00.

82.

82.

40.

00.

013

.10.

00.

00.

30.

7C

56O

vary

.36

00.

90.

00.

01.

41.

30.

41.

52.

22.

51.

421

.29.

513

.713

.132

.114

.22

4.1

C57

Oth

er F

emal

e G

enita

l0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00

0C

58P

lace

nta

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

00

C64

Kid

ney

60

0.0

0.0

0.0

0.0

0.6

0.0

0.0

0.0

0.8

0.0

0.0

0.0

27.4

0.0

0.0

0.0

0.3

1.2

C65

Ren

al p

elvi

s0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C

66U

rete

r0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C

67B

ladd

er11

00.

00.

00.

00.

00.

00.

00.

42.

20.

00.

07.

10.

06.

813

.116

.10.

00.

61.

5C

68O

ther

urin

ary

orga

ns0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

0C

69E

ye5

01.

90.

00.

00.

00.

00.

00.

00.

00.

00.

00.

04.

70.

00.

00.

00.

00.

30.

4C

70-C

72B

rain

, Ner

vous

Sys

tem

150

0.9

0.5

0.6

0.0

0.6

0.0

0.4

0.0

2.5

1.4

4.7

9.5

0.0

13.1

0.0

0.0

0.8

1.5

C73

Thyr

oid

580

0.0

0.0

0.6

1.4

0.0

4.3

3.4

7.0

8.4

5.6

4.7

9.5

20.5

13.1

0.0

14.2

3.2

4.1

C74

Adr

enal

gla

nd4

01.

90.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

20.

2C

75O

ther

End

ocrin

e0

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00

0C

81H

odgk

in D

isea

se16

00.

00.

00.

63.

60.

61.

30.

40.

00.

01.

40.

09.

56.

80.

016

.10.

00.

91.

6C

82-C

85; C

96N

on H

odgk

in ly

mph

oma

330

0.5

0.5

1.8

2.2

0.6

0.0

0.8

1.1

0.8

4.2

16.5

9.5

13.7

13.1

48.2

14.2

1.8

4.3

C88

Imm

unop

rolif

erat

ive

dis.

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

C90

Mul

tiple

Mye

lom

a5

00.

00.

00.

00.

00.

00.

00.

00.

50.

01.

40.

09.

56.

80.

00.

00.

00.

30.

8C

91Ly

mph

oid

Leuk

aem

ia23

05.

72.

10.

61.

40.

00.

00.

00.

01.

70.

00.

04.

70.

00.

00.

014

.21.

31.

6C

92-C

94M

yelo

id L

euka

emia

180

0.5

0.0

1.2

0.0

0.6

1.3

0.8

1.6

1.7

0.0

4.7

0.0

0.0

0.0

32.1

0.0

11.

4C

95Le

ukae

mia

uns

pec.

00

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

00

Oth

erO

ther

& u

nspe

cifie

d27

00.

50.

00.

00.

00.

00.

90.

81.

63.

44.

24.

723

.70.

026

.132

.114

.21.

53.

6A

llA

ll si

tes

792

013

.84.

15.

413

.612

.417

.325

.450

.087

.012

7.7

247.

736

4.4

273.

352

2.7

369.

439

7.0

43.6

92.2

All

but C

44A

ll si

tes

but C

4474

50

13.8

3.6

5.4

13.6

11.8

16.0

23.1

48.4

82.0

120.

723

1.2

350.

225

9.6

483.

528

9.1

368.

741

.085

.8

Part005.indd 85 14-06-2007 12:57:49 PM

86

Part005.indd 86 14-06-2007 12:57:50 PM

PART VIAPPENDICES

Part006.indd 87 18-08-2007 12:54:43 PM

88

APPENDIX: A Reporting Health care Facilities

Abha Private Hospital Mahael General HospitalArmed Forces Hospital South Majaridah General HospitalAhad Rafidah General Hospital Maternity & Children's Hospital Ahli Hospital Namad General HospitalAsir Central Hospital King Abdullah Bin Abdul AzizAsir Hospital NOS Rijal Al MaaBalasmar General Hospital Sabt Al AlayaBisha General Hospital Sarat Obeidah General HospitalDhahran Al Janoob Saudi German Hospital (Abha) Khamys Mishayt Civil Hospital Thaleeth General HospitalKing Fahd Armed Forces HospitalKing Faisal Military Hospital

Baha Hospital NOS King Abdullah Bin Abdul AzizBaljurashi General Hospital

Al Ahsa Hospital (Hofuf) King Fahd Hospital in the Eastern ProvinceAl Mana General Hospital (Dammam) King Fahd MilitaryAl Mana General Hospital (Khobar) King Khalid General Hospital Al Mana General Hospital (Hofuf) King Khaled Military ClinicAl Mana General Hospital (Jubail) Maternity & Children's Hospital Arabian Oil Company Hospital Maternity & Children's Hospital Armed Forces Hospital (Hafr Baten) Mousa Hospital (Hofuf) Astoon Hospital (Thomairy) (Dammam) Mouwasat Hospital Chest Disease Hospital Mouwasat Dispensary Dammam Central Hospital Obeid Hospital (Hofuf) Dhahran Medical Center Prince Saud Bin Jalawi HospitalDossary Hospital Qatif Central Hospital Dr Fakhry & Mouhawis Rasheed HospitalFanateer Hospital Rowdha Dispensary Harbeesh Hospital (Hofuf) Saad Specialist Medical CenterJubail Hospital Safwa Hospital Jufer Hospital Salama Hospital Khafji Operation Hospital Tadawy General Hospital Khafji General Hospital TaheeliKing Abdul Aziz Air Base Hospital Uyun HospitalKing Abdul Aziz Navy Hospital Yousif Hospital King Abdul Aziz National hospital Zamil HospitalKing Fahd Hospital (Hofuf)

Hail General Hospital Rashid HospitalKing Khaled General Hospital, Hail Baqa Hospital

King Fahd General Hospital Samtah General HospitalJazan General Hospital

Asir Region

Baha Region

Eastern Province

Hail Region

Jazan Region

Part006.indd 88 18-08-2007 12:54:43 PM

89

APPENDIX: A (continued...)

Dawamat Jandal Skaka General Hospital Jouf Hospital, NOS Tabarjal General HospitalPrince Abdul Rahman Sudairi Hospital

Quarayyat General Hospital

Al Dar Hospital Mouwasat Hospital Ansar Hospital Ohoud Hospital Badr General Hospital Psychaitric HospitalDr. Hamed Al Ahmadi Hospital Taiba Private HospitalHanakyah Hospital Tariq Bin Laden HospitalKhaybar General Hospital Ula General (Prince Abdullah Bin Abdul Aziz)King Fahd Hospital Yanboa Al Bahr Hospital Madinah National Hospital Yanboa General Hospital Mahad Hospital Zahra Private HospitalMaternity & Children's Hospital Meeqat Hospital

Abuzinada Hospital King Abdul Aziz University Hospital Ajiyad General Hospital King Fahad Armed Forces Hospital Al Abraj Laboratory King Fahad General Hospital Alawi Tunsi & Bros Hospital King Faisal (Taif)Amen Hospital King Faisal Al Sheshah Hospital Ansar Hospital King Faisal Specialist Hospital & Research CentreBakhsh Hospital M S BashrahilBugshan General Hospital Makkah Hospital NOSChildren & Maternity Hospital Maternity & Children's Hospital Dr. Erfan & Bagedo Hospital Mustaqbal (Dhagastani)Dr. Ghassan Pharaon Nahda NationalDr. Solaiman Fakeeh Hospital New Jeddah Clinic El Maghraby Eye Hospital Noor Specialist Hospital Eye Hospital (JD) Qunfudah General HospitalHada Military Hospital Rabegh General HospitalHai Al Jamea Ranyah HospitalHamra Royal CommissionHassan National Hospital Salamah HospitalHera General Hospital Saudi German (JD)Ibn Sina Saudia Airlines Med ServicesJedaani Hospital Sheffaa HospitalJeddah Regional Laboratory Taif Chest HospitalKhurama Hospital Thagher HospitalKing Abdul Aziz Hospital (Taif) Umm Al Qura Poly ClinicKing Abdul Aziz Al Zaher United Doctors HospitalKing Abdul Aziz Hospital & Oncology Center Yanboa General HospitalKing Abdul Aziz Medical City

Jouf Region

Madinah Region

Makkah Region

Part006.indd 89 18-08-2007 12:54:43 PM

90

APPENDIX: A (continued...)

Armed Forces Hospital Najran Najran Hosp NOSArmed Forces Hospital Sharoura Sharourah General HospitalKing Khaled General HospitalNajran General Hospital

Arar Central Hospital Turayf General Rafha General Hospital

Bukairiya General Hospital Midhnab General Hospital Buraidah Central Hospital Onaizah General HospitalKing Fahd Specialist Hospital Qassim Hospital NOS (not otherwise specified)King Saud Hospital (Onaizah) Rass General Hospital Maternity and Children Hospital

Riyadh-Al Kharj Armed forces Hospital King Khaled General HospitalAfif General King Khaled General (Majma'a)Aflaj General Hospital King Khaled University Hospital Al Amal Clinic Mamlaka (Kingdom) Hospital Al Borg Laboratory Mobarak Hospital Armed Forces Wadi Dawasir Mouwasat RiyadhArtwiyah Clinic Nukhba Medical CenterChest Diseases Center Obeid Hospital College of Dentistry Olaya Medical CenterConsulting Clinic Prince Salman Bin Abdul Aziz Hospital Dallah Hospital Quwayiyah Hospital Dawadmi General Hospital Riyadh Care Hospital (Social Insurance Hospital)Dr Abdul Rahman Al Mishari Hospital Riyadh Medical ComplexDr. Al Moagel's Polyclinic Saati Medical CenterDr Al Mofarreh Polyclinic Saudi German Hospital (Riyadh) Dr. Fahd Al Shedoukhy Security Forces Dr Suliman Al Habib Medical Center Shaqra HospitalEman General Hospital Shifa Health CenterFaleh International hospital Specialized Medical CenterGreen Crescent Hospital SulailHammadi Hospital Taawin PolyclinicHotta Bani Tammim Hospital Taif Medical CenterHowtat Sudair Usrah HospitalHuraymila General Hospital Wadi Al DawasserKharj Hospital Watani (Riyadh National hospital)King Abdul Aziz Medical City Yamamah HospitalKing Abdul Aziz University Hospital Zulfi general HospitalKing Fahad Medical CityKing Faisal Specialist Hospital & Research Centre King Khaled Eye Specialist Hospital

Najran Region

Northern Region

Qassim Region

Riyadh Region

Part006.indd 90 18-08-2007 12:54:44 PM

91

APPENDIX: A (continued....)

Dhuba Hospital Prince Fahad Bin Sultan HospitalHaql General Hospital Tabuk Civil HospitalKing Fahad Hospital Umm Lujj General Hospital King Khalid General Hospital North West Armed Forces Hospital

Bahrain Qatar Egypt Singapore Germany SpainIndia Sudan Jordan Syrian Arab Republic Kuwait United Arab Emirates Lebanon United States of America Oman Yemen Philippines

Tabuk Region

International Hospitals in the Following Countries

Part006.indd 91 18-08-2007 12:54:44 PM

92

APPENDIX: B NCR Board Member Contact Information

NCR Main Office MBC 64 PO Box 3354, Riyadh 11211 Saudi Arabia Tel: 01-442-3929 Fax: 01-442-3941 Website: www.kfshrc.edu.sa/NCR/ Email: [email protected] [email protected]

Chairman: Dep. Chairman: Acting Admin. Director: Registrar: Registrar: Epidemiologist: Data Manager:

Shouki Bazarbashi, MD Nasser Al Hamdan, MD Haya Al Eid, BDS, DFE, CTR Mohamed Hayder, CTR Asif Mehmood, CTR Haya Al Eid, BDS, DFE, CTR Suad O. Arteh, MA

Armed Forces Hospitals Riyadh Military Hospital PO Box 7897, Riyadh 11159 Tel: 01-477-7714 x 6747 Fax: 01-477-6743 x 6743

Director:

Rizq Allah Assiri, MD

Central Region King Khalid University Hospital PO Box 2925, Riyadh 11461 Tel: 01-467-9488/2398 Fax: 01-467-9487

Director:

Dahish Ajarim, MD

Eastern Region King Fahd Hospital of the University PO Box 40004, Al Khobar 31952 Tel: 03-896-6741 Fax: 03-869-6741

Director:

Prof. Hassan Al Iddrissi, MD

King Abdulaziz University Hospital Faculty of Medicine & Allied Science PO Box 80215, Jeddah 21589 Tel: 02-624-0000 x 18244/18253 Fax: 02-617-1412

Director:

Mohamoud Shaheen Al Ahwal, MD

King Faisal Specialist Hospital & Research Center MBC-64 PO Box 3354, Riyadh 11211 Tel: 01-442-3938, 464 -7272 x 24541

Directors:

Shouki Bazarbashi, MD Ali Al-Zahrani, MD, PhD

Part006.indd 92 18-08-2007 12:54:45 PM

93

APPENDIX: B Continued....

Madinah & Northern Region King Fahad Hospital Madinah Al Monawarah Tel: 04-486-1500 x 3760 Fax: 04-836-0951

Director:

Ahmed Tarawa, MD

National Guard Hospitals King Abdulaziz Medical City (KKNGH) PO Box 9515, Jeddah 21423 Tel: 02-624-0000 x 4085/4086 Fax: 02-624-0000 x 7242

Director:

Abdulwahab Andejani, MD

Security Forces Hospital PO Box 3643, Riyadh 11481 Tel: 01-477-4480 x 1193 Fax: 01-476-4757, 01-477-4480 x 3184

Director:

Abdulaziz Saleh Aba Hussein, MD

Southern Region King Khalid University PO Box 641, Abha Tel: 07-224-0711 / 224 -7800 x 118 Fax: 07-224-0964 / 224 -7570

Director:

Hassan Trabulsi, MD

Western Region King Abdulaziz Hosp. & Oncology Center PO Box 31467, Jeddah 21497 Tel: 02-637-5555 x 2283/2200 Fax: 02-637-9811

Director:

Hasnah Al Ghamdi, MD

Edward De Vol, PhD Hadir Meir, MD Susan E. Young, CCHRA©, CTR

Director Director Administrative Director

January 2001 - April 2006 January 2001 - August 2005 March 2003 -May 2006

Part006.indd 93 18-08-2007 12:54:45 PM

94

APPENDIX C NCR Data Request Form

Request for data from the National Cancer Registry All requests should be submitted to the attention of the Chairman of Directors, National Cancer Registry,

MCB 64, P.O. Box 3354, Riyadh 11211, Saudi Arabia, Fax: +966 1 442 3941

Name : Date Submitted : Department : Hospital : Telephone : Information Requested: (Specify Patient Population, Time Period, Year/s, Anatomic Site/Histology, Staging information, Region, etc.) Purpose of Request: (Specify Presentation at conference/meeting/publication, clinical/epidemiological study, personal information, etc.) Collaborators and Co-authors: Requesters affirmation statement: I hereby, the requester of the above data affirm that the data given to me by the NCR will be treated with utmost confidentiality in relation to patient’s identity. I also affirm that the data given to me will not be presented or published by me or any of my collaborators as an original work but rather can be cited in my presentations and/or publication with acknowledgment of the NCR.

Requesters Signature Date

For Official use only: Request : Approved Denied Chairman NCR Board of Directors Signature Dr. Shouki Bazarbashi Date

�لسجل �لوطني لأل�� لصحة

�ململكة �لعربية �لسعو�ية

National Cancer RegistryMinistry of HealthKingdom of Saudi Arabia

Part006.indd 94 18-08-2007 12:54:50 PM

95

APPENDIX D Cancer Registration Abstract Form

Part006.indd 95 18-08-2007 12:54:52 PM

96

Part006.indd 96 18-08-2007 12:54:55 PM

Date post:	04-Aug-2020
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times